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Abstract
PURPOSE. TO review new insights in the genetics and cellular electrophysiology, as well as
the current understanding of the clinical diagnosis and treatment of the congenital long-
QT syndrome.
DATA SOURCES. Personal databases of the authors and a search of the PubMed database
from 1966 to 2001.
STUDY SELECTION. Experimental and clinical studies on the congenital long-QT syndrome.
DATA EXTRACTION. From peer-reviewed studies, data were manually extracted, classified,
and summarized. . . ~ - ~ . ~ *
DATA SYNTHESIS. The congenital long-QT syndrome is characterized by abnormally
prolonged ventricular repolarization, which predisposes patients to syncope, ventricular
arrhythmias and sudden cardiac death. The recent discovery that mutations in genes
encoding ion channels are responsible for the manifestation of this disease has improved
our understanding of the cellular origin of this condition. Long-QT syndrome may result
from inherited defects in cardiac K+ and Na+ channels, which both result in prolongation
of the ventricular action potential. The diagnosis is based on electrocardiographic and
clinical criteria. In addition, genetic screening of symptomatic patients or asymptomatic
family members may identify patients at risk for life-threatening ventricular arrhythmias.
Beta-blocking agents are the mainstay in the treatment. In addition, certain patients may
benefit from a pacemaker or implantable cardioverter-defibrillator. Recent studies suggest
that in the near future, genotype-specific treatment will become a novel approach to the
congenital long-QT syndrome.
CONCLUSIONS. The congenital long-QT syndrome is a potentially life-threatening condition
caused by mutations in genes encoding cardiac ion channels. The mechanisms responsible
for these conditions are being increasingly better understood, and will guide genotype-
specific therapy in the near future.
Novel Insights in (he Congenital Long QT-j Syndrome | PACE 10
Introduction
Over the past decade, the discovery of mutations in genes encoding ion channels (1) has
helped to better understand the mechanism of the congenital long-QT syndrome, an
inherited disease characterized by prolonged ventricular repolarization and a propensity for
life-threatening ventricular tachyarrhythmias resulting in syncope and sudden death (2).
Current estimates suggest that 1 in 10,000 persons are gene carriers, and that long-QT
syndrome causes 3000-4000 sudden deaths in children and young adults each year in the
US only (3). The two major clinical syndromes that have been characterized on the basis of
the genetic transmission pattern are a more common autosomal-dominant form (Romano-
Ward syndrome) with a pure cardiac phenotype (4,5) and a rarer autosomal-recessive form
(Jervell and Lange-Nielsen syndrome) characterized by the association with congenital
neuronal deafness (6). Long-QT syndrome, occurring secondary to electrolyte disturbances
or drug-therapy, is called acquired long-QT syndrome (7). - " -" - ^ -.:;.
As a consequence of the genetic information, it became clear that what has
been classified under the unifying name of the long-QT syndrome, actually represents a
variety of different diseases caused by ion channel mutations, all producing alterations in
ionic currents, leading to the same end result: prolonged ventricular repolarization (8).
In addition, the first ion channel gene mutations and polymorphisms that predispose
people to drug-provoked QT-interval prolongation and ventricular arrhythmias have been
identified (9,10).
In this review, we A) classify the forms of congenital long-QT syndrome;
B) discuss the proposed explanations of the cellular electrophysiology of the syndrome;
C) review the clinical characteristics; and D) discuss the identification and management
of patients with congenital long-QT syndrome, including novel approaches such as
genotype-specific therapies.
Chapter 1
Historical Remarks on the Congenital Long-QT Syndrome
T/ie/rst report o/the /ong-QT syndrome profcofc/y dotes bock to 1856. Me/ssner re/oted the
cose 0/0 gi'r/, pup/7 ot t«e Le/'pz/g Scboo/ o/the Deo/ ivho co//apsed ond died whi/e pub//c/y
fldmon/shed by the Director/or 0 misdemeanor (157,). One o/her siMngs hod prei>/ous/y d/ed
sudden/y a/ter 0 ternb/e/r/g/it and another a/ter 0 Wo/ent/t o/rage (151). /n 1901, be/ore the
e/ectrocardiogram u w ivi'de/y ot'o/Vob/e, Morquio reported 0 /orge Uruguayan/am//y in which
severe/ sib/ings repet/'t/Ve/y co//apsed and died ot a young oge (152).
Latham and Munro described /n 7937 a_/am/7y with consanguineous marriage, »r?
which oZ/y/t'e ch/7dren su/Jered/rom congen/to/ dea/ness in ossoci'oti'on with spe//s that were
interpreted os epi/eptic spe//s. One 0/these chi/dren d/ed unexpectedly ("753^ . /n 1953, Herr/in
and M6//er reported the case 0/0 congemta//y deo/boy with frequent episodes o/syncope, and
described, /or the _/irst time, the e/ectrocardiographi'c (ECCJ/eatures o/the /ong-QT syndrome:
a pro/onged QT-interva/, abnorma/ T wafes in the precord/a/ /eads, and brodycard/a f754J.
The case report by Drs.Jerve// and Lange-N/e/ssen, who described the association 0 /
congenital deo/ness with typico/ £CC obnormo/it/es, in conjunct/on wi'th/ji'nting ottac/cs and
a propensity to sudden death, /u//y recognized the c///i/ca/ picture and possib/e re/ecance 0/
the disease (6^. Soon therea/ter, Drs. Romano ^4,155 ,^ ond Word (5,) described independent/y
that^i/nt/ng attacks and inherited QTWnterva/ pro/ongati'on a/so occurred ;'n the absence 0 /
neurona/ dea/ness. The Romano-Ward syndrome (RWSj is now known as the /ong-QT
syndrome with an autosomaZ-dom/nant mode 0/inheritance, a/though 0 recessive variant
has o/so been reported recent/y (79^. Thejerve// Lange-N/e/ssen syndrome (y-N), on the other
hand, inherits in an autosoma/-recessiVe way (6,756-16(5). The concomitant neurona/ deo/ness
may not o/ways be comp/ete (758J, ond may be inherited seporate/y/rom the cardiac de/ect
in certainybmi/ies
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Methods
We searched the PubMed database for literature on the congenital long-QT syndrome,
focusing on advances in the four specified areas (A-D). From peer-reviewed studies,
data were manually extracted, classified, and summarized.
A. Genetics of the Congenital Long-QT Syndrome
Genetic linkage mapping of the autosomal-dominant Romano-Ward syndrome has so far
identified loci on six chromosomes (LQT-i to LQT-6) (n-17). The autosomal-recessive
variant (Jervell Lange-Nielssen syndrome) arises in individuals who inherit abnormal
KC/VQ1 (= /O-LQTi) or KC/VE7 (= m/nK) alleles from both parents (LQT-i, LQT-5).
The abnormal gene can be the same (usually in consanguineous families) or different
(so-called compound heterozygosity) (18). Parents of subjects with Jervell Lange-Nielssen
syndrome are heterozygous for long-QT syndrome mutations, but are usually (but not
always) asymptomatic (19). Most long-QT syndrome genes encode K+ channels, with the
exception of the LQT-3 gene (SC/V5A) that encodes the cardiac Na+ channel (current
indicated by 1 ,^) (20).
Mutations in either the a-subunit encoded by KCNQ1 (LQT-i) or the (J-subunit
encoded by KCNE7 (LQT-5) can cause defects in the l ^ current. Similarly, mutations in
the LQT-2 (KCNH2 = HERG) and LQT-6 (KCNH2 = MiRP7) genes encoding the a- and
(3-subunit of the rapidly activating delayed rectifier K+ channel 1^,, respectively, may cause
long-QT syndrome (17).
B. Functional Consequences of Long-QT Syndrome Mutations
The channels carrying the l«s and l|<, potassium currents are multimeric (15,16); alleles
from both parents are thought to contribute to the channel complexes (21). Using
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FIGURE 1.1
(Aj The yentricu/or action
potential is initiated by current
yfcw through cardiac
No* chonne/s (depo/arijation,
phase o). £ar/y repo/anzation (ij
is caused by the K* current /J-Q.
The action potentia/ p/ateau
phase ^ is maintained fcy /QJ ,^
/K,, and /K, currents, and (ate
repo/arization (3^  is caused by
current /low through /^ and /«,
channe/s. The dotted /ine
represents action potentia/
pro'ongation as can be observed in
the congenita/ /ong-QT syndrome.
(B) /n case o/i.QT-j, most
mutations in Ihe SC5NA gene
cause a smo// non-inactiVating
sodium current that remains
acfiVe during the action potentia/
p/ateau phase (dotted) and
prowdes an additiono/
depo/arizing current, which
pro/ongs repolarization.
(CJ The KCNQi gene encodes the
slow/y activating de/ayed recti/ier
K* channe/ which conducts the
/)(j current, /n case 0/LQT-1,
reduced /K, activity /eads to action
potentia' pro/ongalion.
fD^ The KCNH2 gene encodes
the rapid/y activating de/ayed
recti/ier «* channe/ ivhich
conducts the /^, current, /n LQT-2,
a reduction 0 / /^, causes
pro/ongation o/the repo/arization
phose (dotted /inej.
-90
o 200
TIME (MS)
4 0 0
LQT-3
heterologeous expression systems like
Xe/iopus oocytes or mammalian cell
lines, mutations in KCNQh, /CC/VEi,
KC/VH2, or KCNE2 expressed alone or in
combination with wild-type alleles,
typically exhibit a 'loss of function'
(FIGURE I . I ) . The total current carried by
the defective potassium channel
complexes is impaired by reduced
gating, modified channel kinetics, or
non-expression at the plasma membrane
level by deficient transport from the
endoplasmatic reticulum. Because
potassium channels are tetrameric
proteins, there is also the potential for
the presence of a single (or more)
mutant subunit in a tetramer to disrupt
the function of the remaining wildtype
subunits (so-called dominant-negative
effect) (22-25). Mutations in the cardiac
Na"*" channels linked to LQT-3 generally
promote additional Na+ channel activity
during the plateau phase of the action
potential leading to an extra component
of inward current (26,27). This additional
inward current would be expected to
prolong repolarization and hence underlie the phenotype in carriers of these SCN5A
mutations (8,28). However, this gain-of-function persistent Na+ current is not observed in
all SCN5A mutations (29), which implies that heterogeneity in arrhythmogenic
mechanisms exists among Na+ channel-related long-QT syndrome.
LQT-2
KCNH2
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C. Clinical Characteristics
The International Long-QT Syndrome Registry was started in 1979 to study prospectively
epidemiological and genetic characteristics (30-33). In (symptomatic) probands, 50% had
experienced a first cardiac event by the age of 12 years, and by the age of 40 years this had
increased to almost 90% (33). Multivariate analysis identified as independent risk factors
for syncope or sudden cardiac death: congenital deafness, history of syncope, female
gender, documented torsades de pointes or ventricular fibrillation, age at first episode and
the long-QT syndrome gene affected (31-35). The QTc duration was independently
associated with the risk of syncope or sudden death during follow-up (33). These results
ECC findings f> Points
a. QTc «
> 480 ms'/a • 3
460-480 ms'/2 a
450-460 ms'/* (in males) 1
b. Torsades de pointes (3) 2
c. T wave alternans , 1
d. Notched T wave in 3 leads 1
e. Low heart rate for age W 0.5
Clinical history
a. Syncope
With stress 2
Without stress 1
b. Congenital deafness 0.5
Family history (si
a. Family members with 'definite' long-QT syndrome (*) 1
b. Unexplained sudden cardiac death < 30 yr O.$
among immediate family members
W /n (fie obsence o/medi'cot/on or disorders /cnoivn to o^ect these e/ectrocardiographic/eatures;
W QTco/cu/ated ivith Bazett's/ormu/a (QTc = QT/ Vfifty; W No points //patient is (diking drugs to^a iw
QT pro/ongotion; W Resting neart rate be/cw second percent/7e/or age (45,); fs* The same/ami/y member
can not be counted in A and 6; W 'De/inite' /ong-QT syndrome is defined as /ong-QT syndrome score 0/
a 4. SCORING: £ 1 point, /oiv probability 0//ong-QTsyndrome; 2-3 points, intermediate probabi/ity.
Af/opted/rom: Scbivartz P/ et o/. 7993 (46).
TABLE 1.1
Diagnostic criteria ^ br the
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are in line with the finding that QT-interval prolongation in an apparently healthy
population (36,37) correlates to an increased risk of mortality. The question whether the
QTc variability over time correlates with mortality remains to be resolved (38).
The Influence of Age and Gender
Since the QT-interval duration is shorter in adult males than females (39-44), a diagnosis
of QT prolongation could be made relatively more often in adult females. However, after
the introduction of the 1993 diagnostic criteria for long-QT syndrome (TABLE 1.1), that
define sex specific criteria for QT duration, such bias leading to a female predominance is
less likely. Nevertheless, a female predominance is consistently reported in clinical studies
(32,33,43). In males, the risk of first cardiac events is typically higher in childhood, and
decreases after puberty, probably due to a regression of QTc duration (40,42,43,47,48).
The Influence of Pregnancy
Probands with the hereditary long-QT syndrome are at significant risk for cardiac events
during the postpartum interval, nearly 10% of the probands in the study by Rashba et al.
(49) experienced their first cardiac event during the postpartum interval. The most
important factors contributing to this risk may be related to an increase in sympathetic
activity (2,50), or to increased levels of estrogen and progesterone that directly or indirectly
influence the number and function of mutant ion channel proteins (51,52). Treatment with
P-blockers can reduce the risk for cardiac events (49).
D. Identification and Management of Long-QT
Syndrome Patients
Sudden death or a history of unexplained syncope in a child or young adult can bring the
patient or family member under the clinician's attention. After informing the patient, an
ECC should be recorded, and a detailed family history for syncope and sudden cardiac
death should be taken. Many mutation carriers are asymptomatic despite the fact that they
display electrocardiographic characteristics of long-QT syndrome. Another group consists
of individuals that have been identified as mutation carriers without symptoms or ECG
features (21), or they only intermittently display ECG signs. We recommend genetic
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analysis or referral to a specialized combined genetic-cardiology out-patient clinic for all of
these patients, as the study of Iong-QT mutations may aid to better understand the
pathophysiology of the disease, and may help to develop mutation-specific therapies in the
near future (53). In addition, there is a group of patients that carries ion channel mutations
or polymorphisms, predisposing them to drug-induced Iong-QT syndrome (9).
The following four paragraphs will discuss identification and management of these
subgroups of Iong-QT syndrome patients.
1. Patients with Symptoms of Congenital Long-QT Syndrome
Symptoms
Vertigo, syncopal attacks, cardiac arrest, and unexplained sudden cardiac death among
immediate family members, or family members with definite Iong-QT syndrome point to
inheritance of an affected gene. Neurally mediated syncope and epileptic seizures are the
most common differential diagnoses (54). A careful history of symptoms and signs can
often clarify this diagnostic dilemma. Sudden cardiac death during sleep should also raise
suspicion of the Iong-QT syndrome, particularly the LQT-3 phenotype (55).
LQT-i LQT-2 LQT-3
Gene mutated
Current affected
Estimated prevalence (%)
Events occurring with
exercise or emotional
stress (%)
Exercise related trigger
Other triggers
Events before age 10 (%)
Events before age 40 (%)
Median age 1 " event (yr)
Mean QTc interval (ms'")
QT shortening with exercise
Efficacy (J-blockade to
prevent events
Efficacy mexiletine to
shorten QT
Adopted/rom; Wjfrfe AA et a/. (58;. C/inica/ data deri«d/rom Zareba et 0/. 1998 fa^.
IKS
42
97
Diving
40
63
9
490 ± 43
< normal
45
51
8
39
Loud noise
16
46
12
495 ± 43
normal
Sleep/rest
2
18
16
510 ± 48
> normal
TABLE 1.2
C/mica/ characteristics m common
genotypes o/congen/to/ /ong-QT
syndrome.
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The clinical course of the long-QT syndrome is importantly influenced by the gene affected
(34). By age of 15, almost 60% of LQT-i patients have had a cardiac event (syncope,
cardiac arrest, or sudden cardiac death), compared to less than 10% in LQT-3 patients
(34,35). The number of cardiac events that occurred till the age of 40 years was also higher
among LQT-i (63%) or LQT-2 subjects (46%) compared to LQT-3 (18%). In contrast, the
likelihood of death during a cardiac event was much higher among LQT-3 (20%) compared
to LQT-i and LQT-2 (4%) (36) (TABLE 1.2). Due to the low number of patients, no data are
available yet for LQT-4, LQT-5 and LQT-6 patients.
Triggers_/br Syncopa/
Episodes of sudden loss of consciousness are almost always due to TORSADES DE POINTES
ARRHYTHMIAS in long-QT patients (57). Torsades de pointes can be defined as a
Erampfe 0/torsades de po/ntes polymorphic ventricular arrhythmia showing a peculiar electrocardiographic pattern
characterized by a continuous twisting of the QRS axis around an imaginary baseline (58).
An important characteristic of torsades de pointes is its potential for self-termination or
deterioration into ventricular fibrillation. This explains why affected patients often survive
several syncopal attacks before succumbing to a lethal one.
Recently, it has become evident that triggers for arrhythmic episodes and syncope are also
dependent on the specific long-QT syndrome gene affected (TABLE 1.2) (35,59-61).
In l^s-related long-QT syndrome (LQT-i), exercise- and stress-related events
dominate the clinical picture (48,59,62,63), which is related to activation of the I*; current
by adrenergic stimulation (64). Diving and swimming, as triggers, are almost exclusive for
LQT-i patients (35,60). Patients with LQT-3-associated Na+ channel mutations are at
particularly high risk at rest or asleep because their QT-interval is prolonged excessively at
slow heart rates (63,65). This clear distinction between LQT-i and LQT-3 with respect to
exercise-related triggers does not hold for LQT-2 patients, who tend to display events both
at rest and during exercise (59). However, events provoked by auditory stimuli such as an
alarm clock or telephone ringing almost exclusively occur in LQT-2 patients
(35,59,60,66,67). No data are available yet for LQT-4, LQT-5 and LQT-6 patients.
Treatment Options/or Symptomatic Patients
Symptomatic individuals require treatment (32,33,68). It is important to inform patients
and their parents well about the importance of compliance, as noncompliance exposes
patients to increased risk of cardiac events. This often requires frequent counseling of
young patients to motivate them to continue to take their medication while they are
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asymptomatic. Based on the observations that physical and emotional stress are important
triggers for cardiac events in long-QT syndrome (type 1 and 2) patients (35,59,61), non-
medical treatment should also include life-style advice and information on certain drugs
that should be avoided because of their potential to prolong QT-intervals. Competitive
sports should be generally discouraged, but recreational sports that do not cause sudden
increases in heart rate are usually tolerated well. Finally, patients are instructed how to
respond to excessive electrolyte loss, e.g. during diarrhea or excessive perspiring. Patients
are advised to take drinks that contain minerals such as potassium.
BETA-BLOCKER THERAPY
Administration of (3-blocking drugs is very effective in preventing ventricular arrhythmias in
the long-QT syndrome, although the response is genotype-dependent (5,69-72).
The io-year mortality rates among symptomatic patients dropped from approximately
50% when not treated to below 5% after long-QT syndrome patients were routinely put on
(3-adrenergic receptor blocking therapy (32,33). A recent retrospective study by Moss et al.
(68) among 869 long-QT syndrome patients revealed a significant reduction in the rate of
cardiac events in both probands and affected family members after initiation of beta-
blocking therapy. In patients with aborted cardiac arrest before p-blocker therapy, the
probability of aborted cardiac arrest or sudden death was 6.6% when using P-blockers
(68). In patients with recurrent cardiac symptoms or aborted cardiac arrest, p-blocker
therapy might not be completely effective in preventing sudden cardiac death, and
implantable cardioverter defibrillater (ICD) therapy is warranted for these high-risk
patients. An important criticism to this study is the retrospective nature without evidence
that patients continued to take their P-blockers. After it became clear that the long-QT
syndrome is caused by ion channel mutations and probably not by IMBALANCE OF
THE CARDIAC AUTONOMOUS NERVOUS SYSTEM, the rationale for performing left cardiac
denervation has become less obvious.
CARDIAC PACING
As the onset of torsades de pointes arrhythmias in long-QT syndrome patients has been
associated with bradycardia or pauses during sinus rhythm (73-75), permanent cardiac
pacing has been recommended as an adjuvant to p-blocker therapy in patients who also
have bradycardia or atrioventricular conduction disturbances (76-81), or in carriers of
SC/V5A mutations who usually have slow heart rates (82,83). ' " addition, cardiac pacing
can be an important adjuvant therapy in those patients in whom p-blocking drugs and left
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The Sympathetic Imbalance Theory •"•
/n the seventies and eighties, two opposing hypotheses existed concerning the patbogenet/c
mechanisms in the congenita/ /ong-QT syndrome (LQTS). The 'sympathetic imba/ance' theory
(2,50,762) and the hypothesis 0/0 'primary myocardi'a/ membrane de/ect' (74,75,163) ifere put
/orward.
Tbe/rst hypothesis considered a cr/tica/ ro/e o/the autonomic nervous system in the
pathogenesis o/LQTS on the basis o/c/iTi/ca/ observations (162,164) and experimenta/ resu/ts
(50,165). Bas/ca//y, QT pro/ongation and T wwe a/ternat/on cou/d be induced by either /e/t
ste//ate gang/ion sti'mu/ati'on or b/oc/cade o/the right ste//ate gang/ion. These observations
suggested that LQTS might haye a congenita/ imba/ance between the right and /e/t
sympathetic innervation i*/ith /e/t dominance (50,162). Using "3/-/r)etaiodobenzy/guani'dine
(M/SC) sing/e-photon emission tomography (SPECT) sc/ntigraphy (166,167), some studies
demonstrated impaired regiona/ sympathetic innervation in LQTS patients, /n contrast, using
"C-hydroxyephedrine (H£D) positron emission tomography (P£T), others showed a norma/
cardiac sympathetic innervation in LQTS pat/ents (168). A/though it is now genera//y be/ie^ed
that an abnorma/ distribution 0/cardiac sympathetic nerves is not a common mechanism in
congenita/ LQTS, it cannot be exc/uded that the observed M/8C de/ects might hai^ e been
regions o/enhanced sympathetic actiWty according to (A) the hypothesis o/hyperactiVity 0 /
/e/t sympathetic nerves (165), and (8) echocard/ographic observations o/an increased rate
0/thickening in the posterior wo//, poss/b/y re/ated to /'ncreased sympathetic actiV/ty in this
region (169).
Based upon the assumed pathogenesis o/the disease, therapy with P-b/ocfcers and
surg/ca/ /e/t sympathetic denervation was per/brmed (164). The rationa/ o//e/t cardiac
sympathetic denervation was to shorten the QT-interva/ (107), and to protect against
yentricu/ar arrhythmias (170). /n a wor/d-wide report on 85 patients with /e/t cardiac
sympathetic denervation, Schwartz and co//eagues reported a decrease HI the number 0 /
patients with cardiac events, and m the number 0/cardiac events per patient (171). A/though
a /ow^ife-year morta/ity rate 0 /6% was reported, the study was not designed to alloif a
conc/usiVe ana/ysi's o/a possib/e bene/ic/a/ effect on morta/ity. Because^ew other groups were
ab/e to reproduce these findings, /e/t sympathectomy is not a common/y used treatment option
anymore/or drug-re/ractory patients. Combination therapy 0/p-b/ocfcers with a pacemaker,
or a/ternatiVe/y, an imp/antab/e card/ocerter de/ibri//ator are q/ten pre/erred nowadays (87).
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stellate ganglionectomy have proven inefficacious, even if bradycardia or conduction
disturbances are not present (84). Cardiac pacing should be aimed at preventing (A)
bradycardia, by using a relatively high lower rate limit (> 80 beats/min), and (B) pauses,
by using pause-prevention pacing algorithms such as rate-smoothing. Applications of
cardiac pacing were reviewed by Viskin (82).
IMPLANTABLE CARDIOVERTER DEFIBRILLATORS
Implantable cardioverter defibrillators are increasingly being used in an attempt to prevent
sudden cardiac death (85,86). Aborted sudden cardiac death and recurrent symptoms
while on combined (3-blocker and pacemaker therapy are the most frequent indications for
ICD implantation (85-87). Since the ICD does not alter the underlying substrate leading to
arrhythmias, it is recommended to initiate or continue (3-adrenergic blockade therapy (88).
TOWARDS A GENOTYPE-SPECIFIC THERAPY OF SYMPTOMATIC LONC-QT PATIENTS
The emerging sense that gene-specific therapy might be feasible for some forms of long-
QT syndrome has recently been supported by clinical and experimental studies. One of the
first attempts studies showed that LQT-3 patients shorten their QT-interval more in
response to a Na+ channel blocker (mexiletine) compared to LQT-i and LQT-2 patients
(89). As most LQT-i patients experience syncopal events during exercise, competitive
sports should be avoided. As diving and swimming are particularly strong triggers for
cardiac events in LQT-i patients, it should be strongly discouraged (35,60,90). LQT-2
patients should be advised to remove sources of loud noise from their direct environment
(such as telephone and alarm clocks).
Patients with LQT-i and LQT-2 genotypes typically benefit from fi-blocker therapy
(35,68). Because the amplitude of l|<, increases when extracellular potassium concentra-
tions are increased (91,92), attempts have been undertaken to increase K+ levels in LQT-2
patients by means of intravenous potassium infusion or administration of the diuretic
spironolacton (93). Indeed, QT-intervals have been shown to shorten significantly in LQT-2
(94) but also LQT-i (95) patients. Potassium supplementation is, however, hindered by
difficulties in achieving sufficiently high K+ concentrations with chronic oral therapy (96).
On the other hand, nicorandil, a K+ channel opener, has been shown to normalize
repolarization abnormalities induced by epinephrine infusion in LQT-i patients (97).
A beneficial effect of (3-blocker therapy has not been demonstrated for LQT-3
patients (35,68). Since LQT-3 patients are at higher risk at slow heart rates, they may
benefit from pacemaker therapy. Several clinical and experimental studies suggest a
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beneficial effect of Na+ channel blockers such as lidocaine/ mexiletine (89,98,99),
tocainide (98), or flecainide (83) in LQT-3 patients, although long-term follow-up data are
not available yet. It should be noted, however, that flecainide may cause ECC changes
reminiscent of the Brugada-syndrome (familial idiopathic ventricular fibrillation) in a
significant number of LQT-3 patients (100). The BRUCADA SYNDROME is characterized by
right bundle branch block and ST-segment elevation in the right precordial leads on the
ECC, and may lead to ventricular fibrillation and sudden cardiac death (101). The impact of
the flecainide-induced changes, which might suggest the introduction of a different
arrhythmogenic substrate, is currently unknown. A further therapeutic differentiation on the
basis of the specific mutations in the affected gene can be expected in the near future.
2. Patients Without Symptoms but With Electrocardiographic Characteristics
Suggestive of Long-QT Syndrome
Some individuals are not identified on the basis of their symptoms, but because of typical
electrocardiographic features suggestive of Iong-QT syndrome. The principal diagnostic
hallmark of the Iong-QT syndrome is lengthening of the QT-interval on the 12-lead ECC.
As the QTc value is often not sufficiently long to make or exclude the diagnosis in
borderline cases, an elaborate point scoring system that goes beyond QTc duration was
developed by Schwartz et al. (46) (TABLE 1.1).
QT Pro/ongat/on
QT-interval prolongation is usually most easily identified in lead II, Vi, V3, or V5, but all 12
leads should be examined to identify the longest QT-interval (104-106). Despite ongoing
criticism, Bazett's correction formula (QTc = QT / VRR) for heart rate continues to be useful
(39,46,102,103). The 'cut-off value' commonly used was a QTc interval & 440 ms, but more
recent genotype-phenotype correlations indicated >46o ms to be more appropriate (35,48).
Indeed, 40% of LQT-i and LQT-2 mutation carriers show QTc values (410-470 ms) that
overlap with non-carriers (34, 43). In this QTc range, phenotypic diagnosis from the ECC
becomes imprecise and genetic studies may be helpful in diagnosing Iong-QT syndrome.
When QTc a 460 ms is used, the positive predictive accuracy for Iong-QT syndrome is 96%
in women and 91% in men; almost 100% positive predictive accuracy for Iong-QT
syndrome can be achieved at QTc > 470 ms in males and QTc > 480 ms in females (50).
Finally, QTc intervals tend to be longer in LQT-3 patients than LQT-i and LQT-2 carriers
(34.35.43)-
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QT-/nten/a/ D/spers/on
The second ECG characteristic is QT-interval dispersion, which can be measured as a lead-
to-lead variability in QT-intervals (105-107). It is debated whether this phenomenon reflects
regional differences in ventricular repolarization times (108,109). In normal individuals, the
difference between maximal and minimal QT-intervals measured on the standard resting
ECG has been reported to vary between 48 ± 18 msec (102) and 54 ± 27 msec (102). In
patients with the congenital long-QT syndrome, however, regional dispersion of ventricular
repolarization times has been reported to vary from 93 (±39) to 185 (±26) msec
(105,106,110,111). In long-QT syndrome patients, QT dispersion has been suggested to
correlate with the risk for ventricular arrhythmias (105,112), whereas a reduction in
dispersion of the QT-interval could be used as a marker of therapeutic efficacy (107).
T Waye Morpho/ogy
In long-QT syndrome patients, not only the duration of repolarization is altered (QT-
interval), but also its morphology (113). The most typical presentation of the T wave may
be biphasic (114) or notched (75,114,115), and is most prominent in the precordial leads
(114,115). In addition, T wave alternans is an infrequently recorded highly arrhythmogenic
ECG finding with transient beat-to-beat changes in amplitude, shape, and polarity of the
T wave during sinus rhythm without concomitant QRS changes (116-118).
Sradycardia and Sinus Pauses
Signs of sinus node dysfunction, e.g. sinus bradycardia or sinus pauses (70,119,120), and
lower than expected heart rate during exercise have been reported (33,121-123). Slow heart
rates are particularly striking in younger children (122). During submaximal exercise
testing, many long-QT syndrome patients reach a heart rate level lower than that achieved
by healthy controls matched by sex and age (124,125). Sinus pauses may play a role in the
initiation of pause-dependent torsades de pointes arrhythmias (73,74,126). Long-QT
syndrome might also be complicated by atrioventricular conduction disturbances, which is
generally associated with poor prognosis (50,81,123).
E/ectrophysio/og/ca/ Testing
One of the first comprehensive electrophysiological (EP) studies in long-QT syndrome
patients was performed by Wellens et al. (127). The absence of inducibility by programmed
stimulation indicates that the arrhythmias in long-QT syndrome are probably not the result
of reentrant circuits, but reentry probably plays a role in the perpetuation of torsades de
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pointes arrhythmias in long-QT syndrome. It is therefore generally believed that EP studies
using one or more premature stimuli during ventricular pacing are of limited value in the
diagnosis and treatment of patients with the long-QT syndrome (128,129). On the other
hand, torsades de pointes might be inducible using short-long-short sequences (74,130).
In addition, changes in heart rate provoked by for example the Valsalva maneuver or EP
protocols may lead to clear changes in the T wave or ventricular tachycardia (75).
Response to Exercise
The standard resting ECG as a diagnostic criterion may misclassify members of long-QT
syndrome families (48,131,132). Therefore, an exercise test has been suggested to enhance
diagnostic accuracy, as shortening of QT-interval was shown to be inadequate in LQTS
patients (4,65,133-136). In addition, a submaximal heart rate response during exercise has
been reported (50,124,134). In a recent study by Swan et al. (131), a reduced maximum
heart rate during exercise was found for LQT-i patients, whereas this was normal for LQT-2
patients. During recovery from exercise, LQT-i patients showed an exaggeration of the
QT-interval prolongation compared to LQT-2 patients (131). Finally, Schwartz et al. reported
that LQT-3 patients display a higher degree of QT-interval shortening in response to
increase in heart rate than LQT-2 patients (89) (TABLE 1.2). Holter monitoring may also be
useful (137), but well-defined criteria for QTc seperation of long-QT syndrome from normal
patients are currently not available. Studies have demonstrated that QT-intervals up to 500
ms occur in a significant percentage of healthy individuals (138). Therefore, a QTc > 500
ms, particularly in association with T wave abnormalities, would appear to be necessary
to support the diagnosis of long-QT syndrome (54).
Genotype-Speci/ic E/ectrocordiograpbic Phenotypes in the Congenito/
Long-QT Syndrome
The different time- and voltage-dependence of the ionic currents involved in long-QT
syndrome are probably responsible for distinct ECC phenotypes that have been reported
for the different genotypes. Initial studies by Moss et al. (34,139) reported an association of
certain T wave patterns with LQT-i, LQT-2, and LQT-3. Recently, Zhang et al. (140)
recognized 10 typical ST-T wave patterns that are genotype-specific
(4 LQT-i, 4 LQT-2, and 2 LQT-3) (see FIGURE 1.2 for the most important ECG patterns).
These ECG characteristics, however, cannot be used to diagnose the type of long-QT
syndrome, but are rather useful to select which gene should be investigated first when
performing genetic analysis.
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Treatment o/Asymptomatic Pat/ents w/tn ECG Characteristics o/Congen/ta/ Long-QT
Syndrome
Treatment of asymptomatic patients is still controversial, because the majority of long-QT
syndrome patients will never experience symptoms (34,35) and sudden death during the
first syncopal episode is unlikely to occur (34). While waiting for more definitive data,
Schwartz recommended to begin treatment for asymptomatic patients only in the following
six conditions: in those with congenital deafness; in neonates and for the first year of life
because of the enhanced risk during the first months in life; in siblings of children who
have already died suddenly; in patients with documented evidence of T wave alternans;
when the QTc exceeds 600 ms; and whenever there is manifest anxiety or explicit request
for treatment (88).
3. Mutation Carriers Without Symptoms or Electrocardiographs Characteristics
of Long-QT Syndrome
It is estimated that approximately 10% of all mutation carriers have a normal QTc interval
< 440 ms (140). However, only 2% of all long-QT syndrome mutation carriers have a
normal ST-T wave pattern with a normal QT-interval. Priori et al. (141) showed that in some
families, penetrance of clinical symptoms and QT-interval prolongation may be as low as
25%. This implies that family members considered normal on clinical and electrocardio-
graphic grounds could be silent gene carriers displaying a very mild phenotype (19).
They would be unexpectedly at risk of generating affected offspring and perhaps also of
developing torsades de pointes arrhythmias if exposed to either cardiac or noncardiac
drugs that block potassium channels (9,10). It is therefore recommended to perform
molecular screening in all family members of positively genotyped patients (21). Few long-
QT syndrome patients without ECG abnormalities present with sudden death as their first
symptom (103), although preliminary data suggest that sudden death can occur in silent
gene carriers (142)- Awaiting more definitive data, conservative management of silent gene
carriers seems reasonable, as the value of (J-blocker therapy in this group of patients is still
unknown.
4. Patients Carrying Mutations or Polymorphisms Associated With
Drug-provoked Long-QT Syndrome
Some patients carry a predisposition for drug-induced torsades de pointes arrhythmias on
the basis of congenital long-QT syndrome-related ion channel mutations (7,95,143)-
These patients are usually clinically asymptomatic until administration of a drug. A genetic
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Mefloquine
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Terfenadine
Cisapride
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Clarithromycin
Quinidine
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Oxatomide
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Antimalarial
Antiarrhythmic
Antihistamine
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Antimalarial
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Antiarrhythmic
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(145)
(10)
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predisposition to drug-provoked long-QT syndrome torsades de pointes can be caused by
mutations in the KCNE2 subunit of the l ^ potassium channel (16,144) or a mutation in
the KCNQ7 subunit of the l ^ channel (10,145) (TABLE 1.3). In addition, a polymorphism in
the KCNE1 gene (147), as well as two relatively common polymorphisms in KCNE2
(allelic frequency in both cases around 1.6%) have been associated with quinidine- and
erythromycin-induced long-QT syndrome (9,16). Drug-provoked long-QT syndrome has
also been linked to mutation in SCN5A (146).
However, it should be noted that in most patients with acquired long-QT
syndrome (>85%), no ion channel mutations have been identified thus far. In this case,
acquired long-QT syndrome is thought to result from electrolyte disturbances, hypertrophy,
or treatment with commonly used medications, including some antiarrhythmic,
antihistamine, antibiotic, psychoactive, and gastrointestinal prokinetic agents (148).
In patients without ion channel mutations, it is believed that pro-arrhythmia is induced by
block of the potassium current l|<, (149,172). Recent studies have shed some light on the
fact why so many structurally diverse compounds block KCNH2 channels but not other
potassium channels. Because the fCCNH2 channel has a unique group of amino acids in
the S6 domain that are not present in other voltage-gated K+ channels (K^i-Ky4), many
drugs preferentially block KC/VH2 channels (9), placing patients at risk for cardiac
arrhythmias. It should be noted that acquired long-QT syndrome occurs more often in
females (150).
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Genetic diagnostic approaches in patients with acquired long-QT syndrome should be
restricted to centers with sufficient experience in the genetic identification of these
patients. The relevance of the polymorphisms is not clear yet, and there is no
well-defined set of genes that have to be analyzed. A pragmatic approach is to provide
a list of compounds that should not be used in the future and should be known to both
mutation carriers and patients with long-QT syndrome.
Summary
The congenital long-QT syndrome is a potentially life-threatening condition characterized
clinically by prolonged QT-intervals, syncope, and sudden cardiac death. The abnormally
prolonged repolarization is the result of mutations in genes encoding cardiac ion channels.
The diagnosis of long-QT syndrome is based on clinical, electrocardiographic, and genetic
criteria. Beta-blocking therapy is important in the treatment of long-QT syndrome,
although pacemakers and ICD's are useful in certain categories of patients. In the near
future, mutation-specific treatment will probably become a novel approach to this
potentially lethal syndrome.
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Chapter 2
The Cardiac Sodium Channel
XHT Wehrens
Introduction
Voltage-gated sodium (Na+) channels are transmembrane proteins responsible for the
rapid upstroke of the cardiac action potential and for rapid impulse conduction through
cardiac tissue (for review, see (1,2)). Mutations in the gene encoding the cardiac Na+
channel (SCN5A) have been linked to three forms of primary electrical disease: the long-QT
syndrome (LQTS) (3), the Brugada syndrome (BrS) (4), and cardiac conduction defects
(CCD) (5,6) . This chapter will review the physiology, molecular biology, biophysics,
pharmacology, modulation and regulation of the cardiac Na+ channel, and the relevance to
the congenital long-QT syndrome.
Sodium Channel Current
The upstroke of the action potential of cardiomyocytes and cells of the specialized
conduction system is due to a transient increase in membrane permeability to Na+ ions.
Na+ channels can be viewed upon as macromolecular protein tunnels that span the lipid
bilayer of the cell membrane, which allow ions to flow in or out the cell in a very efficient
fashion (up to 10^ per second) (7,8). This flow of ions creates electrical currents large
enough to produce rapid changes in transmembrane voltage, which is the electrical
potential difference between the cell interior and exterior. The very rapid rates of rise of the
action potentials in these cells predict that the currents responsible for these voltage
changes are rather large (about 1 mA/cm^) (8). Sodium currents were first studied under
voltage-clamp in several multicellular cardiac preparations (9,10), but have now also been
thoroughly investigated in single cell preparations (11), internally perfused canine cardiac
Purkinje cells (12), and embryonic mouse cardiomyocytes (13). Measurements of single
sodium channel activity have also been carried out in membranes of rat (14), rabbit (15),
canine (12), guinea pig (14), and mouse cardiomyocytes (16,17). Although the role of Na+
channel currents in initiating action potentials and impulse propagation is well known, it
has not been as well understood that Na^ channel activity can also contribute to the
duration of the action potential. A very small fraction of Na+ channels fail to enter the
inactivated state of the channel and thus create a small persistent current during the action
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potential plateau phase, that has been referred to as 'window current' through Na+
channels (18).
Molecular Architecture of Voltage-gated Na+ Channels
The tetrodotoxin (TTX)-sensitive Na+ channel is a heterotrimeric voltage-gated ion channel
that is highly selective for Na+ over other ions (8). The voltage-gated Na+ channel consists
of three glycoprotein subunits: a principal a-subunit of 260 kDa (19), which is associated
with a pi-subunit of 36 kDa (20,21), and linked to a |J2-subunit of 33 kDa (20,22). The
primary structure of the a-subunit consists of four homologous transmembrane domains
(DI-DIV) each containing six membrane-spanning segments (S1-S6) with a central pore
region (23-25). The region between segment 5 and 6 of each of the four domains is called
the P-region because it contributes to the pore of the channel (FIGURE 2.1).
In 1992, Gellens et al. (26) cloned and characterized the cardiac sodium channel
a-subunit gene (SCNjA). The SCN5A gene consists of 28 exons and spans approximately
80 kb on chromosome 3p2i (27,28). The SCN5A gene encodes Nav 1.5 Na+ channels, that
belong to the same family as the neuronal and skeletal muscle isoforms (29,30). Nav 1.5
channels have been detected in adult heart (hHi) (19), and in embryonic and denervated
muscle (/1S/CM2) (31). Recent observations indicate that SC/V5A is also expressed in the
brain (32,33). The expression is localized to the limbic system and certain autonomic
structures (32,33), which might implicate the cardiac Na* channel in sudden unexplained
death in epilepsy (34).
At least two a-subunit mRNA transcripts, Nav 1.1 and Nav 1.5, have been
identified in rat (19) and rabbit heart (35). Nav 1.5 cardiac Na+ channels are localized at the
cell surface and T-tubular membranes of cardiomyocytes, but also at terminal intercalated
disk membranes (36). In addition, Nav 1.1 antibody labeling was observed along Z lines in
longitudinal sections (37). Whether the subcellular localization of Na+ channels may play a
role in anisotropic or saltatory conduction, or as a localized voltage-dependent current
amplifier, remains to be established (36).
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FIGURE 2.1
Structure o/the cardiac Na* channef a and p subumts. The a subunit consists o//our homo/ogous domains, D-/ to
D-/V. Each domain consists o/six transmembrane segments, named S1-S6 (indicated in D-/j. The ro/tage-sensors
CS4 segments) important/or yo/tage-dependent activation ore indicated with '+++'. P-/oops (S5-S6) are co/ored grey
(the P-/oop o/D-// is indicated with an orroiv^. The circ/es in the P-/oops correspond with residues/orming the two rings
contributing to the outer pore and se/ecticityfitter, which are o/so important/or tetrodotox/n (/ /X) binding to the Na*
channe/. Residues important/or inactiVation, such as the (FM-moti/in the ///-/V /inter, and the docking sites /or the
/ast-inoctiVotion partic/e, ore represented with b/ack circ/es. The /oca/ anesthetic (LA) binding site in D/V-S4 is indicated
with two white circ/es. The PKA (Ser 525, Ser 528) ond PKC (Ser 1503J-binding sites ore o/so shown. The cardiac Na*
channe/ [3i and (32 subumts consist o/a sing/e membrane-spanning segment, with a short intrace//u/ar C-terminus
and a /arger ertrace//u/ar N-terminus.
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Physical Model
Few studies are available on the actual three-
dimensional structure of Na+ channels. Sato
et al. (25) were the first to perform electron
microscopy studies on the Na+ channel
isolated from E/ectropfiorus e/ectricws
electroplax (electrical eel). A higher
resolution was obtained using helium-cooled
cryo-electron microscopy and single-particle
image analysis of solubilized Na+ channels
(38). The channel has a bell-shaped outer
surface of 13.5 nm in height and 10.0 nm in
side length at the square-shaped bottom,
and a spherical top with a diameter of 6.5
nm (FIGURE 2.2). Several inner cavities are
connected to four small holes and eight
orifices close to the extracellular and
cytoplasmic membrane surfaces.
FIGURE 2.2
Surface representation o/the
No* channe/ prolem (A-D).
(AJ Top woo, (BJ Side f/eiv,
(CJ Bottom view, fDJ View at an
ob/ique ang/e. Aria/ section (Ej
and perpendicu/ar section (F^
marked by the b/acfc arrow in E.
The white arrows in C and F
indicate the centra/ pore o/the
Na* channe/. White fears
fin B and Ej de/ineale the /ipid
bi/ayer. Sco/e bar, 5.0 nm.
Adapted/rom (38J.
Channel Permeation
The first functional view of the Na+ channel was formulated by Hodgkin and Huxley (7) on
the basis of voltage-clamp experiments, and provided a rationale for excitability based on
the elementary properties of cation permeat/on (flux through the pore) and gating (dynamic
conformational changes in response to membrane potential fluctuations). Although their
physical model to explain transient membrane current was revolutionary at the time it was
published (FIGURE 2.3), current theory involves a much more complicated scheme of
conformational states underlying sodium channel function (39).
The Na+ channel pore is the region of the molecule that is specialized to
recognize Na+ ions and to catalyze their transfer across the membrane. The central ion-
conduction pore of the Na+ channel is lined by the S5-S6 linkers (P-loops) from each of the
four domains of the channel. These loops, which are highly conserved among various
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FIGURE 2.3
The Hogdlcin-HuWey mode/ 0/
No* chonne/ gating. The upper
trace shoifs a vo/tage step and trie
middfe trace, trie resu/ting
membrane current. The /oiver
pone/ shows a p/iysica/ mode/ to
account /or the transient current.
(n the resting state, the activation
gate (m) is in the c/osed position
and the inactive tion gate (ty is in
the open position. /tyter
depo/ofizalion, the m gate
assumes the open position,
sodium ions moiv into the ce//.
The h gate then moi<es into the
c/osed position b/ocking ion
movement. When the membrane
is returned to the resting /eve/, the
m gate mot'es into the c/osed
position (deartiVation^. A/ier a
variab/e interva/, the h gate mows
into the open position (recovery
/rom inact/Vation) (courtesy 0/
Dr A Grant (45JJ.
RESTINC OPEN INACTIVATED
species, determine selectivity and conductance properties of the channel (40). Each of
these four P-loop domains has a unique primary structure and a different positioning
relative to the permeation pathway (41-43). Cysteine scanning accessibility mutagenesis
experiments suggest that the domain II pore loop is most superficial, domains I and III
intermediate, and domain IV distinctly deeper, judged by the voltage-dependence of Cd*+
block of the mutated Na+ channels (41). Motions in the Na+ channel pore were
demonstrated by introducing pairs of cysteine residues throughout the pore-lining segment
(44). Domains I and II were found to be closely apposed, because of their ability to form
disulfide bonds, which implies protein dynamics that allow at least occasional proximity.
Outer Pore and Selectivity Filter
The segments that line the pore and define the ion selectivity and conductance of the Na+
channel have been identified. The extracellular mouth of the pore plays an important role
in TTX and saxitoxin (STX) binding to the Na+ channel (8). These toxins are small rigid
molecules of known crystal structure and have been proven crucial in defining the ion
conduction pathway of sodium channels (45). Noda et al. (46) and Terlau et al. (47)
identified residues in the ascending limb of the P-loop (the most important one being
Clu 387 in brain type II sodium channel) using site-directed mutagenesis that impair
affinity for TTX. These residues are likely to surround the extracellular opening of the pore
and contribute to a receptor site for TTX.
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In addition, a second ring of four amino acids located three residues on the amino
terminal site of these is also required for TTX binding (48). The cardiac isoform of the Na"*"
channel is relatively resistant to TTX (IC^ in u.M range) when compared to the brain and
skeletal muscle isoforms (IC50 in nM range). A cysteine at position 373 in the cardiac
isoform (in the P-loop of domain I) is responsible for this phenomenon (49)(FIGURE 2.1) .
The same amino-acid difference is also responsible for the susceptibility of the heart
isoform to C d ^ block, compared to the relatively insensitive neuronal and skeletal muscle
isoforms (50). In addition, mutation of only one amino-acid in the P-loop of domain III
(K1419 in SCN5A) is sufficient to confer Ca*+-channel-like properties to the Na+ channel
(40). Mutations of the tetrad WDCL (amino-acids 1713-1716 in SCN5A) in the D-IV P-loop
affect selectivity among monovalent cations (41).
Na + Channel Gating
Voltage-dependent Activation
Activation of the voltage-gated Na+ channel is thought to result from a voltage-driven
conformational change that opens a transmembrane pore through the protein. The
voltage-dependence of activation of the Na+ channel derives from the OUTWARD
MOVEMENT OF CATING CHARGES in response to changes in the electrical field (7,51).
Recent studies indicate that approximately 12 electronic charges in the Na+ channel protein
move across the membrane electric field during activation (52). Because sequence analysis
of the Na+ channel a-subunit revealed that the fourth transmembrane segment (S4) in
each of the four domains contained repeated motifs of a positively charged residue
followed by two hydrophobic residues, it was postulated that the S4 segment might serve
as the key voltage-sensor that underlies channel activation (53,54), which was subsequently
confirmed by mutagenesis studies (55-57). Changes in transmembrane potential exert a
force on these gating charges, and initiate conformational changes in each domain of the
channel protein that lead to activation.
In the process of activation, several charged residues in each S4 segment actually
transverse the membrane through a narrow tunnel formed by other, not yet identified
regions of the channel (58,59). The sliding helix (60) or helical screw (61) models of gating
propose that these positively charged amino residues are stabilized in the transmembrane
Membrane dcpo/onzaiion causes
outiford movement o/tfie
pos/tiVe/y-criflrged S4 segments,
u'h/c i^ /cads to chonne/ acl/Vot/on.
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environment by forming ion pairs with negatively charged residues in adjacent
transmembrane segments. Depolarization of the membrane was proposed to release the
S4 segments to move outward along a spiral path, initiating a conformational change that
opens the pore. Although this model was quite speculative when it was proposed, its major
features have now received direct experimental support from work on both sodium and
potassium channels (58,59,62).
Fast Inactivation
Voltage-dependent inactivation of Na+ channels is a consequence of the voltage-dependent
activation (51,63). Inactivation is characterized by at least two distinguishable kinetic
components, an initial rapid component (fast inactivation) and a slower component (slow
inactivation). Using site-directed mutagenesis (55,64) and peptide-specific antibodies (65),
the cytoplasmic linker between domains Ml and IV of the Na+ channel a-subunit has been
identified as a key structural component that contributes to fast inactivation. This
cytoplasmic linker serves as the inactivation gate that occludes the Na+ channel pore from
the cytoplasmic side of the membrane during maintained depolarization (so-called 'ball-
and-chain' model) (51). The residues that form a hydrophobic triplet (IFM) in the III-IV
linker are involved in inactivation gating (64). The IFM motif has been suggested to
function as a 'latch' that holds the inactivation gate shut. A cysteine scanning study of the
residues I1485, F1486, and M1487 in the human cardiac Na+ channel revealed that these
amino-acids contribute to stabilizing the fast-inactivation particle in analogy to the brain
Na+ channel (66-68). However, peptide-binding studies suggest that inactivation may not
involve simple occlusive block of the inner mouth of the pore (69). Glycine and proline
residues that flank the IFM motif may serve as molecular hinges to allow closure of the
inactivation gate like a hinged lid ('hinged-lid model') (64,70).
Mutagenesis studies have identified a number of additional residues that reside
in cytoplasmic loci consistent with 'docking sites' for the inactivation gate. Residues on S6
segment of domain IV form part of the intracellular mouth of the pore, and are thought to
form part of the hydrophobic receptor site for the inactivation gate (71) or may stabilize the
inactivated state through an indirect mechanism (72). Residues in cytoplasmic loops
proximal to the III-IV linker including the domain III (73) and domain IV S4-5 loops also
may form part of the 'docking site' (69,74-76) (FIGURE 2.1).
Slow Inactivation
In most published SCHEMES OF THE CARDIAC NA+ CHANNEL, slow inactivation follows fast
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inactivation (39). Structural determinants of slow inactivation are less well known. The
slow inactivation mechanism is unaffected when fast inactivation is prevented by protease
treatment (78) or when movement of the inactivation gate is blocked by specific antibodies
(65), and therefore likely to be an independent gating process. It has been shown that
transposition of all four cardiac isoform P-loops into the human skeletal muscle isoform
(hSfeMi) backbone conferred heart isoform-like slow inactivation properties on the chimeric
construct, suggesting a role for the P-loops in slow inactivation (79,80). Changes in
flexibility of the P-loops may affect slow inactivation (81). Recently, a single residue in the
D-ll P-loop of the cardiac Na+ channel (I891) has been shown to regulate the steady-state
ability of slow inactivation (82). It is suggested that slow inactivation in Na+ channels
involves conformational changes in the outer pore in a fashion analogous to C-type
inactivation in K+ channels (83-85). On the other hand, it has been suggested that other
voltage-dependent structures play a role in slow inactivation. A region near the midpoint of
the S4 segment of D-IV has been shown to play an important role in slow inactivation
(86,87), and suggests a role of S4 segments in slow inactivation.
Coupling of Activation to Inactivation
In neuronal tissue, sodium channel inactivation derives most of its voltage-dependence
from coupling to the activation process driven by transmembrane movements of the S4
voltage sensors (51,197). In heart tissue, however, the thesis has always been defended that
the coupling between activation and inactivation is relatively weak. While channels can
inactivate from a closed state, inactivation is facilitated by previous opening of the channel
(39). There is accumulating evidence that outward movement of the S4 segment in
domains III and IV is the signal to initiate fast inactivation of the sodium channel by
closure of the intracellular inactivation gate (68,88-90). An alternative mechanism based
on physical interaction between regions on the S4-S5 linker of DIV and the DIII-DIV
inactivation particle has also been proposed (75,76). Such an association could be
sensitive to changes in the conformation of S4-S5 of DIV, which are the result of movement
of the voltage sensor of that domain during activation. This could lead to a change in the
position of the inactivation gate relative to its docking sites.
Inner Pore and Local Anesthetic Binding Site
Class I antiarrhythmic drugs such as lidocaine, quinidine, and flecainide (91,92) act by
inhibiting ionic currents through Na+ channels. Tertiary amine local anesthetics, such as
procaine and etidocaine, which are chemically related to lidocaine, act in a similar manner.
IF ?± IS
C3 ^ C2 ^ Cl ^ O
Markov model o/tbe sodium
c/iflnne' (39). C-c/osed state;
O-open state; /F=/ast-inact/i>ated
state; IS-s/oivinactiVated state.
fnactiVation can a/so occur/rom
the dosed state in l/ie absence 0 /
chonnW opening fso-caffed c/osed-
state inactiVation O - » / f ) .
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The efficacy of these drugs stems from their ability to selectively inhibit Na+ channels
during abnormal membrane depolarizations and rapid bursts of action potentials that
characterize cardiac and neuronal pathologies (93).
It is thought that the selectivity of local anesthetics (LA) and antiarrhythmic drugs
for depolarized Na+ channels results from the preferential binding of these drugs to open
and/or inactivate channel states that predominate at depolarized membrane potentials,
rather than the resting channel states that predominate at more hyperpolarized membrane
potentials. The state-dependent drug action can be explained by an allosteric model in
which a modulated drug receptor is in a low affinity conformation when the channel is
resting, and converts to a high affinity conformation when the channel is open and/or
inactivated (93,94). This concept is often being referred to as the 'modulated receptor
model' (93,94), and attributes the complex time- and voltage-dependent effects of LA and
antiarrhythmics to distinct binding affinities for the three putative gated conformational
states of the Na+ channel (closed - opened - inactivated) (7). Mild suppression of Na+
current during, isolated, brief depolarizations is attributed to low affinity binding for the
closed channel conformation (tonic block), while far greater current suppression during
repetitive depolarization, also known as USE-DEPENDENCE (95), is attributed to binding to
states occupied during depolarization (either open or inactivated). Importantly, this model
implies not only distinct high and low affinity drug-receptor sites, but also a complex
interrelationship between channel gating and drug action. Lipid-soluble drug forms are
thought to reach the receptor via a hydrophobic region of the membrane, while charged
and less lipid-soluble forms pass via a hydrophylic region (inner channel mouth). The
hydrophilic pathway is open only when the sodium channel opens.
Hille (94) has proposed that the binding site for both neutral and charged drugs
that are used as local anesthetics and antiarrhythmic agents lies between the channel gates
and the selectivity filter. Starmer et al. (96) have attempted to simplify and formalize some
of these concepts mathematically. Thus, in their 'guarded receptor model', the binding site
is guarded by the channel gates; a drug can bind to its receptor (and inhibit current) only
after the gate is open and the receptor is unguarded.
Local anesthetics and related anti-arrhythmic drugs are thought to bind to a
receptor site on the Na+ channel that is accessible only from the intracellular side of the
membrane, and is more accessible when the Na+ channel is open (8,97). Mutagenesis
experiments of Na+ channels revealed that the local anesthetic receptor is confined to the
DIVS6 segment (98,99). High-affinity binding of local anesthetics to the inactivated state
of the Na+ channel requires two critical amino acid residues, Phe-1764 and Tyr-i77i,
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DIV-S6
located in the DIVS6 transmembrane P-LOOP
segment in the brain HA channel
(corresponding to F1760 and Y1767 in
SCN5/\) (99). The current concept is that the
tertiary amino group of local anesthetics
interact with Phe-1764, which is located
deeply in the pore, and that the aromatic
moiety of the local anesthetics interact with
Tyr-1771, which is located nearer to the
intracellular side of the pore (99) (see
FIGURE 2.4). It is noteworthy that at least
one of the residues implicated in LA block
(F1764) importantly affects inactivation
gating (71,72). While it is likely that DIVS6
forms part of the local anesthetic receptor,
the fact that mutations in this location also
influence inactivation gating makes it
difficult to exclude the possibility that some
of the mutational effects on drug action are indirect. In support of this observation, recent
studies have shown that mutations in the outer pore, C-terminal to the selectivity filter and
putative LA binding site, alter inactivation and LA block (100,101).
C-TERMINUS
FIGURE 2.4
Proposed orientation o/omino
acids in the sixth transmembrane
segment o / D / V o / t h e No*
channel with respect to bound
/oca/ anesthet/c mo/ecu/e in the
conduction pore. The D/V pore
/oop, ivh/ch probob/y a/so
contributes to the receptor site,
is shown as we//. Amino acid
positions 1760, 1764, and 177' <"*
shown/acing the pore lumen.
From: (1OJ,|.
Modulation by Auxiliary (3-subunits
Auxiliary (i-subunits do not form the ion-conducting pore but rather modulate channel Na*
gating and cell surface expression levels, and interact with extracellular matrix and cell
adhesion molecules (103). Although no mutations in (3-subunits have been linked to one of
the inherited arrhythmogenic syndromes, a mutation in the |3i gene (SCN70) (104,105) has
been implicated to play a role in febrile seizures and generalized epilepsy (34).
Brain sodium channels are composed of a single pore-forming a-subunit, non-
covalently bound to a 31-subunit, and linked to the (32-subunit by a disulfide bond, in a
1:1:1 stoichiometry (20,22,62,106). Expression of the Na+ channel a-subunit alone resulted
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in functional sodium channels (65). Co-expression studies of brain Na+ channel a-subunits
with the pi-subunit have demonstrated larger peak 1^, amplitude, acceleration of
activation and inactivation, and a more negative voltage-dependence of steady-state
inactivation than the a-subunit expressed alone (21,104,107-110).
The subunit structure of cardiac sodium channels has been controversial for a
long time. Recently, however, Malhotra et al. (37) determined that cardiac Na+ channels in
rat and mouse cardiac myocytes are composed of a-, pi- and p2-subunits. In addition,
a 33-subunit has been identified in human and rat heart (111), and a splice-variant of the
pi-subunit (PiA) has been identified in rat heart (112). Their functional roles in modulating
cardiac sodium channels, however, remain to be determined.
Nav 1.5 Na* channel and Pi co-expression has been studied in heterologous
expression systems with variable and conflicting results (104,108,110,113-115). When
expressed in Xenopus oocytes, Nav 1.5 channels alone show gating and blocking properties
comparable to native Na+ channels (49). While studies consistently show that Pi-subunit
coexpression in Xe/iopus oocytes enhances the current magnitude, studies differ in regard
to whether gating effects are present (110) or absent (n6). Some groups have reported
that pi has no observable effects on Nav 1.5 functional expression (104,108), while other
reported modulation of channel sensitivity to lidocaine block and subtle changes in
channel kinetics and gating properties in response to pi expression (37,114,115). The recent
study by Malhotra et al. (37) showed that in HEK cells, co-expression with pi shifts the
voltage-dependence of inactivation, whereas P2 does not. The voltage-dependence of
activation is not modified by p-subunit coexpression (37). A possible explanation for the
inconsistent results reported in previous studies is that some HEK cell lines express
endogenously the pia-subunit, which could confound the electrophysiological
measurements (117). Finally, rat Nav 1.1 a-subunits are also modulated by Pi- and P2-
subunits when expressed in oocytes (118).
Structural correlates for the noncovalent a-Pi subunit interaction are thought to
reside on the extracellular and intramembraneous domains of the Pi-subunit (119-121) and
domain I and IV P-loops within the a-subunit (80,120,122). McCormick (121) showed that
the immunoglobulin (Ig)-fold of the Pi extracellular domain serves as a scaffold that
presents charged residues or interaction with the a-subunit. In addition, the cytoplasmic
C-terminal domain of the a-subunit has been implicated to play a yet unknown role in the
interaction with the pi-subunit (115,120).
Cardiac P-subunits, which are type I topology membrane proteins (123),
are characterized by one large extracellular domain at the aminoterminus, a single
Noye/ /nsighls in t/ie Congemta/ Long O_7"-j Syndrome | PACE 50
transmembrane region, and a shorter intracellular C-terminal domain (124). A surprising
finding from determination of the primary structures of the Bi and p2-subunits (21,22) was
their close relationship to the large family of cell adhesion molecules of the
immunoglobulin superfamily (125). No other auxiliary subunits of ion channels have
related structures (62). Both B-subunits interact with extracellular matrix molecules and
participate in homophilic cell adhesion, resulting in cellular aggregation and recruitment
of ankyrin to the plasma membrane at point of cell-cell contact (103). The presence of
B-subunits in cardiac myocytes may facilitate sodium channel localization and clustering to
discrete functional domains via cell-adhesive interactions. Interestingly, the putative
cytoplasmic region of both pi and P3 contains a sequence YLAI 16 amino acids from the
end of the predicted transmembrane sequence. The position and sequence of this motif
fits the consensus for an internalization signal recognized by clathrin-coated pits,
suggesting a possible role for P-subunits in the movement of sodium channels between
cellular compartments (m).
Ankyrins are a family of spectrin-binding proteins associated with the cytoplasmic
surface of the plasma membrane in many cell types. Ankyrins associate via their
membrane binding domains with several ion channels (126). Sodium channels in ankyring-
knockout mice display a reduced current density and abnormal Na+ channel kinetics that
lead to action potential prolongation and abnormal QT-rate adaptation (17), suggesting
that a proper functional localization of Na+ channels is essential. In line with these results,
Undrovinas et al. (127) have demonstrated that breakup of the actin-based cardiomyocyte
cytoskeleton with cytochalasin D produced late Na* current at hyperpolarizing test
potentials, and suggested a role for the cytoskeleton in regulating Na+ channel gating.
Transcriptional and Posttranslational Modification
of Na + Channel Expression
Transcriptional Control of Na+ Channel Cene Expression
Control of excitability can occur at the genomic level by transcriptional regulation of ion
channel genes. The expression of Na+ channels is developmentally regulated (13) and
tissue restricted. Patterns of certain electrical activity can also influence transcriptional
activity, e.g. seizures alter Na+ gene expression in the brain (128). Denervation induces the
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expression of the cardiac isoform of the Na+ channel in skeletal muscle, while transiently
suppressing the expression of the mature skeletal muscle isoform (31). Chronic exposure
to antiarrhythmic drugs which block Na+ channels can increase the steady-state levels of
Na+ mRNA, which would counteract the effects of channel blockade (129). In addition,
chronic treatment with n-3 polyunsaturated fatty acids, which are known to prevent fatal
ventricular arrhythmias (130), reduced mexiletine-induced increase in cardiac Na+ channel
expression in cultured neonatal cardiac myocytes (131). Finally, an increased expression of
neuronal subtype Na"*~ channels was identified in post myocardial infarction remodeled
myocardium, with a reversion toward the fetal phenotype (132).
Post-translational Modification of Na+ Channel Expression
All Na+ channel subunits are modified by glycosylation. The (3i, (32, and brain and muscle
a-subunits are heavily glycosylated (25-40%) (133,134), whereas the cardiac a-subunit is
composed by 5% carbohydrates (135). Sialic acid is a prominent component of the N-linked
carbohydrate of the Na+ channel. Neurominidase treatment to remove sialic acid from
expressed skeletal muscle channels produces a depolarizing shift of steady-state
inactivation (136). Local surface charge is also importantly influenced by charged amino
acid residues that stud the outer mouth of the pore, although the predominant effects in
this case are on permeation rather than gating (41,47). Recently, it has been shown that
incomplete glycosylation during post-translational processing may contribute to Na+
channel-dependent arrhythmogenesis in mice with heart failure (137).
Regulation of the Na+Channel
There is evidence that the cardiac IMa* channel may be the target of modulation by cAMP-
dependent protein kinase A (PKA) and protein kinase C (PKC), although the experimental
evidence for modulation of this channel is not as well established as it is for other ion
channels. Cyclic nucleotide-dependent phosphorylation sites have been mostly studied in
the a-subunit of the voltage-gated brain sodium channel type IIA (138-140). Within the
intracellular linker region between DiS6 and D2S1 (ID 1-2) of the a-subunit of the rat brain
IIA sodium channel five sites matching PKA consensus sequences are found (141), four of
which have been shown biochemically to be involved in PKA phosphorylation of the
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FIGURE 25
Structure o/the cardiac No*
channel asubun/l. Indicated iw'th
the c/rc/cs are long-QT syndrome
mutations ivith the respecln'e
am/no-acid substitutions or
deletions. The tvfiite circ/es
represent mutations that have
been characterized
e/ec1ropnysio/ogica//y, grey circ/es
haiv not been characterized yet,
and block circles represent
mutations characterized in this
thesis.
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channel (119,140). Phosphorylation at the second PKA site (Ser 537) is necessary and
sufficient to diminish amplitude in brain Na+ channels (141).
The cardiac sodium channel has eight candidate consensus PKA phosphorylation
sites of the form KRXXS*, RXXS*, or RXS* in the l-ll linker, all of which are distinct from
the neuronal channel, /n wtro studies of expressed rat cardiac Na+ channels demonstrated
cAMP-dependent phosphorylation of only two of these serines (Ser 526 and Ser 529,
corresponding with Ser 525 and Ser 528 in the human isoform) (142). Phosphorylation by
PKA at these sites augments the Na+ current (142-144), by increasing the number of Na^
channels in the plasma membrane (145,146). Modulation of cardiac Na+ channel gating
has also been demonstrated, including changes in the voltage-dependence of channel
activation and inactivation (146-149).
The effects of upstream receptor-activated stimulation are less clear, with both
increases and decreases in current being reported after treatment with cAMP-elevating
agents or membrane-permeant cAMP analogs (148). In addition to the indirect pathway
mediated by C-proteins acting through second messenger cascades, a direct membrane-
delimited G-protein regulatory pathway involving direct interaction of the stimulatory
G-protein a-subunit with the cardiac Na"^  channel has been proposed (144,145,147,148,150).
Protein kinase C (PKC) also modulates cardiac Na+ channels, both reducing the maximal
conductance of the channel and altering gating. Both effects are largely attributable to
Chapter 2 | PACE 53
phosphorylation of a serine residue in the 111-1V linker that is conserved in the neuronal and
cardiac isoform (151). Interestingly, while PKC phosphorylation of this residue reduces Na+
current in both isoforms, the gating defects diverge. Phosphorylation of Serine 1503 in the
cardiac isoform induces a negative shift in the voltage-dependence of steady-state
inactivation (implying stabilized inactivation), while in brain Na+ channels,
phosphorylation of the same residues slows and destabilizes inactivation (64,151).
Because the III/IV linker sequences are conserved, interaction of the phosphorylated
serine with other domains may differ for the two isoforms.
Slip-mode Conductance of the Cardiac Na+ Channel
Nav 1.5 Na+ channels can become permeable to Ca^ + after activation of protein kinase A
(152). This slip-mode conductance of the Na+ channel only occurs in transfected cells in
the presence of both pi and fte-subunits (153). The Ca*+ flux through this pathway can
increase subcellular Ca*+ and thereby activate sarcoplasmatic reticulum (SR) Ca*+ release,
Ca*"*" sparks, and the Ca*+ transient. This is an intriguing finding, as consensus PKA sites
are remote from the pore and selectivity filter. Yet sympathetic stimulation results in a
dramatic change in the calcium selectivity of the sodium channel. The mechanism involved
in this potentially physiologically important phenomenon remains to be further
established.
Long-QT Syndrome Na + Channel Mutations
Mutations in the cardiac Na+ channel ot-subunit gene SCN5A were linked to LQTS by a
candidate gene approach and positional cloning (3). First, the LQT-3 locus was mapped to
chomosome 3P21-24 (154). Subsequently, the SC/V5A gene was mapped to chromosome
3p2i (28), and mutations in SCN5A were linked to type 3 LQTS (3).
Seventeen distinct mutations associated with LQT-3 (see FIGURE 2.5) have been
reported to date. The first mutation discovered was a 3-amino acids deletion (residues
1505-1507) in the cytoplasmic linker region between Dill and DIV of the Na+ channel
a-subunit (AKPQ mutation). Other mutations involve amino acid substitutions (n=i5) and
a deletion (n=i) (TABLE 2.1). In this thesis, the biophysical properties of D1790C, and the
novel E1295K and L619F mutant LQT-3 Na+ channels will be described (FIGURE 2.5; and
CHAPTERS 3, 5, and 6).
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AKPQ Mutation (Deletion K1505, P1506, Q1507): Defect in the Inactivation Lid
The first functional phenotype reported, and hence the 'prototypical LQT-3 phenotype' is
caused by the AKPQ mutation (28,64). Using two-electrode voltage-clamp recordings from
Xenopus /oef/s oocytes, a TTX-sensitive persistent Na+ current of less than 5% of the peak
inward current was identified during prolonged repolarizations (28). In addition, time
constants for current decay were decreased in the AKPQ mutant, and there was a -6 mV
shift of the potential at which half of the current is inactivated (28). At the single channel
level, brief dispersed reopenings and infrequent long-lasting bursts of openings were
responsible for the macroscopic non-inactivating Na+ current (28,165,166). AKPQ mutant
Na+ channels were also studied in human embryonic kidney (HEK) cells using whole-cell
patch-clamp analysis (158,166,167). The presence of a non-inactivating Na+ current during
prolonged depolarizations was confirmed. In HEK cells, current inactivation was speeded,
recovery from inactivation faster, and the voltage-dependence of inactivation shifted
towards more negative potentials (158,166).
Nucleotide
change
AA2971TC
C3340A
C3911T
A3974C
C4138A
C4501C
del45ii-45i9
del485O-4852
C4868A
G4868T
C4931A
G4934T
G5329A
G5349A
G5360A
A5359G
A5384G
Aminoacid
substitution
S941N
D1114N
T1304M
N1325S
A1330P
L1501V
deli5O5-i5O7
delFi6i7
R1623Q
R1623L
R1644H
T1645M
V1777M
E1784K
S1787N
D1790G
Y1795C
Channel
domain
DII/DIII
DII/DIII
DIII/S4
DIII/S4-5
DIM/S4-5
DIII/DIV
DIII/DIV
DIV/S3-4
DIV/S4
DIV/S4
DIV/S4
DIV/S4
C-terminus
C-terminus
C-terminus
C-terminus
C-terminus
Exon
16
18
2 2
23
23
26
26
28
28
28
28
28
28
28
28
28
28
NoofRW
families
1
1
1
1
1
1
4
1
2
1
2
1
1
2
1
1
1
Reference
(155)
(156)
(157)
(158)
(159)
(156)
(3)
056)
(156,160)
(156)
(156,158)
057)
(161)
(156,162)
(156)
(163)
(164)
y
TABLE 2.1
Summary o/a// pub/isried
S C N ^ mutations.
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N1325S and R1644H Mutation: Defect in Inactivation Lid Docking Site
The N1325S mutation occurs in the S4-S5 region of domain III, R1644H near the
cytoplasmic end of the S4 segment of domain IV. Both regions are highly conserved
between the cardiac, skeletal muscle, and brain Ha isoforms suggesting their importance
(26,53,168). Both the N1325S and R1644H mutations lead to persistent, non-inactivating
Na+ current (158,165). The N1325S mutation also causes a negative shift in the voltage-
dependence of inactivation and slower recovery from inactivation (158,165). Interestingly,
mutation T1645M (directly adjacent to residue R1644) in the first cytoplasmic residue of
the S4-S5 linker in domain IV has also been associated with LQT-3 (157).
S941N Mutation: Sudden Infant Death Syndrome
The sporadic SCN5A mutation S941N was identified in a 44-day old infant with congenital
LQTS, resuscitated from ventricular fibrillation. The aspartate at amino-acid position 941
(Asp94i) is located in the highly conserved intracellular loop between the second and third
transmembrane domains of SCN5A (27). When expressed in Xenopus oocytes, this
mutation was characterized by a late sodium current of 1.8-2.5% (155)- The mechanism by
which a substitution in this part of the channel protein leads to a persistent inward current
is not yet understood.
R1623Q Mutation: Uncoupling of Activation-inactivation
The de no^o missense mutation R1623Q was identified in a Japanese girl severely affected
by a sporadic form of the long-QT syndrome (169). The positively charged R1623 is the
outermost residue of the S4 segment of domain IV. When expressed heterologously in
Xenopus oocytes, a small non-inactivating current was found at the end of the 100 ms
depolarizations (< 3% of peak current) (170), comparable to previously described LQT-3
mutations. Striking difference between R1623Q and WT current was a slowed rate of
macroscopic current decay, a unique feature not observed in other mutations reported in
familial LQTS mutations (28,158,165).
During single channel recordings, the R1623Q exhibited multiple, prolonged
openings early in the depolarization period, which give rise to the slow decay. The ability of
open channels to inactivate is impaired (160,170). The underling mechanism may involve
uncoupling activation from inactivation (59,171). In addition, Kambouris et al. (172)
reported that the voltage-dependence of availability of l^ a was shifted to more negative
potentials when expressed in Xenopus oocytes, indicating that inactivation from closed
states is increased. A slowing of open-state inactivation with co-existent enhancement of
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closed-state inactivation for this SCN5A mutation is consistent with gating phenotypes
reported for mutations in the domain IV-S4 segment of the human skeletal muscle Na+
channel (hS/cMi) linked to paramyotonia congenita (171,173). The precise mechanism of
impaired inactivation of the R1623Q mutation may be a functional defect in activation-
inactivation coupling of the Na+ channel that has been previously reported in the
paramyotonia congenita mutations R1448H/C (65).
Genetic analysis of LQTS families enrolled in the International Long-QT Registry
has indicated that the C-terminus of the SCN5A gene is a hot-spot for LQT-3 mutations
(156). Approximately 30% of all LQT-3 mutations have been identified in this part of the
Na+ channel.
E1784K Mutation: C-terminal Mutation
The E1784K mutation occurs in a highly conserved acidic domain immediately following
the D4/S6 segment, within the carboxy terminus of the cardiac Na+ channel (162).
Electrophysiological analysis of E1784K channels in Xenopus oocytes (162) and HEK cells
(174) revealed a 2-4% maintained Na"*" current, a -12 mV negative shift in the V,^ of steady-
state inactivation, and a faster recovery from inactivation. These results suggest a
destabilization of the inactivated state of the Na+ channel. Additional mutagenesis
experiments in the early C-terminus domain suggest that the biophysical mechanism may
be allosteric rather than caused by direct interference with channel-gating properties (162).
The early part of the C-terminus (adjacent to DIV-S6) of the human cardiac Na+ channel
has clusters of negatively charged amino acid residues (162). Little research has been
performed as to the function of this highly conserved segment of the Na+ channel. The
accentuation of the functional defect by the pi-subunit was observed in the E1784K and the
nearby D1790G mutations. It is, however, difficult to reconcile these findings with the work
of other groups demonstrating that the cytoplasmic domain of the (ii-subunit might not
be required for its functional effects on mammalian sodium channels (119-121).
D1790C Mutations: Impaired a - Pi Subunit Interaction
The D1790C (negatively charged aspartic acid to a neutral glycine) mutation is also located
in the C-terminal part of the channel (163). In contrast to most other LQT-3 mutations, it
does not lead to a sustained Na+ current when studied in a heterologous expression
system (115). Although a disturbed interaction between the a and pi-subunit of the cardiac
Na+ channel were suggested to cause the D^goG phenotype, the exact mechanism by
which this mutation may lead to an arrhythmogenic phenotype remained to be established.
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In CHAPTER 3 of this thesis, novel insights in the electrophysiological consequences of this
mutation will be described. . -
Interestingly, the mutation Ei784K (negatively charged glutamic acid to positively
charged lysine), located only 6 aminoacids away from D1790G, does lead to sustained
inward current. In contrast, the mutation E1784D (a mutation conserving the negative
charge) was indistinguishable from wild-type current with respect to sustained current
(174). This implies that subtle changes in amino-acid charges in the early carboxyterminal
domain may have profound effects on gating of the cardiac Na+ channel.
Arrhythmogenic Mechanism of the Non-inactivating Na+ Current
The fact that several LQTS Na+ channel mutations spanning nearly the entire a-subunit,
modify fast inactivation suggests that Na+ channel inactivation depends upon complex
ensembled interactions among many structural domains. Incomplete inactivation leading
to persistent inward current has been shown to be a common consequence of most of the
identified SCN5A mutations (28,158,160,162,165-167,170). This resultant non-inactivating
component of Na+ channel current exceeds the physiological levels of Na+ current during
the action potential plateau phase (18,175).
Using a single-channel based MARKOVIAN computational model, Clancy and Rudy
(39) were able to demonstrate elegantly that sustained Na+ current during the plateau
phase of the action potential may lead to arrhythmogenic consequences at the cellular
level. Although the amplitude of the persistent current is very small, only 1% of the peak
l^a. it is sufficient to shift the delicate balance of currents that exists during the action
potential plateau (176-179). The additional current carried by sodium acts in opposition to
repolarizing outward currents and prolongs the APD (39).
Molecular Pharmacology of LQT-3 Na+ Channel Mutations
The precise identification of genetic defects that cause different forms of LQTS opened up
the possibility of discovering new therapeutic approaches to the management of this
disorder based on the molecular pharmacology of the mutant ion channels encoded by the
specific gene defects (180). Because it is possible to investigate the functional properties of
the mutant genes using heterologous expression systems, /n w'tro tests can be carried out
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to identify unique drug-channel interactions that may occur as a consequence of the
interrupted gene defect and that may be exploited to devise novel pharmacological
approaches to disease management (CHAPTER 4).
Class IB antiarrhythmics, such as lidocaine and mexiletine, are drugs that block
Na+ channels in a voltage-dependent manner. As discussed previously, channel block
depends on the state of the channel in a complex manner, being influenced by the relative
number of resting, open, and/or inactivated channels (93,94,181). Because certain Na+
channel mutations that underlie LQT-3 have been shown to modify inactivation (28), it is
very likely that these mutant Na+ channels will be modified in a unique manner by local
anesthetic drugs.
There have been several reports indicating that such a specific interaction is
indeed clinically relevant. Experiments carried out in transfected HEK cells (180) and
Xenopus oocytes (182) revealed that maintained Na+ current through non-inactivating
mutant channels was more sensitive to local anesthetic block than peak inward current.
This suggests that Na+ channel current that underlies impulse conduction (peak current)
will be less sensitive to class IB drugs than currents that underlie QT prolongation in
carriers of LQT-3 gene mutations. This observation has been reinforced in preliminary
clinical pharmacological studies (183,184). Schwartz et al. showed that the class IB agent
mexiletine effectively shortens the QT-interval of patients identified as carriers of the
SCN5A gene mutations AKPQ and R1644H (183). In addition, Rosero et al. (184) reported
QT-interval shortening in two AKPQ carriers by short-term intravenous lidocaine and long-
term oral tocainide therapy.
When more LQT-3 Na+ channels were characterized electrophysiologically, it
became clear that class IB Na+ channel blockers might not constitute a universal approach
to LQT-3. As predicted on the basis of the absence of maintained current in D1790C
mutant Na+ channels (115), lidocaine did not correct QT-interval prolongation in two
patients with the D1790C mutation (185). However, the class IC antiarrhythmic agent
flecainide did shorten QT-intervals and other repolarization parameters in D1790C
mutation carriers significantly (185). The molecular basis of this observation is the subject
of CHAPTER 4 in this thesis.
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Other Arrhythmogenic Syndromes Caused by Na+ Channel
Mutations
Na+ channel mutations can also cause the Brugada syndrome, a hereditary cardiac disease
characterized by right bundle-branch block (RBBB), an elevation of the ST segment in leads
Vi through V3 on the electrocardiogram, and ventricular fibrillation that can lead to sudden
cardiac death (186). In patients with Brugada syndrome, missense mutations T1620M (4),
R1512W (174), A1924T (187), splice-donor, and frameshift mutations have been identified in
SCN5A (4). For further information on the electrophysiological phenotypes of these
Na+ channel mutations, the reader is referred to the reviews by Bezzina et al. (2) and Vatta
etal. (188).
Although LQTS and Brugada syndrome are known as distinct disorders, a recent
study reported a mutation in the SCN5A gene that causes both syndromes (189). An in-
frame insertion of three nucleotides in the carboxyterminal region resulting in an additional
aspartate at position 1795 was found to be responsible for this 'overlap syndrome'.
Subsequent reports described the biophysical phenotype of this Na+ channel mutation
(190,191).
Progressive slowing of cardiac conduction is a common electrophysiological
manifestation of the progressive fibrosis in the conduction system of elderly patients (192).
Progressive cardiac conduction disease (PCCD) or Lev-Lenegre syndrome, was first
recognized as such by Drs. Lev (193) and Lenegre (194), and is characterized by
progressive impairment of cardiac conduction through the His-Purkinje system leading to
right or left bundle branch block. This may deteriorate into complete atrioventricular block,
causing syncope and sudden death. Surprisingly, Schott et al. (5) demonstrated that a
single nucleotide deletion at position 5280 in SCN5A causes early-onset PCCD in a Dutch
family. Deletion of C5280 is predicted to lead to a frame-shift resulting in a stop-codon.
The resulting truncated channels might contribute to an overall reduced Na+ current
density, which might explain slow conduction in these patients.
Tan et al. (6) reported a SCN5A mutation that causes a sustained sinoatrial and
atrioventricular conduction defect with pathological slowing of the cardiac rhythm in the
absence of other cardiac abnormalities. The missense mutation G514C was identified in the
channel protein. The gating defects of this mutation are likely to cause slow myocardial
conduction, but do not provoke rapid cardiac arrhythmias associated with LQTS and
Brugada syndrome (6). A previous study reported linkage of an isolated cardiac conduction
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disease to chromosome i9qi3-3- It is interesting to note that the gene encoding the
pi-subunit of the cardiac Na"*" channel maps to a locus on chromosome i9qi3.i-2 (105).
Aim of This Thesis
The identification and study of SCN5A mutations related to the congenital long-QT
syndrome may serve several purposes (TABLE 2.2). Common techniques to characterize
functional defects related to mutations in the cardiac sodium channel included
heterologous expression studies in Xenopus /oew oocytes (28) and human embryonic
kidney (HEK) cells (115). More recently, transgenic mice have been used to study the
functional consequences of sodium channel mutations on the cellular and whole organism
level (195).
Although considerable progress has been made in terms of the biophysical
characterization of long-QT syndrome-related Na+ channel mutations, few of the
mechanisms so far are really fully understood. For example, the Di7goG mutation was the
first Na+ channel mutation identified, that did not lead to non-inactivating current upon
prolonged depolarization (115). Although it was initially suggested that defective a-Pi
subunit interactions underlie the channel defect (115), is was not obvious from these data
how this might prolong cellular action potentials. In CHAPTER 3, we extended these findings
by incorporated whole-cell patch-clamp data of the D1790G mutation into the Luo-Rudy
computer model of the ventricular action potential.
Motivations to Identify and Characterize SCN5A Mutations
1. Identification of patients with symptoms of the long-QT syndrome mutation
2. Screening of (asymptomatic) family members of long-QT syndrome patients
3. Study of structure-function relationship of the sodium channel
4. Study of molecular pharmacology
Methods to Characterize SCN5A Mutations
1. Heterologous expression studies in Xenopus /aei>/s oocytes
2. Heterologous expression studies in HEK cells
3. Transgenic mice
TABLE 2.2
TTie rationale and methods 0/
studying SCN5A mutations.
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A recent clinical study by Benhorin et al. (185) showed that in carriers of the D1790C
mutation, class IB sodium channel blockers were ineffective, whereas class IC blocker
flecainide significantly shortened all heart rate-corrected repolarization parameters. In
CHAPTER 4, we investigated the molecular pharmacological basis of this intriguing clinical
observation. Other clinical studies support the idea that considerable heterogeneity exists
in carriers of long-QT syndrome related ion channel mutations (183,196). In an attempt to
assess whether this was also true for carriers of different Na+ channel mutations, we
studied two novel SCN5A mutations, E1295K (CHAPTER 5) and L619F (CHAPTER 6).
Finally, after describing several novel mechanisms by which Na+ channel
mutations may prolong ventricular action potentials, and thus the QT-interval on the
electrocardiogram, we summarize current concepts regarding the LQT-3 phenotypes.
We discuss these data in perspective of the structure-function relationship of the cardiac
Na+ channel, and review the implications of our findings for the mutation-specific
treatment of the long-QT syndrome type 3.
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Chapter 3
Arrhythmogenic Mechanism of the DiygoG Mutation of
the Human Heart Na+ Channel a-Subunit
Based on:
WEHRENS XHT, Abriel H, Cabo C, Benhorin J, Kass RS.
Arrhythmogenic Mechanism of an LQT-3 Mutation of
the Human Heart Na+ Channel a-Subunit - A Computational Analysis.
Circulation 2000:102:584-90.
Abstract
BACKGROUND. D1790C, a mutation of SCN5A the gene that encodes the human
Na+ channel a-subunit, is linked to one form of the congenital long-QT syndrome (LQT-3).
In contrast to other LQT-3-linked SCN5A mutations, D1790G does not promote sustained
Na+ channel activity but instead alters the kinetics and voltage-dependence of the
inactivated state.
METHODS AND RESULTS. We modeled the cardiac ventricular action potential (AP) using
parameters and techniques described by Luo and Rudy as our control. On this background,
we modified only the properties of the voltage-gated Na+ channel according to our patch-
clamp analysis of D1790G channels. Our results indicate that Di7goG-induced changes in
Na+ channel activity prolong APs in a steeply heart rate-dependent manner not directly due
to changes in Na+ entry through mutant channels but instead to alterations in the balance
of net plateau currents by modulation of calcium-sensitive exchange and ion channel
currents.
CONCLUSIONS. We conclude that the D1790G mutation of the Na+ channel a-subunit
can prolong the cardiac ventricular AP despite the absence of mutation-induced sustained
Na+ channel current. This prolongation is calcium-dependent, is enhanced at slow heart
rates, and at sufficiently slow heart rate triggers arrhythmogenic early afterdepolarizations.
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Introduction
The congenital long-QT syndrome (LQTS) is an inherited cardiac disorder that is defined in
part by prolonged ventricular repolarization, an association with recurrent syncope, a
propensity to polymorphous ventricular tachycardia (torsades de pointes), and sudden
death (1,2). Multiple genes that encode ion channel subunits have now been shown to be
linked to LQTS (3) and in most cases, the functional properties of the mutant gene
products are consistent with the disease phenotype, i.e., increase of inward or decrease of
outward plateau current (4,5).
LQT-3 is linked to the gene encoding the a-subunit of the cardiac voltage-gated
sodium channel (SCN5A on chromosome 3) (6). Functional analysis of initially reported
5CN5.A mutations revealed mutant Na+ channels that fail to inactivate completely on
prolonged depolarization (7,8) and produce a small but functionally important
enhancement of inward plateau current sufficient to delay repolarization and increase
vulnerability of the heart to arrhythmias (9). All subsequently reported LQT-3 mutations
with the exception of D1790C (DC) promote sustained Na+ current and are expected to
prolong repolarization through this common mechanism (9-14).
The purpose of the present study was to use a computational approach to
determine whether or not the biophysical properties of DC mutant Na+ channels might
affect the cellular action potential (AP) through mechanisms other than a direct
contribution to maintained Na+ channel plateau current. We modeled the cardiac
ventricular AP using parameters and techniques described by Luo and Rudy (15) as our
control and modified only the properties of the voltage-gated Na+ channel according to our
patch-clamp analysis of DG channels. Our results indicate that the DG mutation can
prolong AP duration (APD) despite the absence of mutation-induced inward Na+ channel
current during the plateau phase. Instead, the mutation indirectly affects other electrogenic
pathways, which have a common interdependence on altered cellular calcium homeostasis.
The computations predict DG mutation-induced AP prolongation, which is heart rate-
dependent and driven by subsequent changes in the intracellular calcium transient.
These results are important not only for the novel fundamental insight into the
mechanistic basis of inherited arrhythmias but also because they suggest novel targets
(i.e., calcium-handling proteins) as therapeutic agents.
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The Luo-Rudy Model of the Ventricular Action Potential
The s/'/nu/ot/o/is in this chapter were conducted using the Luo-Rudy (LRdJ mode/, a t/ieoret/ca/
dynamic mode/ o/o mamma/ion yentricu/ar action potent/a/ (FIGURE 3.sij. 77ie mode/ is
cased most/y on guinea pig expen'menta/ data; /t inc/udes membrane ionic channe/ currents
that are/ormu/ated mathematica//y using tne Hodg/cin-Hux/ey approach, as we// as ionic
pumps and exchangers. The mode/ a/so accounts ybr processes that regu/ate intrace//u/ar
concentration changes o/Na+, /C+ and C a ^ (9,29,30). /ntrace//u/ar processes represented in
the mode/ inc/ude C a ^ uptake and C a ^ re/ease by the sarcop/asmic reticu/um (SRj as we// as
Ca^ "*" ou^er/ng by ca/modu//n and tropon/n (/'n the myop/asm) and co/sequestn'n (in the SR).
As ft ivas shown that reduced density 0 / / ^ can resu/t in e/ectr/ca/ and pharmaco/ogica/
properties that are i*ery s/mi'/ar to those o / M ce//s (31), consistent with experimenta/ data by
LI'M et a/. (32), M-ce// properties were/ormu/ated by /ower/ng / ^ density whi'/e keeping / ^
constant.
U(CA) IC»(T) ICA.«
IN5(CA)
FIGURE 3.si Schematic diagram o/the Luo-Rudy mamma/ian ven«ricu/ar ce// mode/, / ^ . / as t Na+ current;
'cofL)' ^ ° " current through the (.-type Co" channel; 'coro» Co** current through the T-type Ca^ + channe/; Vp^ist
component o/the de/ayed recti/ier K* current; /^ , s/ow component o/the de/ayed recti/ier K* current; 1 -^,, iniwjrd
recti/ier IC* current; / ^ , p/ateau K+ current; /((^rp), ATP sensitive K+ current; / ^ ^ , Na+-)C+ pump; /NO<> NO*-CB**
exchange current; 'p(Co)' ^"^* pump in the sorco/emma; l ^ j , Na+ background current; /<-y,, Co^ + background
current; /nj^o;. nonspeci/ic Ca^* activated current CactiVated on/y under conditions o/Ca'* over/oadj; ( ^ Ca^ +
uptake/rom the myop/asm to network sarcop/asmic reticu/um fNSR^; / „ , , Ca'+ re/ease/rom the junctiona/
sarcop/asmic reticu/um (JSR); /,^^, Ca'+ /eakage/rom NSR to myop/asm; / „ , Ca*+ trans/ocat/on^om NSR toJSR;
Ca/modu/in and Troponin, myop/osmic Ca'* bujfers; Co/sequcstnn, S/? Ca'* bujer.
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Methods
Computer-generated AP Reconstruction
The AP was calculated by solving the differential equation I j ^ -C^dV^ /d t ) , where 1 ^
is the total transmembrane ionic current (u-A/cm*), C^ is the specific capacitance of the
membrane (1 u-F/cm*), and V^ is the transmembrane potential (mV). All ionic currents
were formulated according to THE LUO-RUDY MODEL OF THE VENTRICULAR AP (15), except
that the sodium current was formulated to reproduce our patch-clamp experiments in
HEK 293 cells. The differential equation was solved numerically with a discretization
time step of 10 u.s.
Experimental parameters used in the model were determined from experimental
data for voltage-dependence of steady-state activation and inactivation and the kinetics of
the onset and recovery from inactivation. Parameters for Boltzmann relationships and time
constants were extracted as previously described (16). Rate constants were adjusted with
temperature, assuming Q,^ factors (the factor is usually between 2 and 3 for rate constants
between different states in ionic channels).
To simulate wild-type (WT) channels, we used m,.=i/{i+exp[-(V^+32.5)/9]} and
h*(=i/{i+exp[(Vm+57.87)/7]}. To simulate DC channels, m,(=i/{i+exp[-(Vm+29)/io.5]} and
h^.(=i/{i+exp[(V^+74.3)/6.5]} were used. In the DC channels, the time constants of onset
of inactivation (h) and the slow inactivation gate (j) were half of those used in the WT
channels. The maximum sodium conductance was 27 mS/cm*. In all simulations, the
maximum conductance of the slow component of the delayed rectifier potassium current,
IKS. was reduced by 40% to uncover AP differences between cells with WT and DC
channels. These APs thus simulate endocardial or M-cell activity (5,17-20). APs were
initiated by intracellular 0.5 ms current pulses (100 jiA/cm*). Initial conditions were
established by stimulating cells with WT and DC channels once per second for a 3 minute
period. Cells were stimulated 20 times at a constant cycle length (500-4000 ms).
Expression of Recombinant Na+ Channels
Na+ channels were expressed in HEK 293 cells as previously described (11). Transfections
were carried out with equal amounts of Na+ channel a-subunit cDNA (WT or DC,
respectively), with hpi- and/or h[}2-subunit cDNA subcloned individually into the pcDNA3
(Invitrogen) vector (total cDNA 2.5 (xg). Control experiments (data not shown) indicated
no significant differences in channel activity for these subunit combinations.
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Electrophysiology
Membrane currents were measured with whole-cell patch-clamp procedures (21) with
Axopatch 200B amplifiers (Axon Instruments) as previously described (11). Unless noted
otherwise, recordings were made at room temperature (22°C) with previously published
solutions (11). Data acquisition and analysis were carried out with pClamp 7 (Axon
Instruments), Excel (Microsoft), and Origin (Microcal Software). Steady-state inactivation
was determined after application of 500 ms conditioning pulses applied once every
2 seconds. Recovery from inactivation was measured in paired pulse experiments,
with a test pulse applied at variable times after a TOO ms conditioning pulse to -10 mV.
Holding potentials were -80 mV.
Results
Biophysical Properties of DC Mutant Channels: Computational Parameter Set
FIGURE 3.1 shows families of experimental records of WT and DC mutant channels
expressed in HEK 293 cells as well as analysis of the experimentally determined voltage-
dependence of the time constants of the onset of inactivation. As illustrated in FIGURE 3.IA,
we compared experimental recordings of WT and DC channels at 22°C (top) and 2g°C
(bottom). Clearly, increasing temperature speeds the kinetics of both WT and DC mutant
channels, as expected (22) but it neither changes the relationship between WT and DC
mutant channel time constants nor promotes DC-induced sustained inward current.
FIGURE 3.IB summarizes time constants obtained by fitting experimental records with
functions containing one exponential component. Although in a limited number of
experiments, we previously reported no effect of the DG mutation on the kinetics of the
onset of inactivation, in a more complete analysis we have found that, in fact, this
mutation speeds the onset of inactivation (FIGURE 3.1) and slightly alters the voltage-
dependence of activation (FIGURE 3.3). Using these data, we extrapolated the temperature
coefficient (Q,o) of 2.1 for inactivation kinetics for both WT and DC mutant channels to
compute the effects of the mutation on APs at physiological temperatures.
FIGURE 3.2 shows the simulated changes in Na+ channel currents and the time constants
of the onset of inactivation generated by the computer-based model. As is the case for the
experimental data, the simulated currents reflect the speeding of the onset of inactivation
as a function of membrane potential but do not exhibit enhanced sustained current.
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FIGURE 3.1
D C mutotion speeds onset 0 /
inactiVation at 22°C (topj and
2 9 X (bottom^. A, Representative
current traces erokfrf by 20 ms
pu/ses to voltages indicated in
inset/or cetts expressing ICTor
D C mutant No* channe/s.
Maximum currents have been
norma/ized to/oci/itate
comparison o/V/T and DC
current traces. B, Time constants
(mean±S£M, n-3 to 7/or each
data point} determined/rom best-
yit sing/e exponen!io//uncl/ons to
dato, p/otted «test-pufse
potentia//or WT Co^  and
DC f»; chonne/s.
WT D1790C
1 MS
' • 5 ,
0-5'
O WT
• DC
-80 mV—I I—
•35 30 -25 -20 15 10
V M ( M V )
F I CURE 3.2
fleets 0 / DC mutation on
simu/at«d No* channe/ currents.
A, fleets o/ca/cu/oled lime
constants on computed^/ami/ies
0 / V/T and DC currents.
B, Vo/tage-dependence o/time
constants o/inactiVation/or
V/T and DC channe/s
Current traces/or V/Tand
DC No' cfiannef currents are
simulated at 37*C.
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FIGURE 3.3
ExperimentaHy determined (A)
and simu/oled fB) ejects 0 /
DC mutation on channel
properties. Each pane/ shoifs
steady-state inactirat/on and
activation (top,) and recovery/rom
inoct/Vation (bottom) /or V/T (o)
and DC (•} cnanne/s. Theorelico/
curves (Bj generated with
parameters obtained in A in
Luo and Rudy mode/ (note that
recovery/ram inartivation is
mode/ed as a sing/e exponentia/
/unction) as/o//cws: T=25.2 ms/or
W7;T-i2.6ms/or DC.
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FIGURE 3.3 illustrates experimental and computational data showing the effects
of the DC mutation on the voltage-dependence of steady-state inactivation and activation
and on the time course of recovery from the inactivated state. For activation, peak
currents (measured in 30 mmol/L [Na^y were normalized to driving force to determine
conductance. The mutation causes a marked negative shift of the voltage-dependence of
inactivation (WT, DG: V,^-64, -79 mV; k 5.9, 5.5; n=i3) with relatively minor changes in the
voltage-dependence of activation, (WT, DC: V^j-23, -17; K: 6.9, 9.2 (n=6), as we previously
reported (11). The mutation also causes a small but significant speeding of the recovery
process (averaged experimental time constants and relative weights are WT (o):
Tf,,,=2O.4 ms, af«,=o.87, ^,^=351 ms, a^=o . i3 ; and for DC (.): 7^=14.9 ms,
3fast=°-97> ""'siow=2i49 ms, 8510^=0.03). The results obtained in experiments (A) were
incorporated into the simulated channels (B).
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Simulation of Cellular Electrical Activity:
AP Prolongation That Is Heart Rate-dependent
FIGURE 3.4 shows the consequences of these mutation-induced changes in channel
properties on cellular electrical activity that is predicted by the computer-generated model.
At a basic cycle length (BCL) of 1000 ms, there is little effect of the DC mutation despite
a significant APD prolongation. At a BCL of 3000 ms, however, it causes dramatic APD
prolongation, which results in the generation of early afterdepolarizations (EADs).
The results of similar calculations repeated over a series of BCLs are summarized in
FIGURE 3.5, in which APD is plotted versus BCL for both WT and DC channels.
The expression of mutant DC channels markedly alters this relationship, FIGURE 3.5 shows
that even at moderately long BCLs (1000 to 2000 ms), the DG mutation prolongs APs
compared with cells expressing WT channels. This effect becomes very pronounced
(note change in vertical scale) as heart rate slows further, and at a BCL of 3000 ms,
as illustrated above, the mutation-
induced action prolongation is
sufficient to induce EADs (arrow).
Similarly, the DG mutation induces
EADs after pauses in AP activity
(FIGURE 3.6).
850 1
800 -
300:
_ 250.
O IOOO
BCL (MS)
3000 4000
FIGURE 3.5
DC-induced AP prolongation
is steep'y heart rate-dependent.
P/otted is fe/at/onship betu'een
APD and 8CL At BCL 0/
3000 ms, mutotion-induced
action pro/ongation is su/f/cient
to induce EADs (arrou'J at
8Ct >25OO ms.
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F IGURE 3.6
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in stimulation. Lost 2 APs in a
train 0 /20 ot BCL 0/500 ms
/o'fou'ed by 1500 ms pause and
postpause A P. Pause in ort/i'/ly
induces an £AD forrou'J /n ce//s
expressing DC but not
WT channe/s.
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fleets o / D C mutation on No*
channel actiVi'ty during AP and
AP upstroke (BCL 0/3000 mi j .
Membrane potential (top^ and
computed No* channe/ currents
(bottom^ /or ce//s expressing
WT (dotted lines; and DC
(so/id /ines^ channe/s.
A, Sfotf time base recording:
note absence 0/sustained mivord
Na* current and reduction
o/AP overshoot (arroiv^.
B, ffjfpanded time base.
DC mutation reduces contribution
o / N a * channe/ ocliVily and s/oivs
initi'a/ upstroke o/AP.
>
4 0
-40 -
-80 -
-300-
_j -400 •
4 0 0 600 800 1000
4 0 .
-40.
• 8 0 .
0 1 2 3 4 5 6
-200
-300
•400-
o 2 0 0
TIME (MS)
4 0 0 600 800 1000 0 1 2 3 4 5 6
TIME (MS)
Novel Insights in the Congenital Long QT-3 Syndrome | PACE 82
Ionic Basis of DC Cellular Phenotype: A Role for [Ca*+]j
FIGURES 3.7 and 3.8 show the effects of the DC mutation on several key ionic pathways
underlying the computed APs. These computations reflect steady-state conditions during a
BCL of 3000 ms, but the patterns revealed are the same as those that occur in DC-induced
pause-dependent AP prolongation (data not shown), FIGURE 3.7 focuses on computed Na+
channel currents and illustrates current during the AP plateau (A) as well as, on an
expanded time scale, during the upstroke (B). As predicted by the voltage-clamp data,
the DC mutation does not promote sustained inward Na"*" current that would account for
AP prolongation (A, lower row). In fact, the computations show that the overall effect of
this mutation is to reduce the contribution of Na+ channel activity to the initial upstroke
and overshoot (arrow) of the AP. FIGURE 3.8 illustrates DC mutation-induced changes in
other pathways that occur during the
duration of the AP. The computations
reveal an increase in Ca*+ influx
through L-type Ca*+ channels, an
increase in the magnitude of the
transient change in [Ca^];, changes in
Na+/Ca^ exchange current, and an
initial reduction followed by prolonged
activation of the slowly activating K+
channel current, L,.
40 •
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TIME (MS)
6 0 0 800
FIGURE 3.8
DC mutation averts Ca**-
sensitiVe polhifoys. S/mu/ot/on
o/e/fects o/DG mutation on APs
and key underlying pathways
that occur at BCL 0/3000 ms.
Shown are/oMowing computations
/or ce//s expressing Vl/T (doited
/ines^ and DC (so/id /ines^
No* channe/s 'top to bottom^:
membrane potentia/, (.type Ca"
channe/ currents; intrace//u/ar/ree
Co", Na*/Ca'* exchange current;
and de/ayed recli/ier current, /^ ,.
Arroif in second row indicates
peak Co'* in/lux with VCT channe/.
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DC-Induced Changes in [Ca**], Determine Frequency-dependent ADP Prolongation
Perhaps the most prominent feature of the DC cellular phenotype predicted from these
computations is the marked dependence of APD on heart rate (FIGURE 3.5).
FIGURE 3.9 shows marked DC mutation-induced changes in the calcium transient that
are steeply frequency-dependent. At low stimulation frequencies (long BCLs), the calcium
transient in cells expressing DC Na* channels is increased in both amplitude and duration.
At faster heart rates (BCLs on the order of 1000 ms), there is little difference between
calcium transients of WT and DC-expressing cells (A). The computations thus suggest
a complex calcium-dependent pathway regulating APD that becomes altered, as described
above, by DC-induced changes in calcium entry. Because the effects of these changes on
the calcium transient are predicted to be steeply frequency-dependent, the calculations
suggest a strong interdependence on the filling and subsequent emptying of intracellular
calcium stores in this process.
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Discussion
Sustained Na+ Channel Current Is Not Necessary to Prolong the Ventricular AP
The major finding reported in this study is the fact that biophysical properties of DG
mutant Na+ channel a-subunits prolong computer-simulated ventricular APs, even though
this mutation does not promote sustained Na+ channel current during the AP plateau
phase. This study thus extends our understanding of the molecular basis of the disease
phenotype, the prolonged QT-intervals, and confirms the importance of computational
studies in bridging information relating functional changes in individual ion channel
subunits to predictions of cellular and even system phenotypes.
The plateau phase of the cardiac ventricular AP is maintained by a delicate
balance between inward and outward movement of ions, and even very small changes in
ionic currents during the plateau are expected to have marked effects on APD (4,23).
The functional properties of channels encoded by DC mutant a-subunits have defied
interpretation within a framework that requires direct mutation-dependent increase in
Na+ channel current during the AP plateau, because this mutation does not promote
sustained Na+ channel activity in the face of cellular depolarization (11). Instead, the most
prominent characteristics of DG channels are a negative shift in channel availability as a
function of membrane potential and a speeding of the kinetics of the onset of inactivation.
However, our computations reveal the importance of these biophysical changes in channel
properties to events that determine the duration of the AP and show that events that occur
during the initial 5 ms of the AP can have profound effects on electrical activity that occurs
during the following several hundred milliseconds.
DC-Induced Decrease in Na+ Channel Activity Leads to an Increase in
the [Ca*+]; Transient
FIGURES 3.7, 3.8, and 3.9 provide insight into the mechanism(s) by which the DG mutation
delays AP repolarization. Because of the changes in Na+ channel kinetics, fewer channels
are available for activation at the cellular resting potential, and once opened, these
channels inactivate faster than WT channels. This results in a reduced Na+ channel
current, slower upstroke, and more importantly, a less positive overshoot of the AP
(FIGURE 3.7, arrow). The change in dV/dt and overshoot occurs during the very early stages
of ventricular depolarization, as seen in FIGURE 3.8, and in turn causes an increase of Ca*+
entry via L-type Ca*+ channels during this crucial period of electrical activity. The primary
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mechanism underlying this effect is not a change in gating parameters for Ca*+ channel
activation and inactivation, but the effect of the DG mutation on the AP overshoot and
subsequent change in the driving force for Ca*+ entry via L-type Ca*"*" channels (not
illustrated). With this alteration in Ca*+ entry, the model predicts that the subsequent
transient will be altered in both time and magnitude, and as a result, all [Ca^-dependent
processes will subsequently be altered (FIGURE 3.8). Two important ionic pathways, the
Na^/Ca^ exchanger (24) and the slowly activating delayed K+ channel current, 1^ (25) are
affected (FIGURE 3.8). The result is a net increase of inward plateau current and
corresponding increase in APD. The fundamental difference between the generation of the
cellular phenotype in the case of the DC mutation compared with previously described
LQT-3 mutations is that the increase of inward current does not come from a direct
contribution of altered Na+ channel activity but rather from other pathways.
The computations also reveal a critical role of l ^ in the DG-induced cellular
phenotype (FIGURE 3.8) as a result of the reduction in this current that occurs as a
consequence of mutation-induced changes in V^. Thus, although the disease-linked
mutation is in the SCN5A gene, the cellular phenotype is due in part to changes in activity
of channels encoded by LQT-i- and LQT-5-linked genes (26,27).
Relationship Between Cellular and Clinical Phenotypes
The work presented here is the result of incorporation of biophysical properties of
human WT and DG mutant Na* channels expressed in a mammalian cell line into a
computational model that integrates experimental data obtained from a variety of cell types
and species (15). Extrapolation of these results to a precise understanding of human
pathophysiology is not possible and goes beyond the scope of this study. Qualitative,
but not quantitative, conclusions may be drawn from this work. Nevertheless, comparison
to appropriate clinical parameters that have been measured for carriers of the DG
mutation is important, and in fact, a stringent test of the validity of the methodology.
The model suggests that under steady-state pacing conditions, the Na+ current
is smaller in myocytes expressing DG mutant channels next to WT channels. This will most
likely lead to a reduced rate of rise of the AP upstroke (dV/dt) as predicted for the cellular
model, and this, in turn, would be expected to be reflected in a widening of the QRS
complex on the ECG of mutation carriers. Indeed, DG carriers tend to have wider QRS
complexes than control patients (28). The computational work clearly indicates that for this
mutation, bradycardia will potentiate APD prolongation. It is interesting to note that heart
rates of DG carriers have been found to be slower than those of noncarriers (10). In fact,
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in several members of the DC family that have been studied, sinus slowing and even arrest
may have been as significant as APD prolongation. This raises the interesting and
important question as to a causal relationship between pacing and the DC mutation,
a question that certainly is beyond the scope of the present study.
Role of I j o >" Modulating the Effect of the DC Mutation on APD
In the computations that we have carried out and reported, we have not included a
contribution of the transient outward current (IJO)- We did, however, test for its effects in
calculations, which we have not illustrated. We find, as might be expected, that if expressed
at sufficiently high levels, this current will tend to offset the effects of the DC mutation and
modify its influence on APD. Thus, cells expressing I-J-Q at the highest densities (epicardial
cells) would be expected to have substantially shorter APDs than cells in which IJO is
expressed at the lowest densities (endocardial cells), because the additional contribution
of DC mutant channels would then follow the same anatomic pattern (20). This pattern of
channel expression would thus be expected to favor enhanced T wave dispersion (19)
which, interestingly, is what is observed in carriers of the DC mutation (28). Heterogeneity
in the expression of ion channel genes, no doubt, remains an important area of
investigation that will be needed to provide a causal link between expression of specific
gene mutations and generation of the systemic disease phenotype.
Novel Therapeutic Strategies for LQT-3
Our analysis has revealed that beat-dependent changes in intracellular calcium that occur
as a consequence of the DC LQT-3 mutation should be considered major factors in
generating the disease phenotype (delayed ventricular repolarization) in carriers of this
gene defect. This work therefore strongly suggests that a therapeutic strategy that includes
inhibition of L-type calcium channel activity may be beneficial for carriers of the DC gene
defect.
In summary, our computations show that the biophysical properties of DC mutant
channels are sufficient to account for a cellular phenotype consistent with LQT-3:
prolongation of the ventricular AP. This occurs despite the absence of mutation-induced
sustained Na* current. This finding not only is a necessary step in understanding the
molecular basis of QT prolongation in carriers of the DC mutation but also raises the
possibility that previously overlooked functional properties of other LQT-3 SCN.5>4
mutations may also contribute to the disease phenotype and may require further
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investigation. Furthermore, our work suggests that novel therapeutic strategies may
include modulation of calcium as well as sodium channel activity.
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Abstract
!W WT/VV UW
BACKGROUND. Multiple mutations of SCN5A, the gene that encodes the human
Na* channel a-subunit, are linked to one form of the congenital long-QT syndrome
(LQT-3). D1790C (DG), an LQT-3 mutation of the C-terminal region of the Na+ channel
a-subunit, alters steady-state inactivation of expressed channels but does not promote
sustained Na+ channel activity. Recently, flecainide, but not lidocaine, has been found to
correct the disease phenotype, delayed ventricular repolarization, in DC carriers.
METHODS AND RESULTS. TO understand the molecular basis of this difference, we studied
both drugs using wild-type (WT) and mutant Na+ channels expressed in HEK 293 cells.
The DC mutation conferred a higher sensitivity to lidocaine (ECJQ, WT=894 and DC=2O5
p.mol/L) but not flecainide tonic block in a concentration range that is not clinically
relevant. In contrast, in a concentration range that is therapeutically relevant,
DC channels are blocked selectively by flecainide (EC50, WT=n.o and DG=i.7 fj-mol/L),
but not lidocaine (EC^, WT=3i8 and DG=O76 |xmol/L) during repetitive stimulation.
CONCLUSIONS. These results (1) demonstrate that the DC mutation confers a unique
pharmacological response on expressed channels; (2) suggest that flecainide use-
dependent block of DC channels underlies its therapeutic effects in carriers of this gene
mutation; and (3) suggest a role of the Na+ channel a-subunit C-terminus in the
flecainide/channel interaction.
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Introduction
The congenital long-QT syndrome is an inherited cardiac disorder defined by prolonged
ventricular repolarization, recurrent syncope, a propensity to polymorphous ventricular
tachycardia (torsades de pointes), and sudden death (1,2). Molecular genetic studies have
identified defects in the a-subunit of the cardiac voltage-gated ion channel (SCN5A) that
are linked to one form of the disease: LQT-3 (3). Initial functional analysis of most SCN5A
mutations has revealed mutant Na+ channels that fail to inactivate completely on
prolonged depolarization (4-8), a property sufficient to delay repolarization of the
ventricular action potential and increase vulnerability of the heart to arrhythmias (9). In
contrast, the D1790G (DC) SCN5A mutation (10), located in the cytoplasmic region of the
a-subunit C-terminus, causes a marked negative shift in the relationship between channel
availability and membrane potential and alters inactivation kinetics of mutant channels (11)
but does not promote sustained inward current (7).
Pharmacological analysis of LQT-3 mutant channels expressed heterologously has
provided evidence that sodium channel blockers that interact with either the inactivated or
open state of the channel (12,13) effectively block maintained current conducted by mutant
channels (14-20), shorten action potential duration in cellular studies (21,22), and in
preliminary studies correct QT prolongation in patients (22,23).
Because the biophysical properties of the DC mutation do not promote
maintained current during the action potential plateau phase, it had been suggested that
agents such as lidocaine would not be effective in correcting the disease phenotype linked
to this mutation (7). Clinical studies (24) have confirmed this prediction but, in addition,
have shown that flecainide, which preferentially blocks open but not inactivated channels
(25), is effective in correcting DC-induced QT prolongation in patients carrying the DC
gene defect. However, the mechanism underlying this mutation-specific therapeutic
efficacy has not yet been determined.
Here, we report the pharmacological profile of DG channels expressed in a
mammalian cell line and show that this point mutation confers a flecainide sensitivity that
is distinct from wild type (WT) and at least one other LQT-3 mutant channel (20). Our
results reveal marked drug-specific differences in channel modulation that are consistent
with the clinical efficacy of both lidocaine and flecainide and suggest that over
concentration ranges that are used clinically, it is the marked difference in flecainide's use-
dependent block (UDB) of DC compared with WT channels that underlies its therapeutic
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efficacy. The results of this study provide further support for the approach of mutation-
specific pharmacology as a basis for the management of inherited cardiac arrhythmias.
Materials and Methods
CF.CFjO
CF,CFjO O
F/ecoin/de
Expression of Recombinant Na+Channels
HEK 293 cells (Cold Spring Harbor Laboratories) were grown under culture conditions and
transfected with equal amounts of Na+ channel a- (WT or DC, respectively), hpi-, and/or
hp2-subunit cDNAs subcloned individually into the pcDNA3 (Invitrogen) vector
(total cDNA, 2.5 u,g) by a lipofection procedure previously described by us (7). Control
experiments (data not shown) indicated no significant differences in channel activity
with or without drug for these subunit combinations. (3-Subunit cDNAs were gifts of
Drs L. Isom (University of Michigan, hfte) and A. George (Vanderbilt University, hpi),
and the DC mutation was constructed as previously described (7).
Electrophysiology
Membrane currents were measured by whole-cell patch-clamp procedures (26) with
Axopatch 200B amplifiers (Axon Instruments) and the following solutions (mmol/L):
internal: CsCI 60, aspartic acid 50, CaClj 1, MgCI^ 1.2, HEPES 10, ECTA 11, and Na^ATP 5;
pH corrected to 7.2 with CsOH; external: NaCl 130, CsCI 5, CaCI., 2, MgCI^ 1.2, HEPES 10,
and glucose 5; pH corrected to 7.4 with CsOH. Drug (Sigma Chemical Co.) solutions were
made from 10 mmol/L (FLECAINIDE) or 100 mmol/L (LIDOCAINE) stock solutions in H^O.
Experiments were carried out with pClamp7 software (Axon Instruments), and data were
analyzed with Origin software (Microcal Software). Unless otherwise specified in the figure
legends, experiments were carried out at room temperature (22°C). Measurements at
higher temperature were performed with a solution heater (In-line Heater SH-27B, Warner
Instrument Corp) warming the superfusate to 37°C. Recordings were made during 25 ms
test pulses to -10 mV from -100 mV holding potentials. Tonic block (TB) was measured at
0.033 Hz after steady-state was achieved in the presence of drug (1 minute for lidocaine
and 2 to 4 minutes for flecainide). Steady-state inactivation was measured with 5 second
conditioning pulses followed by a test pulse (-10 mV), with an interpulse interval of
30 seconds. Steady-state UDB was reached in response to trains of variable numbers of
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pulses (100 to 600, -10 mV) at frequencies indicated in the figure legends. UDB was
measured as block induced by pulse trains relative to TB for a given drug concentration.
UDB data were normalized to currents recorded with the same protocols but in the
absence of drug.
Data are represented as mean±SEM. Two-tailed Student's t-test was used to compare
means; a value of P<o.O5 was considered statistically significant.
Results
TB of WT and Mutant Channels
Because the DC mutation alters the voltage-dependence of steady-state inactivation of
expressed channels (7), we first tested for differences between the interactions of lidocaine
and flecainide with the inactivated state of WT and DC channels, FIGURE 4.1 shows that
lidocaine, but not flecainide, induces marked hyperpolarizing shifts in the steady-state
inactivation relationship for both WT and DG channels. Furthermore, the effects of
lidocaine on inactivation are approximately the same for WT and DC channels.
The lidocaine-selective shift in inactivation predicts greater TB of DC versus
WT channels by lidocaine, but not flecainide, at physiologically relevant holding potentials.
This prediction is confirmed in the experiments summarized in FIGURE 4.2 However, at
clinically relevant concentrations (27) of lidocaine (30 u.mol/L) and flecainide (3 u.mol/L),
neither drug discriminates between WT and DC channels on the basis of TB.
UDB: Distinctions Between WT and DC Channels
Therefore, we next compared block that accumulates with repetitive activity when DC
mutant and WT channels are exposed to lidocaine and flecainide (FIGURE 4.3). Again at
clinically relevant concentrations (30 u.mol/L), there is no difference between lidocaine
block of WT and DC channels (FIGURE 4.3A). In contrast, there is a statistically significant
(P<o.ooi) difference between flecainide UDB of DC and WT channels at the clinically
relevant concentration of 3 nmol/L This difference is evident over a broad concentration
range: EC^ for flecainide UDB of DG channels is roughly 5 times lower than for block of
WT channels (FIGURE 4.3B). In contrast, UDBs of WT or DC channels by lidocaine are
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FIGURE 4.1
Ejects o//Jecainide and /idocome on steady-state martiVation o/V/T and DC channe/s. Steady-stote awji/abi/ity 0/
channe/s ivas measured fMethods^ in absence and presence o/eoch drug. A and B, Current traces, normafaed to peak
drug-/ree currents, i/Zustrate ejects o//idocaine (300 jimo//L^ and//ecain/de 3^0 (j.mo//LJ. Arroivs indicate drug-
induced changes in peed currents/or each condition. C and D, Averaged steady-state acai/abi/ity curves are shoum in
absence (circ/es^ and presence o//idocaine (300 (imo//L, squares^ and/ecainide ^30 (jimo//L, triang/es^/or V/T (C,)
and DC fDJ chonne/s. Na+ currents e/icited by -10 mV test pu/ses u»ere norma/ized to /argest currents obtained in
contro/ conditions/rom hyperpo/arized ho/ding potentia/s. Graphs show norme/ized current p/o««d against
conditioning pu/se ro/tage. Smooth /ines are according to Vf '+"P/fK-Vi/2y<^, where V£ is conditioning potentia/,
V^, is ro/tage/or which ha//the channe/s are not avai/ab/e, and It is the s/ope/actor. V,^(mV9/or WT is -66.2±0.9
/or contra/, -69.^0.9 with/eceinide, and -85.7±1.4 with /idocaine; V,^(m\/)/or DC is -8i.S±i.4/or contro/,
-873±24 with/ecainide, and -iO2.5±z.7 with /idocaine; n=4 ce//s per condition.
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FICURE 4.2
TB 0/ U/T and DC mutant No* channels. A and B, (n/ii'bi'tion 0/ Wo'*' current e/ici'ted in H f (f ce//s expressing VCT or
DC channe/s with //docaine fA^ ory/ecainide (B^. Traces shoiv currents in contra/ so/ut/on and a/ter steady-stale TB
ivas attained (arTOu^ 2 to 4 minutes a^er ce// superfusate ivas changed to one containing /idocaine ^300 (imo///.^
or//ecainide (30 (imo//L^, respectiVe/y. C and D. Concentration-dependence o/TB o/WT (»^ and DC fo^ channe/s
by /idoca/ne fQ and_/?ecainide fD). Graph shows peak current a/ter drug app/ication, normo/ized to peak current in
absence o/drug, p/olled as a/unction o/drug concentration. Smooth /ines are according to 7/(i+fdrug//£C,oJ".
ECjo /or /idocaine is 894 CWT) and 205 CDC ;^ ECj,, /or/ecainide is 59.3 fWT) and 48.2 fDC^; n=3 to 6 ce//s
per condition.
Chapter 4 | PACE 97
0.8
0.6
. 0.4
<
z
o
1O IOO 1OOO
LlDOCAINE (|1MOI/L)
1 1O IOO 1OOO
FLECAINIDE (JIMOL/L)
z 0.6-
o.
UJQ
UJ
3 0.4-
<
z
o
C 0.2-
PULSE FREQUENCY (Hz) PULSE FREQUENCY (HZ)
FIGURE 4.3
DC mutation increases sens/tiV/*y o/channe/s to UDB by/ecainide but not //docaine. Concentration dependence 0/
UDB o/V/T (»J and DC foj channels by /idocaine (Aj and/ecainide (BJ. Currents ivere eraked by pu/ses app/ied at
a/requency 0/5 Hz in presence 0/drugs unt/7 steady-state UDB was achieced and norma/ized to TB /eve/s be/ore
high-/rec)uency train protoco/ u<as started. Smooth /ines are according to i/fi+/drug//5CjJ". ECj^ ybr /idocaine
is 3t8 fWTJ and 176 fDC^; ECJQ /br/ecoinide is JI.O ^V/Tj and 1.7 (DC); n-3 to 6 ce//s per condition.
C and D, Frequency-dependence 0//idocaine andyfecainide b/ock 0/WT f») and DC foj channe/s affixed drug
concentrations. Trains 0/100 to 600 pulses were app/ied at various/requencies in presence 0//idocaine
(300 Limo//L, C) or^/ecaimde fio p.mo//L, D .^ Graphs shoiv peak current during steady-state UDB norma/ized to peak
current during/irst pu/se 0/train p/ottcd against stimu/us/requency; n=4 ce//s per condition. *P<o.o5, **P<o.oi.
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approximately the same over all concentrations tested. In addition, the distinction in use-
dependent drug action between WT and DC channels is retained when the frequency range
of pulse application is extended to a broader frequency range (FIGURE 4.3c AND 4.3D).
0.8 -
£ o , 6 -
o 0.2 -
z
• WT control
• DC control
• WT flecainide
O DC flecainide
Effect of DC Mutation on Recovery From Flecainide Block
Block that accumulates as a consequence of repetitive channel activity (UDB) is caused by
a balance between the time course of the onset of block (during depolarization) and the
recovery from block (during repolarization) (12,13). To understand the marked sensitivity of
DG channels to UDB, we next investigated the time course of the recovery from UDB.
Here, we focused only on the effects of flecainide, because there was little difference
between WT and DC channels in response to UDB by lidocaine (FIGURE 4.3A and 4.3c).
In these experiments,
we applied a "conditioning"
train of pulses (to -10 mV,
from a -100 mV holding
potential) for a fixed duration
(25 ms) and frequency (25 Hz)
to induce flecainide block of
channels. Test pulses were then
imposed after variable recovery
intervals at holding potential.
Currents were normalized to
steady-state current levels TIME (MS)
during slow pacing (once every
30 seconds). Normalized current is plotted against recovery interval. As illustrated in
FIGURE 4.4, in the absence of the drug, DC channels tend to recover faster from
inactivation that occurs as a consequence of the conditioning train. In the presence of
flecainide, repriming of channels is very different: now DC channels recover very slowly.
Even after 10 seconds at the holding potential (-100 mV) under pulse-free conditions,
only a small fraction of the flecainide-blocked current recovers. This result suggests that
the flecainide-bound DC channel is very stable and that infrequent pulsing can still be
very effective at accumulating block because once blocked, channels remain
nonconducting for tens of seconds.
FIGURE 4.4
Eject 0/ DC mutation on lime
course 0/recovery/rom
inactiVation and^Jecainide Wock.
UDB o/WT fso/irf symbo/s; and
DC (open symbo/s] mutant
chonne/s ivas induced be/ore
(squares] and a/ier fcircfesj
app/ication 0/10 jimoi/1.
/ecainide; n»4 ce//s per condition.
*P<O.O5, **P<O.O7, ***P<0.007.
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Clinical Efficacy of Flecainide: Distinctions Between UDB of WT and DC Channels
The dramatic slowing of flecainide unblock caused by the DC mutation (FIGURE 4.4) has
important implications for the clinical usefulness of this compound in the treatment of
LQT-3 in carriers of the DC mutation. Because use-dependent flecainide block
discriminates between WT and DC mutant channels (FIGURE 4.3), it is important to
demonstrate UDB of DC channels under conditions that more closely resemble those
encountered in the heart. Thus, we tested for differences between WT and DC channels in
the response to flecainide (3 u.mol/L), when longer pulses (400 ms), which mimic the
duration of action potentials in LQT-3 patients, are applied at a physiological frequency
(1 Hz) and temperature (37°C). These experiments (FIGURE 4.5) confirm that, even under
these conditions, the extremely slow recovery from flecainide block of DC channels is
sufficient to cause significantly greater block of DG versus WT channels.
FIGURE 4.5
0/ DC fs V/T channels under
pfoys/ofogica/ conditions.
A, Current traces be/ore and
o/ter steady-state UD8 farrows}.
Shown ore superimposed records
o//!rst and IOO'** (races in trains
applied to WT (7e/t; and DC
(right) crtonne/s. B, Bar graphs
summarize steady-state UDB
p/otted ns/rnction 0/current
b/ocJced in response to the pu/se
train; n-6 ce//s per condition.
**P<o. 01.
Discussion
Molecular Basis for Mutation-specific Pharmacology:
Implications for a Role of C-Terminus in Inactivation and Drug Activity
The principal finding of this study is that a LQT-3-linked mutation of the heart a-subunit of
the Na* channel dramatically and specifically changes the manner by which channels
encoded by the mutant gene interact with sodium channel-blocking drugs. The mutation
confers a higher sensitivity to UDB by flecainide, but not lidocaine, over a clinically relevant
concentration range. Flecainide TB is not affected by the DC mutation. Our findings thus
illustrate the importance of investigating mutation-induced changes not only in channel
function but also in channel pharmacology.
Voltage-dependent block of Na+ channel currents by antiarrhythmic drugs is a
consequence of distinct interactions with different states of the voltage-gated Na+ channel.
Lidocaine and flecainide differ in their modes of action in that lidocaine interacts
preferentially with inactivated channels, and drug block is not necessarily dependent on
channel openings (25,28), whereas flecainide requires channels to open and is not
dependent on channels entering the inactivated state to promote block (25,29).
We observed that the DG mutation does not influence the interaction of lidocaine
with the Na+ channel, even if TB was greater than for mutant channels (FIGURE 4.2).
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Indeed, this effect is explained by the fact that lidocaine shifts the steady-state inactivation
curve by the same amount for WT as for the DG mutant channel, but the DC mutation by
itself already shifts this curve by -20 mV in the absence of drug. Because flecainide has a
much weaker effect on the inactivation curve (FIGURE 4.1), there is little difference between
flecainide-induced TB of WT and DC channels. In contrast, the DC mutation markedly
increases flecainide UDB of channels, in large part because of the pronounced slowing of
the repriming of DC channels in the presence of the drug (FIGURE 4.4).
This specific alteration of the sensitivity to UDB by flecainide is not a general
property of all LQT-3 mutant channels. Recently, Nagatomo et al. (20) found that LQT-3
AKPQ mutant channels have an intrinsically higher affinity than WT channels to flecainide,
but in the case of this mutation, sensitivity to both TB and UDB is increased. Thus, our
data indicate that the DC point mutation causes a unique pharmacological response of the
expressed channels, which is distinct not only from WT but also from AKPQ mutant
channels.
The DC mutation is a nonconservative change from an aspartic acid to a glycine only
18 amino acids away from transmembrane segment S6 in the C-terminus of the Na+
channel a-subunit, a region of the channel not previously considered to play a major role
in the molecular interactions of flecainide (30). Our data clearly show that this is not the
case and raise the possibility that other residues of the C-terminus may also be important
in determining pharmacological responses of Na+ channels. Importantly, one other
nonconservative C-terminus LQT-3 mutation (Ei784K) has been reported recently (6),
and a C-terminus insertion mutation (i795insD) has been linked to both Brugada's
syndrome and LQT-3 (31). Our work strongly suggests that these mutations may also
modify the interactions of the encoded channels by flecainide (and probably other drugs),
raising the possibility of pharmacological targeting of a broad range of mutation-induced
phenotypes. As has been shown for AKPQ and DC channels, however, determination of
the pharmacological profile must be carried out systematically on a mutation-by-mutation
basis before this would be possible.
Relationship Between Molecular Pharmacology and Therapeutic Efficacy
Our data on recombinant human Na+ channels complement those of Benhorin et al. (24),
which have shown that flecainide, but not lidocaine, significantly decreased the QTc
interval in DG carriers by 10% but was without effect in control patients. This difference
was even more striking when the effect of flecainide on the marked repolarization
Chapter
heterogeneity seen in DC carriers was considered. Our experiments indicate that over the
clinically relevant drug concentration range and under physiological conditions, flecainide
discriminates between WT and DC primarily because of the pronounced effect of the
DC mutation on flecainide UDB. The correlation between the clinical results and our data
strongly suggests that it is this mechanism of action that underlies the therapeutic
usefulness of flecainide compared with lidocaine in the treatment of carriers of the
DC mutation. Interestingly, flecainide has also recently been shown to be very effective in
treating carriers of the AKPQ LQT-3 mutation (A.J. Moss, personal communication),
even though, as discussed above, the interactions of flecainide with AKPQ and DC mutant
channels differ. In the case of both channel defects, however, recovery from the drug-
blocked state is markedly slowed compared with WT channels, and it may be this common
mode of action that makes this drug so useful as a therapeutic tool in the treatment of
carriers of these gene defects.
In summary, we have found that the LQT-3 DC mutation changes the pharmacological
response of encoded channels in a manner that differs not only from WT but also from
other LQT-3 rnutant channels. The pharmacological profile of DC channels shows distinct
changes that occur over a therapeutically relevant concentration range. Our data provide
further support for the usefulness of a mutation-specific pharmacological approach for the
management of distinct inherited ion channel defects.
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Variant 3 of the congenital long-QT syndrome (LQT-3) is caused by mutations in the gene
encoding the a-subunit of the cardiac Na* channel. In the present study, we report a novel
LQT-3 mutation, Ei295K (EK), and describe its functional consequences when expressed
in HEK293 cells.
The clinical phenotype of the proband indicated QT-interval prolongation in the absence of
T wave morphological abnormalities and a steep QT/R-R relationship, consistent with an
LQT-3 lesion. However, biophysical analysis of mutant channels indicates that the EK
mutation changes channel activity in a manner that is distinct from previously investigated
LQT-3 mutations.
The EK mutation causes significant positive shifts in the half-maximal voltage (V^ ) of
steady-state inactivation and activation (+5.2 and +3.4 mV, respectively). These gating
changes shift the window of voltages over which Na+ channels do not completely
inactivate without altering the magnitude of these currents. The change in voltage
dependence of window currents suggests that this alteration in the voltage dependence of
Na+ channel gating may cause marked changes in action potential duration because of the
unique voltage-dependent rectifying properties of cardiac K+ channels that underlie the
plateau and terminal repolarization phases of the action potential. Na+ channel window
current is likely to have a greater effect on net membrane current at more positive
potentials (EK channels) where total K+ channel conductance is low, than at more negative
potentials (wild-type channels), where total K+ channel conductance is high.
These findings suggest a fundamentally distinct mechanism of arrhythmogenesis for
congenital LQT-3.
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Introduction
Electrical activity in the heart is the result of a complex interaction of a large number of ion
channels, pumps, and exchange mechanisms that serve unique physiological roles in
anatomically distinct regions (1,2). The action potential duration (APD) of ventricular cells
is determined by a long-lasting (hundreds of milliseconds) depolarization or plateau phase
that is controlled by a fine balance between small inward and outward ionic currents and
during which there is little change in membrane potential (3). Key to an energetically
favorable maintenance of depolarization are the voltage-dependent rectification properties
of at least two types of potassium channel currents, l|<, and 1^, which restrict outward
movement of potassium during the plateau but permit large outward currents during the
terminal phases of repolarization as the membrane potential becomes more negative (4,5).
Physiological insight into the roles of ion channels in the control of the human
cardiac action potential (AP) plateau phase has grown rapidly during the past 5 years from
studies of the congenital long-QT syndrome (LQTS), an inherited cardiac arrhythmia,
which is clinically characterized by prolongation of the ECG QT-interval, syncope, and
sudden death (6-12). The unexpected importance of Na+ channel activity to the control of
QT-intervals has been revealed by studies of LQT-3, which is caused by mutations in the
SCN5A gene, which codes for the a-subunit of the cardiac Na+ channel (8,10,13).
Expression of LQT-3 mutant channels in heterologous systems has revealed
mutation-induced channel activity that either directly (14-16), or indirectly (17-20) causes
a small increase in net inward current over the voltage range and time course of the AP
plateau. Computational analysis has shown that this increase in inward current is sufficient
to explain the cellular phenotype of APD prolongation (17,21). Nevertheless, not all LQT-3
mutations alter Na+ channel functional properties in the same manner, and distinction in
mutation-induced changes in channel properties is important to document, not only
because of the possibility of mutation-specific clinical phenotypes but also because such
changes may have implications for therapeutic intervention.
In the present study, we report the biophysical consequences of a novel LQT-3
mutation that change a conserved negative into a positive amino acid (E1295K [EK]) in a
region immediately adjacent to the extracellular portion of the S4 segment of channel
domain III (DIIIS4). Expression of mutant channels in a mammalian cell line indicates that
the primary effect of this mutation is to cause small positive shifts in the voltage
dependence of both activation and inactivation gating of the channel, which, in turn, shift
Chapter 5 | PACE 107
the window of voltages over which noninactivating Na+ channel activity can be measured
(22-24). These small changes in the voltage dependence of Na+ channel gating occur
over the plateau range of membrane potentials for which two cardiac K+ channel currents,
IK, and 1^, show strong inward rectification (4,25-32). Window current that flows during the
terminal phase of repolarization (wild-type [WT] channels), where rectification of 1 ,^ and
l«, is being relieved, is likely to be less effective than window current that flows over more
positive voltages (EK channels) where the conductance of these two channels is minimal.
The linkage of these small changes in Na+ channel gating to delay in ventricular
repolarization through LQT-3 confirms the important principle of balance of currents
necessary to maintain the AP plateau phase and the role of membrane input impedance in
determining the effects of small changes in ion channel currents on cellular electrical
activity (3). Thus, our findings are important because they further support the concept of
phenotypic heterogeneity of LQT-3 that has to be taken into account when developing new
therapeutic strategies for this disorder.
Materials and Methods
Molecular Screening
Cenomic DNA was extracted from peripheral blood lymphocytes by standard techniques.
The coding region of the SC/V5A gene encoding the cardiac Na+ channel was screened
using single-strand conformation polymorphism (SSCP) on polymerase chain reaction
(PCR)-amplified genomic DNA samples. The abnormal conformers were directly
sequenced using an ABI310 genetic analyzer or cloned (TOPO-TA cloning, Invitrogen)
and sequenced using plasmid-specific oligonucleotides. SSCP shifts were also checked
against a panel of genomic DNA from 300 (600 chromosomes) healthy reference
individuals. The presence of a second mutation in the remaining LQTS-related genes
(i.e., KCNQ7, HERC, KCNE1, and KCNE2) was excluded by molecular analysis.
Mutagenesis and Expression of Recombinant Na+ Channels
The E1295K mutation of SCN5A was engineered into WT cDNA cloned in PCDNA3.1
(Invitrogen) by overlap extension using mutation-specific primers and Quik Change™ Site-
Directed Mutagenesis Kit (Stratagene). The presence of the mutation was confirmed by
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sequence analysis. WT and mutant Na+ channels were expressed in HEK293 cells. Briefly,
transient transfections were carried out with equal amounts of Na+ channel a-subunit,
with hfii and/or hf}2 subunits cDNA subcloned individually into the PCDNA3.1 (Invitrogen)
vector (total cDNA 2.5 u.g) using a previously described procedure (17). Control
experiments (data not shown) indicated no significant differences in channel activity for
these subunit combinations. We found no difference in the properties of expressed
channels with or without cotransfection of hfte.
Electrophysiology
Membrane currents were measured using
whole-cell patch-clamp procedures, with
Axopatch 200B amplifiers (Axon
Instruments, Foster City, CA). Recordings
were made at room temperature (22°C)
using an internal solution containing
(mmol/L) CsCI 60, cesium aspartate 80,
ECTA 11, MgClj 1, CaClj 1 (effective free
calcium 100 nmol/L), HEPES 10, and Na^-
ATP 5, pH adjusted to 7.2 with CsOH. In
experiments recording I/V curves, external
Na+ was reduced to 30 mmol/L using n-
methyl-glucamine as a Na+ substitute.
The use of these solutions in our
experiments allowed us to make very stable
recordings with minimal time-dependent
changes in voltage-parameters of activation
and inactivation.
We have carried out control
experiments for both voltage-dependence of
activation and inactivation. After an initial
time of i to 2 minutes, we determined that
there are no significant changes in the
voltage-dependence of activation or
inactivation for periods at least as long as
12 minutes (FIGURE 5.1). However, in order
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FIGURE 5.1
Stobi/ity 0/recordings ivith
intrace//u/ar so/uti'on used in this
study. fnactiVat/on (A) and
acliVotion (B^ curves recorded at
trie indicated times. We detect no
signi/zcant change in trie yo/tage-
dependence o/inact/Vation or
actiVat/on oi'er the recording
periods used in this study.
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to ensure reproducibility, we systematically timed each experiment and thus restrict
recording times between 3 min and 8 min after rupturing the membrane to establish
whole-cell conditions. pClamp 7 (Axon Instruments, Foster City, CA); EXCEL (Microsoft,
Seatle, WA); and Origin (Microcal Software, Northampton, MA) were used for data
acquisition and analysis. Protocols used have been described previously by us (14,17).
Holding potentials were -80 mV unless otherwise indicated. Control experiments of
voltage-dependence of activation and inactivation with -100 mV holding potentials did not
yield significantly different values. Data are represented as mean±SEM. Two-tailed
Student's t-test was used to compare means; P<o.O5 was considered statistically
significant.
Results
Description of a New LQT-3 Mutation in a Patient with QTc Prolongation
The patient, an 18-year-old white man, was referred to us because of the documentation of
QT-interval prolongation at medical checkup. No history of syncope and cardiac arrest was
present. Family history was negative for syncope and sudden death. The 12-lead ECG
showed normal sinus rhythm and normal atrioventricular and intraventricuiar conduction;
a QT-interval prolongation (QTc D2: 480 ms), in the absence of T wave morphological
abnormalities, was also observed. No ventricular ectopies were found at 24-hour Holter
recording or elicited at the exercise stress test. Interestingly, QTc interval was shorter
during relative tachycardia (both at Holter and exercise stress test, FIGURES 5.2A and 5.2B),
indicating a steep QT/R-R relationship, FIGURE 5.2c, which compares the relationship
between QT and R-R intervals for this proband and a noncarrier indicates almost a
doubling of the QT/R-R slope for the proband. These data show an increased propensity to
excessive QT prolongation at slow heart rate for the carrier of the EK mutation and suggest
increased risk of arrhythmia during bradycardia. This abnormal adaptation of the QT-
interval has been reported in carriers of LQT-3 mutations (33) but not in carriers of LQT-i
or LQT-2 mutations or in control subjects (33,34). Thus, the clinical phenotype suggested
the possibility of an LQT-3 lesion.
Analysis of the DNA of the proband by SSCP in fact revealed an abnormal
conformer in the exon 22 of the SCN5A gene. Subsequent DNA sequence analysis of this
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exon with specific primers for the regions of introns 21 and 22 flanking exon 22 showed
a single nucleotide transition from C to A at the first base of the codon 1295 leading to the
missense mutation Glui295l_ys, changing the charge at this location from negative to
positive. Because this change in charge occurs close to the extracellular extremity of
DIIIS4, a critical contributor to channel gating, we next sought to determine whether
functional changes accompany this amino acid change.
Biophysical Characterization of the EK Mutation in HEK293 Cells
We performed a detailed characterization of mutant EK channels to look for biophysical
properties that may explain the observed clinical phenotype. HEK293 cells transiently
transfected with EK cDNA expressed Na+ currents similar in amplitude and time course to
WT channels (FIGURE 5.3A). Mean peak current density was not different in cells expressing
WT or EK channels: 254±2i pA/pF (n=i3) and 259*31 pA/pF (n=io), respectively.
FIGURE 5.3B shows that, in contrast to most of the previously reported LQT-3 mutations,
we did not measure any mutation-induced increase in sustained current in response to
voltage pulses applied near the expected peak of the I/V relationship (-10 mV). The
measured fractional tetrodotoxin (TTX)-sensitive current after 50 ms was o.29±o.og%
(n=9) of peak current with WT channels and o.24±o.O7% (n=5) with mutant channels.
We next fitted the time course of the onset of current inactivation with a
monoexponential decay function, because it is possible that changes in inactivation
kinetics may contribute to control of APD. In some cells, this fit could be slightly improved
FIGURE 5.2
£CG recordings o/the EK corner
during relative tachycardia (A)
and bradycardia (Bj, shewing the
increase o / Q T corrected/or heart
rate with Bazett's/ormu/a (Q7c)
at s/oiver heart rates. C, Anafysis
o/the QT versus R-R interval
relationship in the EK comer
measured in /ead D2 during
12-fead Ho/ter recording/or the
mutation carrier and/or a hea/thy
contro/ subject (the mother o/the
proband^. The QT/R-R s/opes
were 0.254 ""d 0.745/or the EK
patient and the contro/ subject,
respectiVefy.
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FIGURE 5 3
A, Representative No* currents in
HEK293 ce//s transiently
trons/erted iv/th V/Tond EK
cDNAs. The currents u^re evoked
by 25 ms pu/ses to vo/toges
«">ging/rom -80 to +70 mV
(5 mV st«ps^  u/itfi a 30 mmo//t
No* extrace//u/ar solution.
B, 7TX-sens/t/Ve current
(30 (j.mo//y evoked by 0 test
pu/se to -70 mV (traces ore
average 0/10 siveeps .^ Traces ivere
norma/ized/or comparison (peak
WT-5.5 nA and £((-7.1 nA;.
/nsets, some recordmgs but u>ith
expanded scafe.
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when a biexponential function was used, but in these fits, the slower component of
inactivation never exceeded 10% of the total weight (data not shown). Therefore, we used
a monoexponential model for simplicity. The effect of the EK mutation on kinetics was
restricted to the voltage range between -35 and -20 mV where it significantly slowed the
onset of inactivation (FIGURE 5.4A). We then measured the time course of recovery from
inactivation (RFI) (after a 100 ms conditioning pulse to -10 mV) and observed a mutation-
induced speeding of this process (FIGURE 5.4B). Time constants and relative weights
on the averaged data are as follows: WT (o): T f j j ^ o . i ms, af35,=o.87, 7510^=446 ms,
aslow=°-i3; EK (.): Tf.^11.6 ms, afast=o.9O, T , . | ^ = 4 6 4 ms, a ,^=o. io . Time of half-
recovery (Twj) from inactivation was significantly faster with EK channels than with
WT channels when this parameter was determined for each individual cell:
WT T,/2=i8.2±4.o ms (n=6) and EK T,/j=9.6±i.6 ms (n=8); P<o.O5.
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A, Time constant 0/onset 0 /
JnactiVation 0 / V/T and FK
chonne/s fitted with 0
monoexpomrntia/ decay versus
command membrane fo/tage
(n-6/or V/T and n=7/or EK).
B, Recovery _/rom inactiVation ivas
fitted with a biexponentia/
/unction (see results).
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We next evaluated the effects of the EK mutation on the voltage dependence of steady-state
activation and inactivation. Activation was determined from I/V relationships by
normalizing peak current to driving force and maximal current and plotting normalized
conductance versus voltage (FIGURE 5.5). This analysis showed small but consistent
positive shifts in activation. We detected a larger mutation-induced positive shift in the
voltage dependence of inactivation that is also illustrated in FIGURE 5.5. Boltzmann
relationships were fitted to steady-state activation and inactivation data, and we obtained
the following results. Slope factors of inactivation and activation were not different. For
inactivation, V ^ : -65.2±o.2, -6o.o±o.2; k: 6.i±o.2, 6.i±o.i (n=i3 for WT and n=io for EK);
for activation: V-,^: -2i.5±o.3, -i8.6±o.3; k: 6.g±o.3, 6.7±o.2 (n=6 for WT and
n=7 for EK). All differences between inactivation and activation V ^ are statistically
significant at P<o.oi.
Mutation-induced Shift
in Window Current
Are these effects on the voltage dependence
of activation and inactivation related to the
cellular phenotype: APD prolongation?
Close inspection of the effects of the EK
curves in FIGURE 5.5 suggests that the
mutation changes the window of voltages
where these two curves overlap. To test for
this, we used a slow-voltage ramp protocol
FIGURE 5.5
Steady-state actiValion and
inactiVati'on re/ationships were
measured with protoco/s presented
in the insets. For actiVation
measurements, peak currents were
norma/ized to dnVing/orce to
determine conductance. Fits to
experimenta/ data yieWed the
resu/ting So/tzmann parameters
(see resu/tsj.
•80 -6o
V M (MV)
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FIGURE 5.6
Currents with WT, £K, and AKPQ
channels e/icited with a ramp
protoco/ ranging/ram -too to
+50 mV in 2 seconds. Recordings
shown are sca/ed/or comparison and
are TTXsubtract«d (30 n.mo//lj.
to measure window currents. Such slowly rising voltage ramps promote inactivation of
transient currents and have proven useful in the measurement of the voltage dependence
of noninactivating Na+ current for other LQT-3 mutations (35). We applied this protocol
before and after the application of 30 u.mol/L TTX to first measure and then subtract
background currents. As illustrated in FIGURE 5.6, we measured small Na+ channel window
current for WT and EK channels. Current density of the window current was not modified
by the mutation (WT=o.54±o.2i pA/pF (n=8); EK=o.4O±o.i2 pA/pF (n=io); NS). However,
the peak of the window current is shifted. The average voltage of the peak was shifted by
about +10 mV by the EK mutation: WT=
-44.5±i.3 mV (n=8) and EK=-35.5±i.o mV
(n=io); P<o.ooi. The I/V relationship
obtained from this protocol indicates a very
restricted range of voltages over which
noninactivating Na+ current is expressed for
the EK channel, a range of voltages that
coincides only with the window of overlap
between the two gating curves (FIGURE 5.5).
Furthermore, this voltage dependence
-25 o 25 50 distinguishes the activity of EK mutant
channels from other LQT-3 mutant channels
that conduct sustained channel activity over
a broader voltage range and have a fundamentally distinct response to voltage-ramp
protocols as illustrated by the AKPQ mutation (16,35,36) in FIGURE 5.6. Moreover, note that
peak AKPQ channel currents evoked with this protocol were on average 6 to 8 times larger
than window currents (3.44±o.84 pA/pF; peak voltage -i5.o±o.6 mV; n=4), again pointing
to a fundamental different mechanism underlying mutation-induced gating changes.
E1295K
AKPQ
•100 75 -50
V M ( M V )
Discussion
Novel Mechanism of APD Prolongation Linked to the LQT-3 Syndrome
The main findings of this study are that a novel SCN5A mutation, which is linked to
a clinical phenotype of LQT-3 (33)i changes the biophysical properties of expressed
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channels in a manner that is distinct from previously reported LQT-3 mutations. In
contrast with other previously investigated LQT-3 mutations such as the AKPQ mutation,
the EK mutation promotes sustained channel activity only over a very narrow window of
voltages that differs from WT channels only in the voltage range of the window.
To significantly alter net membrane current, the mutation-induced window current
must flow when currents through repolarizing channels are small.
Heterogeneity in the Pathological Mechanisms in LQT-3
Thus far, seven mutations linked with LQT-3 have been functionally studied (18,20,35,37-
40). Most of these mutations alter the fast inactivation properties of the channel-inducing
sustained Na+ current on prolonged membrane depolarization over a wide range of
plateau voltages. Such a defect is consistent with an increase in inward current during the
entire plateau phase of the AP, which consequently prolongs the APD. This is not the only
mechanism by which LQT-3-linked Na+ channel mutations are able to prolong cellular
APD. Recent studies (17,18) showed that an LQT-3 mutation in the carboxy-terminus region
of the channel (D1790G), which does not produce persistent current different from
WT channels, prolongs APD indirectly through effects on other ion channels. In the
present work, we report yet a third mechanism by which an LQT-3 mutation is likely to
prolong the cellular AP.
Roles of K+ Channel Rectification in EK Channel Cellular Phenotype
It has been known for almost 50 years that the plateau phase of the cardiac AP is a period
in which the cellular input impedance is maximal (3). Consequently, during this plateau,
small changes in net ionic current will cause large changes in membrane potential.
Repolarization of the AP normally begins when outward current through delayed rectifier
(l«5 and IK,) channels is sufficient to just balance and eventually exceed the total flow of
inward current across the membrane. As repolarization begins, the cellular membrane
potential reenters the voltage range for which WT Na+ channels may again open to
contribute as window current. This voltage range, however, coincides with voltages at
which rectification of inward rectifier (IK,) and HERC channels (32,41,42) is relieved.
Consequently, the effect of WT Na+ channel window current is minimal. In the case of cells
expressing EK channels, the range of voltages over which window current can flow is more
positive, and the contribution of these channels is more pronounced because window
current through them is activated over a voltage range in which rectification of lg, and
1^ channels minimizes their contribution to total membrane current.
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Note that because the functional effects of this mutation are most pronounced when
background K+ channel currents are minimized, it is likely that the cellular (and hence
systemic) effects of the mutation may be more pronounced in cells with smaller outward
repolarizing current such as M cells (43). If one assumes heterogeneity of repolarizing
current across the ventricular wall (44), then it is likely that the effect of the EK mutation
will be blunted in cells with higher density of outward currents. A difference between
repolarization in different cell types might therefore exacerbate heterogeneity in APD
within the myocardial wall and increase the likelihood of an arrhythmic event (45).
Structure-function Relationship
Glutamic acid (E1295), mutated into a positively charged lysine in this patient, is found in
a 4-amino acid extracellular loop connecting Dill S3 with DIIIS4. E1295 is the amino acid
closest to DIIIS4, which is one of the voltage sensors for activation gating process of the
channel (46). The presence of a negative residue just external to the DIIIS4 segment is not
only conserved among cardiac channels of different species but also among all different
isoforms of the Na+ channel. We postulate that this mutation-induced change in charge
alters the voltage dependence of activation and/or inactivation gating sensor and that this
is reflected by the recorded shifts in steady-state activation and inactivation curves.
Window currents are found at voltages where there is overlap of the activation and
inactivation curves, and as there is a concomitant shift of both, window currents are
shifted accordingly (FIGURE 5.6). The EK mutation hastens the RFI after a TOO ms
inactivating pulse. This observation is consistent with recent observations (47,48)
showing that movement of DIIIS4 and DIVS4 is coupled to fast inactivation. These
changes in channel kinetics may also have to be taken into account when considering
the basis of frequency-dependent changes in cellular electrical activity induced by the
EK mutation.
Clinical and Therapeutic Implications
This study provides a further illustration that the LQT-3 type of LQTS is aggravated by
bradycardia (FIGURE 5.2). Beta-blockers are the mainstay in the management of the LQTS;
however, the efficacy of this treatment in LQT-3 patients has been questioned (49) mainly
because the decrease in heart rate that accompanies this treatment can enhance QT
prolongation in LQT-3 carriers. Because the present study provides evidence that
bradycardia markedly aggravates the phenotype (prolonged QT) in the case of the EK
mutation, our results predict that beta-blockers may worsen the phenotype carriers of this
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mutation by slowing heart rate. Clearly, our results emphasize the importance of identifying
the genotype of LQTS patients in general and LQT-3 patients in particular, before an
optimum therapeutic regimen can be planned. For example, in the case of the EK
mutation, alternative strategies such as pacing (which prevents bradycardia) or
administration of mexiletine (which by shifting the inactivation curve to more negative
voltages may normalize the voltage dependence of the window current) might prove to
be more effective in preventing arrhythmias.
Implications for Drug-induced LQTS
Our investigation into the functional consequence of the EK mutation on Na+ activity
provides one more example of the delicate interplay of small inward and outward currents
that control the plateau phase of the cardiac AP. In the case of the EK mutation, there is no
net increase in the magnitude of inward current flowing through Na+ channels; instead,
there is a shift in the voltages over which channels can reopen. Such small changes in the
voltage-dependent properties of inward Na~*~ channel current can have marked effects on
APD only if they occur in the presence of a highly nonlinear background of outward
K+ channel currents (50). By inference, these results suggest that alteration in background
K+ channel activity against different patterns of Na+ channel activity would be expected to
have distinct effects on APD. It is interesting to speculate that subtle changes in
Na+ channel gating caused by coding changes in the a-subunit, insufficient to cause
substantial changes in cellular APD by themselves, may lead to excessive changes in APD
in the face of inhibition of one of these key K+ channels and thus contribute to some forms
of drug-induced LQTS. Experiments are underway to test for this possibility.
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Abstract
BACKGROUND. Congenital long-QT syndrome type 3 (LQT-3) is caused by mutations in the
gene encoding the a-subunit of the cardiac Na+ channel (SC/V5A). Previous studies have
linked homozygous mutations in SCN5A and the K+ channel gene KCNH2 (HERC) to
congenital long-QT syndrome with functional 2:1 atrioventricular block (AVB), a severe
phenotype with a particularly bad prognosis.
METHODS AND RESULTS. In an infant with 2:1 AVB and major QTc prolongation
(657 ms'/^J, mutational analysis identified a heterozygous missense mutation (L6igF)
in the domain l-ll linker of the cardiac Na"*" channel. Whole-cell patch-clamp analysis of
recombinant L619F mutant channels expressed in HEK293 cells showed a mutation-
induced increase in persistent TTX-sensitive inward sodium current (WT: o.26±o.o6;
L619F: o.79±o.i7 pA/pF; P<o.oi). In addition, a 5.8 mV positive shift in the voltage-
dependence of inactivation caused a shift in the peak voltage (WT: -44^0.7; L619F:
-4O.7±o.g mV; P<o.O5), and an increase in the amplitude of Na+ channel 'window-current'
(WT: o.58±o.i2; L619F: i.O7±o.i7 pA/pF; P<o.O5).
DISCUSSION. This study provides the first evidence that a heterozygous missense mutation
in SCN5A may cause LQT-3 with functional 2:1 AVB in an infant. The L619F mutation
promotes an increase in sustained (non-inactivating) current as well as an increase in
Na+ channel window-current, two mechanisms which are expected to delay ventricular
repolarization. The defective inactivation imposed by the L619F mutation implicates
a novel role for the domain l-ll linker in the Na* channel inactivation process.
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Introduction
Congenital long-QT syndrome (LQTS) is an inherited disorder characterized by prolonged
ventricular repolarization and a propensity to sudden cardiac death caused by
polymorphous ventricular tachycardia (torsades de pointes; TdP). LQTS is considered a
pure 'electrical disease', and is usually not associated with congenital heart disease or
acquired cardiac disabilities (1,2). The symptoms of LQTS may surface at any age as
episodic dizziness, syncope, epileptic seizures, and sudden cardiac death. LQTS may also
be involved in some cases of sudden infant death syndrome (3).
Long-QT syndrome in association with two-to-one atrioventricular block (AVB)
typically occurs in fetuses, neonates and young infants, and is probably the result of a
severely prolonged action potential duration in association with a relatively long effective
refractory period of the His-Purkinje system and/or the ventricular myocardium (4,5). It has
been suggested that LQTS resulting in AVB in the neonatal period has a particularly poor
prognosis (6,7). Despite traditional management with beta-adrenergic blockade and/or
cardiac pacing, a large proportion of infants may not survive childhood (6).
Recently, three reports described the association of homozygous mutations in the
KC/VH2 (HERG) (8,9) and SCN5.A genes (10) with a severe cardiac phenotype involving
marked prolongation of the QT-interval and 2:1 AVB. In contrast, heterozygous carriers
were free of symptoms, and had normal or marginally prolonged QTc intervals. In the
present study, we describe the first case of an LQTS patient with functional 2:1 AVB due to
a heterozygous mutation of the SCNy^ gene. Biophysical characterization of the SCN5A
mutation L619F revealed a novel combination of enhanced non-inactivating Na+ channel
activity during prolonged depolarization with increased Na* channel window current, two
channel properties that, by themselves, would be expected to delay repolarization and
prolong the QT-interval (n). Moreover, the location of the L6igF mutation in the domain
l-ll linker suggests a novel role of this region in Na+ channel inactivation.
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Materials and Methods
Clinical Data
The study was performed according to a protocol approved by the Leuven University ethics
committee and informed consent was obtained. The patient studied was the second child
of asymptomatic, non-consanguineous Western European parents.
Mutation Analysis
Cenomic DNA was extracted from peripheral blood lymphocytes using standard
techniques. The entire coding regions of the known LQTS genes were amplified using PCR.
Denaturing high performance liquid chromatography (D-HPLC; Wave Transgenomics) was
performed to analyze the KCNQi, KCNH2 and KCNE2 genes. The KCNEi and SCN5A gene
were analyzed by sequence analysis of the complete coding region by the Big-Dye
terminator ready reaction kit (PE Applied Biosystems) on an ABI-3100 genetic analyzer
(PE Applied Biosystems). The mutation L619F was excluded in a control panel of 150
(300 alleles) healthy individuals.
Construction and Expression of Recombinant Na+ Channels
The mutant hHi/Ci855T was engineered using the QuikChange-XL™ site-directed
mutagenesis kit (Stratagene, La jolla, CA) using the following mutagenic sense and
antisense primers: 5'-CC.CCA.CCA.ACC.CAC.CTC.TTC.CCC.CCT.CTC.ATG.CTA.G-3'
5'-C.TAC.CAT.CAC.ACG.GCC.GAA.CAC.GTC.CCT.TCC.TCG.GC-3'
Na+ channels were expressed in HEK293 cells. Transient transfections of wild-type (WT)
and L619F mutant Na+ channels were carried out with equal amounts of Na+ channel
a -subunit, [Ji-subunit, and CD-8 antigen cDNA subcloned individually into the PCDNA3.1
(Invitrogen) vector (total cDNA 2.5 mg) using a previously-described procedure (12).
Transfected cells were identified by light microscopy and the use of anti-CD8-coated beats
(Dynabeads M450 CD8).
Electrophysiology
Membrane currents were measured using whole-cell patch-clamp procedures, with
Axopatch 200B amplifiers (Axon Instruments, Foster City, CA). Recordings were made at
room temperature (22T) using an internal solution containing (mmol/L) CsCI 60, cesium
aspartate 80, EGTA 11, MgClj 1, CaClj 1 (effective free calcium 100 nmol/L), HEPES 10,
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and NajATP 5, pH adjusted to 7.2 with CsOH. In experiments recording I/V curves,
external Na+ was reduced to 30 mmol/L using n-methyl-glucamine as a Na~*~ substitute.
The use of these solutions in our experiments allowed us to make very stable recordings
with minimal time-dependent changes in voltage-parameters of activation and inactivation
(13). Protocols to analyze mutant channel gating have been described previously (13,14).
Statistical Analysis
Data were collected and analyzed with pClamp8 (Axon Instruments, Foster City, CA);
Excel (Microsoft, Seattle, WA); and Origin (Microcal Software, Northampton, MA).
Data are represented as mean ± SEM. Two-tailed Student t-test was used to compare
means; P<o.O5 was considered statistically significant.
Results
Clinical Characteristics
The mother of the index patient was referred at a gestational age of 27 weeks for
ultrasound evaluation because of fetal bradycardia and a large perimembraneous
ventricular septal defect. Echography at 35 weeks revealed AVB with ventricular bradycardia
of 72 bpm. Maternal serum was negative for anti-SSA/Ro antibodies.
A female baby, weighing 2840 gram, was born prematurely at 36 weeks of
gestation by uneventful vaginal delivery. Initial ECC after birth showed sinus rhythm of 139
bpm, normal atrioventricular conduction, signs of pre-excitation, and a prolonged QTc
interval of 538 msV* (FIGURE 6.IA). Serum levels of potassium, magnesium, and calcium
were within normal limits. No evidence of impaired hearing was found. In the second week
after birth, symptomatic 2:1 AVB developed when sinus rate exceeded 140 bpm. Treatment
with propranolol was instituted (3x3 mg/day) in order to slow the sinus rhythm to allow 1:1
AV conduction. Continuous ECG recording (Holter) performed on day 10 after birth
confirmed frequency-dependent conduction anomalies with episodes of 2:1 AVB (FIGURE
6.1 B), and intermittent pre-excitation without documented episodes of supraventricular
tachycardias. A clinical challenge with mexiletine had no effect on the QTc interval. Digoxin
therapy was initiated in order to prevent development of cardiac failure in anticipation of
the closure of the ventricular septal defect. Patient was discharged on beta-blocker and
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digoxin therapy in combination with cardiac home monitoring. Two weeks later, while
temporarily disconnected from the monitor for breast feeding, patient underwent a period
of paleness and hypotonia, which could be rapidly reversed by mouth-to-mouth
resuscitation by the father. Evaluation in hospital showed sinus rhythm, prolonged QT-
intervals, and intermittent episodes of 2:1 AVB, which were clinically well tolerated. Breast
feeding was discontinued and propranolol increased to 4x3 mg/day. Subsequent follow-up
until 11 months of age is uneventful, with QTc values ranging between 481 and 657 ms'/^.
Despite several weeks of continuous monitoring, and multiple Holter and ECG recordings,
no ventricular ectopy has ever been observed in the first year of life. At the age of
5 months, digoxin therapy was discontinued and the ventricular septal defect was surgically
closed.
FIGURE 6.1c, which compares the relationship between QT and R-R intervals for
the proband and an age-matched non-carrier indicates almost a doubling of the QT/R-R
slope for the proband. These data show an increased propensity to excessive QT
prolongation at slow heart rate for the carrier of the L619F mutation and suggest increased
risk of arrhythmia during bradycardia. This abnormal adaptation of the QT-interval has
been reported in carriers of LQT-3 mutations (13,15), but not in carriers of LQT-i or LQT-2
mutations or in control subjects (15). Thus, the clinical phenotype suggests the possibility
of an LQT-3 lesion.
Insights in the Congenital Long QT-J Syndrome | PACE 126
None of the family members had experienced any symptoms related to LQTS. The father
has normal QTc intervals, the mother has a borderline positively prolonged QTc interval of
450 msV2, and information for the older sibling is lacking.
Identification of the SCN5A Mutation
Bidirectional sequencing analysis of the SCN5A gene revealed a single nucleotide transition
(C-T) at position 1855, which is expected to cause a change from a leucine (L) to a
phenylalanine (F) at codon 619 within the cytoplasmic linker between domains I and II
(FIGURE 6.2). In addition, D-HPLC analysis of the proband revealed a heteroduplex
fragment with abnormal elution profile in the KC/VE2 gene, and subsequent sequence
analysis revealed the common polymorphism T8A-M/RP1 in the KC/VE2 gene (16).
The L619F mutation in SC/V5A and polymorphism in KC/VE2 were also present in the
mother, but not in the father. No mutations were identified within the KCNQ1, KCNH2,
and KCNE1 genes.
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Biophysical Properties of L619F Mutant Na+Channels
Macroscopic Na+ current was recorded from HEK 293 cells expressing wild-type (riHi/WT)
and mutant channels (riHi/L6i9F). Peak current density was not affected by the L619F
mutation (WT: 362±4O pA/pF (n=i2); L6igF: 3Oi±33 pA/pF (n=io); P=NS). At low
recording gain, there is no marked difference between the waveforms of WT and L619F
channels (FIGURE 6.3A), but at higher gain, recordings reveal a mutation-induced increase
in sustained channel activity (FIGURE 6.3B). Assayed as the tetrodotoxin (TTX)-sensitive
current at -10 mV and 150 ms, this mutation-induced increase in sustained current is
significant (WT: o.26±o.o6 pA/pF (n=g); L619F o.79±o.i7 pA/pF (n=g); P<o.oi).
The L619F mutation does not affect the kinetics of the onset of inactivation
(FIGURE 6.4A), but almost halves the time for recovery from inactivation (RFI)
(FIGURE 6.4B). T,/j (time to half recovery from inactivation) was 2.78±o.i9 ms for WT
(n=i2); i.45±o.i2 ms for L619F (n=io); P<o.ooi. Similar speeding of the RFI for L619F was
measured when the holding potential was -6omV, -8omV, or -i2omV (data not shown).
L619F also results in a +5.8 mV shift in the voltage-dependence of channel
availability (WT: -64.o±o.8 mV (n=8); L619F: -58.2+1.1 mV (n=io); P<o.O5) (FIGURE 6.5A).
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A positive shift in the voltage-dependence of channel availability, in the absence of a
change in the voltage-dependence of activation, would be expected to change the window
of voltages where non-inactivating (window) current can be measured (17). In combination
with the mutation-induced increase in sustained current at voltages outside of this window
of activation/inactivation overlap (FIGURE 6.3B), the data predict that the L619F mutation
should cause marked changes in the voltage-dependence of steady-state (non-inactivating)
Na+ channel current. We used a ramp voltage protocol for which voltage-changes are
imposed at a sufficiently slow rate to reveal steady-state Na+ channel currents as a
function of membrane potential (13). The L619F mutation increases the current density of
the peak window current (WT: o.58±o.i2 pA/pF (n=7); L619F: i.og±o.i7 pA/pF (n=7);
P<o.O5), and shifts the voltage at which the maximum window current occurs by +3.6 mV
(WT: -44.3±o.7 mV (n=7); L6igF: -4O.7±o.9 mV (n=7); P<o.oi) (FIGURE 6.5B), consistent
with the effects of the mutation on the voltage-dependence of activation and inactivation.
In addition, the window current waveform also indicates the presence of non-inactivating
channels over a broad voltage-range as evidenced by the 'shoulder' in the curve (see the
arrow in FIGURE 6.5B). Thus, the voltage-dependence of the non-inactivating component
of L6i9F channel activity is due to both the overlap in steady-state activation and channel
availability (FIGURE 6.5A) as well as to mutation-induced sustained Na* current
(FIGURE 6.3s).
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Discussion
Previous studies have reported the association of homozygous mutations in the SCN5A
and KCNH2 genes with congenital long-QT syndrome and 2:1 atrioventricular block (8-10).
In the present study, we describe a novel heterozygous LQT-3 missense mutation, L619F,
identified in a neonate with prolonged QT-intervals and episodes of 2:1 AVB.
Long-QT Syndrome and 2:1 Atrioventricular Block
Long-QT syndrome with 2:1 AVB is rare, with an incidence of 4% reported in pediatric
series of long-QT syndrome patients (6), and to the best our knowledge 64 cases reported
so far in the world literature (1,4-10,18-30). Electrophysiological studies have revealed that
during 2:1 atrioventricular conduction, AVB may occur within the His bundle (24,28), or
more distal in the Purkinje system and/or ventricular myocardium (4,7,23). In 95% of the
reported cases of LQTS with 2:1 AVB, QTc prolongation exceeded 500 ms'/^, and despite
the usual treatment regime of beta-blockers with or without a pacemaker, infant mortality
approximated 50%.
In only three previous cases, the genotype of the patient with LQTS and 2:1 AVB
was assessed (8-10). Two separate cases of homozygous mutations in HERG (8,9), and
one case of a homozygous mutation in SCA/^ A were responsible for this severe phenotype.
Our case is unique, as it represents the first case of a heterozygous Na+ channel mutation
Nove/ fnsights in the Congenita/ Long QT>3 Syndrome | PACE 130
associated with LQTS and 2:1 AVB. In addition to the SC/V5A mutation, our patient was
carrier of the amino acid polymorphism T8A-M/RP1 in the ^-ancillary subunit accessory of
the IK,- channel (31), which is a relatively common polymorphism with an allelic frequency
of 1.6% in the general population. We believe that this polymorphism probably did not
contribute to the clinical phenotype, as T8A-M/RP7 does not significantly affect 1^ channel
properties in the absence of QT prolonging drugs (16). Interestingly, the mother of the
index patient, who also carried both the SCN5A mutation and the M/'RPi polymorphism,
displayed only borderline QTc interval prolongation, and did not experience any long-QT
syndrome-related symptoms.
Association long-QT syndrome, 2:1 AVB, and VSD
The complex cardiac phenotype of long-QT syndrome with functional 2:1 AVB,
in combination with a ventricular septal defect has been reported in 6 cases so far
(TABLE 6.1). Most cases were identified prenatally because of fetal bradycardia
or (supra)ventricular tachycardia. Neonatal QTc intervals were usually very long
TABLE 6.)
Characteristics o/Zong-QT
syndrome patients with 2:7
atriouentricu/ar conduction,
and a iwtricu/ar septa/ de/ect.
Gender Presentation
n.a.
n.a.
M
F
F
F
fetal SVT
fetal brady
brady
fetal brady
fetal VT
fetal brady
fetal brady
Family
history
Neonatal
QTc (sec)
0.693
0.666
0.633
0.636
0.860
0.538
Symptoms TWA/TdP Treatment
TWA
TWA/TdP
TWA
TdP
TdP
TdP
•
BB
BB.mexil.
BB.PP
BB.PP
TP
BB
Dead
18 d.
26 mo
4 d .
Reference
(24)
(6)
(27)
(30)
(30)
This study
Legend: F= Remote; M= mote; n.a. = not assessed; brady= bradycard/a; TWA= Twai>e o/temans; TdP= torsades de pointes;
(S^ VT= (supra-^entricu/ar tachycardia; SB= beta-b/oclker; mexi/.= mexi/etine; TP = temporan'/y pacemaker, PP = permanent pacemaker.
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(538-860 ms'/2), and all 6 previously reported infants died before the age of 2 years
(6,22,24,27,30,31), despite treatment with beta-blockers (n=4) or pacemakers (n=3).
It is possible that the presence of long-QT syndrome and VSD in our patient
occurred by chance, but the recognition of seven patients with an association of two
uncommon disorders may suggest otherwise (TABLE 6.1). Although it is attractive to
assume that the association is not random, and that a genetic mechanism may be
responsible, our data suggest that this may not be the case. Importantly, the proband and
mother carry the same SCN5A mutation and M/RPi polymorphism, but only the infant had
a VSD and experienced severe QT-interval prolongation. Since proband and mother are of
the same sex, the distinction in clinical presentation strongly suggests that other factors
likely contribute both to the structural and electrical dysfunction. In terms of the electrical
problem, it is possible that the developmentally distinct modifier gene activity may, in
combination with the detected Na+ channel defect, produce severe changes in QT
prolongation seen in the proband.
Novel Biophysical Phenotype of the L619F Mutation
Functional analysis shows that the biophysical phenotype of the L619F mutation is novel,
as it combines increased non-inactivating sodium current as reported previously for several
other LQT-3 mutations (33,34), with an increase in the magnitude of window current as
first reported by Abriel et al. (13,35). Using a single channel based model of the ventricular
action potential, Clancy and Rudy (11) showed that an increased sustained sodium current
can prolong ventricular repolarization, which may cause arrhythmogenic early
afterdepolarization (11). The increase in Na+ channel window current is most likely
sufficient to cause prolongation of the QT-interval by itself, as two previous studies (13,35)
reported such channel defect in SCN5/\ mutants associated with the long-QT syndrome.
Neither of these mutations, however, caused non-inactivating sodium current as well. An
increase in Na+ channel window current is expected to offset the delicate balance between
inward and outward membrane currents during the final phase of repolarization (13), which
may lead to prolongation of the ventricular action potential. Thus, the biophysical changes
caused by the L619F mutation are consistent with the expected cellular phenotype: action
potential prolongation.
We also observed a speeding of the recovery from inactivation kinetics in L6igF
mutant Na+ channels. Although faster recovery kinetics are observed in the majority of
LQT-3 mutants (13,14,34,35), it is currently not fully understood whether or not this change
in gating contributes to action potential prolongation, but this change in recovery kinetics
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will certainly shorten refractory periods in the ventricle and predispose the heart to
premature excitation. Interestingly, the mother of the index patient, who also carried the
SCN5A mutation, displayed only borderline QTc interval prolongation, and did not
experience any long-QT syndrome-related symptoms. This suggests that other (genetic)
factors, in combination with the channel defect, may be necessary to induce the long-QT
syndrome phenotype.
First LQTS Mutation in the Cytoplasmic Linker Between Domain I and II of SCN5A
The L619F mutation is the first LQTS mutation in SC/V5A to occur in the cytoplasmic loop,
connecting domains I and II. This mutation causes the substitution from an evolutionary
conserved leucine to phenylalanine, which is likely to change the protein secundary
structure. Previously, two SCN5A mutations linked to Brugada syndrome have been
reported in the same domain of the Na* channel. Culcheney et al. (36) reported the
missense mutation T632M, and Priori et al. (37) reported the L567Q mutation in a 14-
month old girl that died of ventricular fibrillation due to Brugada syndrome. Wan et al.
(38) studied the biophysical properties of L567Q Na+ channels in HEK cells, and
demonstrated that L567Q channels accelerate fast inactivation, and enhance closed-state
inactivation. The resulting decrease in Na+ channel availability is believed to be responsible
for idiopathic ventricular fibrillation (38).
Together with our results, the data of Wan et al. (38) implicate a role of the
intracellular l-ll linker in the control of Na+ channel inactivation. The L619F mutation
speeds the recovery from inactivation, which suggests that the fast inactivated state of
mutant Na+ channels is destabilized. Whether the L619F mutation directly interferes with
the fast inactivation particle (39), or its docking sites (40,41), or whether this phenomenon
is due to allosteric interactions, remains to be determined.
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Summary
In summary, we have identified a novel heterozygous mutation in the SC/S/5^  gene in an
infant with congenital long-QT syndrome and 2:1 atrioventricular block. The clinical
presentation and the electrophysiological findings make this mutation very likely to be the
cause of the disease. The L619F mutation causes a unique biophysical phenotype, as it
combines increased non-inactivating Na+ current with a larger window current. •
The defective inactivation imposed by the L619F mutation implicates a novel role for
the domain l-ll linker in the Na+ channel inactivation process.
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Overview of Cardiac Ion Channelopathies
In 1995, it became clear that the congenital long-QT syndrome resulted from mutations in
cardiac ion channels (1). Mutations in cardiac potassium channels, followed by the cardiac
sodium channel, and auxiliary P-subunits of potassium channels have all been linked to the
long-QT syndrome (1-7) . At present time, a molecular genetic diagnosis can be made in
about 80-90% of all patients with familial long-QT syndrome (P. Doevendans, persono/
commun/cat/on), implicating that mutations in proteins not yet identified may also underlie
this disease. It is in the line of expectation that other ion channels, as well as auxiliary
subunits, and proteins involved in the regulation of cardiac ion channels, will be linked to
TABLE 7.1
OKervieif 0/genes causing
cardiac ion chonne/opoth/es.
Syndrome
LQT-i
LQT-2
LQT.3
LQT-4
LQT-5
LQT-6
BrS
PCCD
ICCD
Andersen's syndrome
CPVT
ARVD2
Gene
rCC/VQi
/CCNH2
SCN5A
(CCfVEi
KCNE2
SCN5A
SCN5A
SCN5A
(CCA/J2
RVR2
RVR2
Ion channel
<Ks
<Kr
<N,
-
'KS
>Kr
>N,
•N,
•N.
'Kira.i
Ryanodine receptor
Ryanodine receptor
Reference
(3)
(2)
0)
(4)
(5)
(6)
(»)
(12)
('3)
(14)
05)
(16)
BrS- Brugada syndrome; PCCD= progress/Ve cardiac conduct/on diseose; /CCD= iso/oted cardiac
conduction disease; CPVT= catecho/aminergic po/ymorph/c i>entncufar tachycardia;
ARVD2= arrhythmogenic right yentricu/ar dysp/as/a type 2.
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the long-QT syndrome in the near future (8). Alterations of any of these components may
interfere with normal function of ion channels, and thus lengthen ventricular
repolarization.
The congenital long-QT syndrome was the first cardiac ion "channelopathy"
to be identified. Since then, a whole spectrum of inherited arrhythmias based on cardiac
ion channel mutations has emerged (TABLE 7.1). Although familial arrhythmic syndromes
are relatively uncommon, they can provide significant insight into the mechanisms
underlying more general conduction and repolarization abnormalities (9). The under-
standing of the genetic basis, or the molecular origin, of inherited cardiac arrhythmias
is likely to have major impact on the diagnostic approach, prevention and treatment of
these disorders (10).
Biophysical Phenotypes of Congenital Long-QT Syndrome
Na+ Channel Mutations
As reviewed in CHAPTERS I and 2 of this thesis, congenital long-QT syndrome type 3
(LQT-3) 's caused by mutations in the SCN5A gene, which encodes the cardiac sodium
channel. After the first mutations were discovered in 1995 (1), the function of recombinant
sodium channels encoded by mutated SCN5A genes were studied in heterologous
expression systems, in particular Xenopus /aew's oocytes and human embryonic kidney
(HEK) cells (17-19). From these early studies, it became clear that most of the LQT-3
mutant sodium channels failed to completely inactivate, which leads to so-called
'noninactivating current' visible during prolonged depolarizing pulses (17,19). In addition
to 'destabilizing' the inactivated state of the sodium channel (i.e. allowing reopenings of
inactived channels) (17,19-22), an allied mechanism has been described for R1623Q mutant
channels, which exhibit a slowed rate of entry into the fast-inactivated state, causing a net
'gain of function' by prolonging Na+ current decay (23,24).
In 1998, An et al. (25) reported the D1790G mutation, located in the early
C-terminal part of the sodium channel, which does not lead to incomplete inactivation of
the sodium channel. In CHAPTER 3 of this thesis, we have extended the finding that
noninactivating current is absent (26), and used the Luo-Rudy computer model of the
ventricular action potential to get a better idea how this mutation might evoke action
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potential prolongation (26). In short, the changes in D1790C Na+ channel kinetics reduce
Na+ current during the action potential upstroke, which is predicted to produce a less
positive overshoot of the action potential (CHAPTER 3). The computational model predicts
an increased Ca*+ entry via L-type Ca*+ channels, leading to an augmented subsequent
Ca*+ transient. Two important ionic pathways, the Na+/Ca^* exchanger (27) and slowly
activating delayed K+ channel current l^, (28), are affected, which is predicted to cause a
net increase of inward plateau current and corresponding increase in action potential
duration. Because the Luo-Rudy computer model may oversimplify intracellular calcium
handling, future studies using transgenic mice harboring the D1790G mutation are needed
to confirm that action potential prolongation is indeed dependent on Ca^-sensitive ionic
pathways. Recently, Baroudi et al. (98) measured noninactivating Na+ current in HEK cells
expressing D1790G channels. Other parameters also differed from those measured in our
study (26), in particular V,^ values for steady-state activation and inactivation, which might
reflect differences in experimental conditions. Additional studies are required to further
investigate these interesting observations.
The Ei295K mutation, described in CHAPTER 5, is another example of an LQT-3
mutation that does not promote sustained sodium channel activity during prolonged
depolarizations (29). This mutation prolongs the ventricular action potential in a distinctly
different way. The mutation-induced gating changes shift the window of voltages over
which Na* channels do not completely inactivate, and this causes marked changes in
action potential duration because of the unique voltage-dependent rectifying properties
of cardiac K+ channels that underlie the plateau and terminal repolarization phases of
the action potential. Because the peak of the E1295K Na+ channel window current occurs
at more positive potentials, it is likely to have a greater effect on net membrane current
because total K+ channel conductance is lower at these more positive potentials (29).
The same biophysical phenotype has been reported for LQT-3 mutation A1330P (30).
Interestingly, the novel L619F mutation, described in CHAPTER 6, is the first LQT-3
mutation that combines both noninactivating sodium current and an increase in window
current. These data clearly demonstrate that there are at least four different mutation-
induced gating changes in LQT-3 sodium channels. Although distinctly different, and not
always associated with noninactivating sodium current during sustained depolarization,
all of these biophysical phenotypes seem to result from mutation-induced defects in the
inactivated conformational state of the sodium channel. The first combination of such
gating changes has been described for the L619F mutation, and it is likely that in the near
future even more variations in biophysical phenotypes will be described.
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Correlating Na+ Channel Structure and Gating Function
in LQT-3 Mutations
The functional characterization of sodium channels containing LQT-3 mutations revealed
the biophysical mechanisms causing aberrant conduction of sodium current. Based on the
knowledge that has been obtained from mutagenesis experiments over the past decade,
a picture of the structure-function relationship of the different domains in the sodium
channel has emerged (for review, see CHAPTER 2, and (31,32)). In the following paragraphs,
we try to integrate the LQT-3 mutations into the latest insights in the structure of the
sodium channel (FIGURE 7.1).
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Fast Inactivation Particle: Domain III-IV Linker
The finding that the AKPQ deletion in the loop between domain III and IV reduces fast
inactivation of Na+ currents was not unexpected (17). It was already recognized that this
region serves as the inactivation particle of the IMa* channel (33,34). A cluster of three
hydrophobic amino acids (11485, F1486, M1487) is thought to bind to a receptor region on
the cytoplasmic surface of the channel protein. It is therefore likely that the AKPQ deletion
due to its close proximity to the IFM motif may disrupt the inactivation particle, hereby
interfering with fast inactivation.
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Rohl et al. (35) determined the three-dimensional structure of the central portion of
the inactivation gate as a peptide in a phosphate buffer using multidimensional NMR
methods. The experiments revealed a rigid a-helix flanked on its N-terminal side by two
turns, the second of which contains the IFM motif. They found that M1487 (residue
number in the cardiac isoform) of the IFM motif hydrophobically interacts with Y1494 and
Y1495, consistent with a three-dimensional structure of the IFM motif itself. The structure
of the inactivation gate peptide in solution suggests that the rigid helix serves as a scaffold
to present the IFM motif and the adjacent Ti488 to a receptor in the mouth of the pore as
the gate closes (hinged lid model).
Since the interaction of the inactivation particle with its receptor is considered to
be mediated by the hydrophobic forces (36), the conformation Rohl et al. (35) determined
in phosphate buffer seems to represent the IFM motif at a resting or open state of the
channels, but not in an inactivated state. Miyamoto et al. (37) determined the solution
structure of the III-IV linker in sodium dodecyl sulfate (SDS) micelles (a relevant
environment at the inactivated state of the channels), and confirmed the presence of a
large hydrophobic cluster composed of the IFM motif, Y1494, Y1495, and Mi498. In
addition, a subsequent study revealed that T1488 probably is bound to I1485 by hydrogen
bounds (38). This large hydrophobic cluster may assist the docking of the IFM motif within
its receptor regions.
Docking Stations for the Inactivation Particle: Domain III-S4/S5 and
Domain IV-S4/S5
The S4-S5 linkers of domain III and IV are thought to form the docking stations for the
inactivation particle (39-42). Recent data from Miyamoto et al. (43) extended these
electrophysiological data, and it now seems reasonable to assume that after initial
depolarization, two hydrophobic clusters in DIV-S4/S5 interact with the III-IV linker.
This hydrophobic interaction would then reduce polarity around the IFM motif, allowing
I1485-F1486 to meet the hydrophobic cluster as a result of a conformational change
(37,44). The inactivation gate then closes by interacting with A1326 in domain III-S4/S5
and/or with N1659 in DIV-S4/S5 (43) (FIGURE 7.2).
Several naturally occurring long-QT syndrome mutation occur in the DIII-S4/S5
(N1325S, A1330P), and DIV-S4/S5 loops (R1644H, T1645M), and it seems tempting to
reconcile them with the discussed structural picture of fast inactivation (FIGURE 7.1 and
7.2). Whereas the N1325S and R1644H mutations show persistent inward current
consistent with disrupted fast inactivation, the A1330P (30) and T1645M (Wehrens et al.,
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do not show these electrophysiological properties. The N1325 residue is
directly adjacent to A1326, which is believed to interact with the phenylalanine of the IFM
motif (40,43). For now, it remains unclear how the other long-QT syndrome mutations
cause structural changes directly affecting channel gating, and it is more likely that
allosteric changes are responsible for impaired channel inactivation.
Role of the C-Terminus in Channel Inactivation
Little is known about the function of the C-terminal region of the voltage-gated sodium
channels. Recently, the study of long-QT syndrome mutations in the C-terminus of the
human cardiac sodium channel implicated a role possible of this channel region in fast
inactivation (see also CHAPTER 3) (20,22,26,45). Using chimeric channels between the
human heart isoform (/1H1) (46) and the human skeletal muscle isoform (foSfcMi) (47),
Deschenes et al. (48) showed that the first TOO amino acids of the C-terminal region of the
a-subunit of the sodium channel are responsible for differences in current decay kinetics
between heart and skeletal muscle channels. These results together with the modeling
study by Sato et al. (49) link the C-terminus to fast inactivation, along with the inactivation
gate.
Considerable heterogeneity consists in the biophysical properties of the four long-
QT syndrome mutations reported so far in the first 23 amino acids of the C-terminus
(20,22,25,45). All but one, D1790C, promote non-inactivating Na+ current during
prolonged depolarizations. On the other hand, whereas three mutations cause a large
negative shift in the steady-state inactivation curve, consistent with increased close-state
inactivation, the Y1795C mutation does not alter this parameter (TABLE 7.2). Based on
computer model predictions of the sodium channel structure, it is believed that the
negatively charged proximal C-terminus might interact with the positively charged III-IV,
and possibly also the ll-lll cytoplasmic linker regions of the Na+ channel (49). More
comprehensive structural analysis of the carboxy-terminus will be essential to better
comprehend the biophysical changes imposed by long-QT syndrome mutations in this
region of the channel.
A Role for the Domain l-ll Linker in Channel Inactivation?
In CHAPTER 6, we reported that the L619F mutation in the cytoplasmic loop connecting
domain I and II speeds recovery from inactivation, and is thus likely to destabilize the
inactivated state of the sodium channel. The intracellular domain between domain I and II
is relatively unconserved between sodium channel isoforms (50,51). In the cardiac isoform,
1
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two mutations in this region have been linked to the Brugada syndrome. Wan et al. (52)
studied the biophysical properties of one of these, the L567Q mutation, in HEK cells and
demonstrated that L567Q channels accelerate fast inactivation, but at the same time
enhance closed-state inactivation which decreases Na* channel availability, which is
believed to cause idiopathic ventricular fibrillation (52).
Our data from CHAPTER 6 along with the data from Wan et al. (52), suggest that
the l-ll linker region is involved in Na+ channel inactivation (FIGURE 7.1). However, it is
impossible to conclude whether these mutations in the l-ll linker directly interfere with the
fast inactivation particle (17,36), or its docking sites (39,42,53,54), or whether this
phenomenon is due to allosteric interactions.
Conclusions Regarding LQT-3 Biophysical Phenotypes
In the last couple of years, it has become apparent that LQT-3 mutations over a fairly wide
range of the sodium channel a-subunit can destabilize the inactivated state of the channel,
directly or through possible allosteric effects. This suggests that the structural
requirements for normal inactivation are fairly precise, and depend upon complex
ensemble interactions among many structural domains (31).
Some biophysical properties occur commonly in LQT-3 mutations, most notably a
speeding of the onset of inactivation, and a faster recovery from inactivation (TABLE 7.2).
Whereas some features such as increased bursting (noninactivating current) and increased
window current are easily correlated to a cellular phenotype (29,55), other kinetic properties
may also contribute to action potential prolongation in subtle, as yet unexplored, ways.
Molecular Pharmacology of LQT-3 Mutations
Local Anesthetic Action is Cating-dependent
In CHAPTER 2, we described that local anesthetic/ class I antiarrhythmic drug activity is
gating-dependent (the 'modulated receptor theory') (56-59). Indeed, mutagenesis
experiments have revealed that amino acid residues critical to drug binding and channel
gating overlap to some degree. For example, alanine substitution of residues F1760 and
Y1767 (in SCN5A) in D4S6 increase the IC^ for depolarization-dependent block by
lidocaine up to two orders of magnitude (60,61). In addition, mutations in DiS6
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(N406 and L409 in the cardiac isoform) also reduce drug affinity (62,63). Interestingly,
channels with the mutation F1760A show impaired fast inactivation (64,65), and
substitution of the residue N406 alters both fast and slow inactivation (62). Current
conceptualization predicts that the channel inactivation process may alter the orientation
of amino acid side chains in S6 domains in a manner that facilitates drug binding (62,66).
Proximity of the Local Anesthetic Receptor Site and the Pore Segments
A pore-plugging motif for LA molecules is well supported by evidence that permanently
charged lidocaine derivatives (i.e. QX-314) move deeply (50-70%) into the pore from the
cytoplasmic site (67-69). This implies that the putative LA binding residues in S6 lie
intracellular to the selectivity filter, which is formed by the 'DEKA' ring contributed by the
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P-loops of each domain (CHAPTER 2). P-loop residues in domains I, II, and IV limit external
access (and escape) of hydrophilic LAs, and the domain III lysine residue repels the LA
through an electrostatic interaction with the ionizable amino group (70,71). These findings
suggest proximity between the S6 segments of domains I and IV and the P-loop selectivity
filter regions (70,71), which could provide a rationale for LA induced conformational
changes involving the outer P-loops (FIGURE 7.3).
Tonic Block of Sodium Channels: Interaction of Local Anesthetics with
the Fast-inactivated State
The earliest modulated-receptor schemes for LA and class I antiarrhythmic drug action
assigned a high affinity for the drugs to the open channel state (57). However, experiments
that disabled the inactivation gate by replacing the hydrophobic triplet IFM by QQQ in the
cytoplasmic III-IV linker suggested an interaction between Na+ channel blockers and the
inactivated conformational state (69,72). However, more recent studies suggest that LA
block can occur without affecting the inactivation gate directly (73). Although lidocaine
accelerates depolarization-dependent binding of the inactivation particle to its receptors,
it does not 'trap' the fast-inactivation gate as proposed in earlier studies (73), and therefore
seems to function as an allosteric effector.
Studies by Hanck et al. (74,75) examined the S4 voltage sensors during lidocaine
block, and revealed that the maximum gating charge (Ig) associated with channel
depolarization is reduced by lidocaine. Moreover, site-3 toxins (that specifically inhibit
movement of the voltage-sensor associated with inactivation) have an additional effect with
lidocaine to suppress the maximum gating charge, further suggesting that lidocaine does
not 'stabilize' the Na+ channel in the fast-inactivated state (75). These studies suggest that
lidocaine may alter closed-state inactivation by influencing the voltage sensors coupled to
inactivation gating.
Differential Pharmacological Effects of Na+ Channel Blockers in LQT-3 Patients
From clinical studies, it became clear that Na+ channel blockers may be particularly useful
in managing patients with LQT-3 mutations (76,77). The noninactivating inward current
conducted by certain LQT-3 mutations is potentially inhibited by lidocaine and its
analogous (19,78). The selective blockade of the late current probably accounts for the
QT-interval shortening without QRS prolongation in these patients (76).
However, the class IB antiarrhythmics lidocaine and mexiletine may not have
beneficial effects on all LQT-3 mutations. Enhanced sensitivity of the R1623Q peak sodium
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current to lidocaine raised concerns regarding the pro-arrhythmic potential of Na+ channel
blockade in these patients (79). The pro-arrhythmic consequences of Na+ channel blockade
are well known from the CAST trial (80). In addition, lidocaine did not correct
repolarization abnormalities in carriers of the D1790C mutation (77), a mutation that does
not enhance late Na+ current (25,26). Interestingly, the class IC antiarrhythmic drug
flecainide did correct QT-intervals in D1790C mutation carriers (77). Furthermore, there
are now clinical data that flecainide might also be effective in carriers of the AKPQ
mutation (81).
Molecular Pharmacology of Sodium Channel Blockers and LQT-3 Mutations
Certain LQT-3 mutations reduce stability of the inactivated state, inducing a small
noninactivating plateau of inward current during depolarization (17,19). When exposed to
very low concentrations of the class IB antiarrhythmic agents lidocaine or mexiletine,
AKPQ channels exhibit gating behavior that approaches the wild-type phenotype (78,82).
At the single channel level, lidocaine suppresses the bursting mode (82) and isolated late
channel openings (83) of AKPQ mutant channels.
Studies of the R1623Q sodium channel mutation exposed an alternative
mechanism for lidocaine action on sustained current (79). This study revealed that not
only the sustained current component, but also the peak sodium current was unusually
sensitive to lidocaine. Further studies revealed that 'closed-state inactivation' (as evidenced
by a hyperpolarizing shift in the steady-state inactivation curve) in drug-free conditions was
increased (79), in contrast to the more obvious mutation-induced disruption in open-state
inactivation (as evidenced by a slowed onset of inactivation) (23). Using a quantitative
Markovian model, it was demonstrated that state-dependent lidocaine affinity could further
augment closed-state inactivation through an allosteric effector mechanism (79). The same
model was also sufficient to reproduce observed effects of lidocaine on sustained current
induced by the AKPQ mutation, suggesting that an allosteric interaction between lidocaine
and the closed-state inactivation state may be more generally applicable. Although the
complete picture is still emerging, it is increasingly clear that interactions among multiple
mutation-induced gating processes influence local anesthetic action, thereby affording
tremendous pharmacologic diversity.
Use-dependent Sodium Channel Block
The previous paragraphs discussed the sensitivity of IMa+ channels to blockade that ensues
immediately upon depolarization ('first-pulse' or 'tonic' block), which correlates primarily
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to block that develops during a stimulus delivered after a long diastolic pause. Additional
mechanisms may be involved in modulating drug activity that develops during repetitive
depolarizations ('use-dependent' block) {84,85). A recent study (70,86) revealed that slow
recovery of drug-bound channels between depolarizing stimuli may involve an interaction
between local anesthetics and slow-inactivated conformational states. Ong et al. (86)
showed that an electrostatic interaction between the domain III P-loop residue K1419/F1418
and the lidocaine amino terminus might induce structural rearrangements associated
with slow inactivation that move Na+ channel P-loops into positions that stabilize the
interaction between lidocaine and the pore (FIGURE 7.3). Therefore, 'use-dependent'
block may occur when lidocaine induces sodium channels to occupy a slow inactivating
state (86). However, further evidence is required before definite conclusions may be
drawn regarding the role of slow inactivation in use-dependent local anesthetic
block.
LQT-3 Mutations that Alter Use-dependent Block of Sodium Channels
Flecainide, which is thought to preferentially block open but not inactivated channels,
is effective in correcting DC-induced QT prolongation in patients carrying the DG gene
defect, while lidocaine has no effect (77). Using heterologously expressed D1790C
channels, we showed that this disparity is based on markedly increased use-dependent
block sensitivity to flecainide (compared to wild-type channels), but not to lidocaine (87).
It was already known that flecainide, as other type IC agents, dissociates relatively slowly
after it binds primarily to activated sodium channels (88), and is capable of producing
strong use-dependent block of sodium channels (89). From our study (CHAPTER 4),
however, it is not clear how a mutation in the C-terminal part of the sodium channel may
selectively alter channel sensitivity to use-dependent flecainide block.
Interestingly, the specific alteration of the sensitivity to use-dependent block by
flecainide is not a general property of all LQT-3 mutant channels. Recently, Nagatomo et al.
(90) found that LQT-3 AKPQ mutant channels have an intrinsically higher affinity than
wild-type channels to flecainide, but in the case of AKPQ, sensitivity to both TB and UDB is
increased (90,91). These results implicate that AKPQ channels are susceptible to enhanced
tonic flecainide block as a result of increased closed-state inactivation gating (91). Thus,
our data indicate that the D1790G point mutation causes a unique pharmacological
response, which is distinct not only from wild-type but also from AKPQ mutant channels.
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Conclusions Regarding Mutation-specific Pharmacotherapy for LQT-3 Patients
Present knowledge suggests that fast and slow inactivation gating play important roles in
sodium channel blockade. Inherited LQT-3 mutations can alter these gating processes,
which may substantially influence the response to antiarrhythmic drugs. On the basis of
molecular pharmacological studies in combination with current concepts regarding the
interactions of local anesthetic with the sodium channel, the clinical usefulness of
particular antiarrhythmic drugs may be predicted.
Carriers of the AKPQ mutation, and other mutations that cause late Na+ current
during the action potential plateau phase, may benefit from treatment with lidocaine/
mexiletine (76,78,82,83,92), or flecainide/ pilsicainide (81,83,90). In contrast, patients with
the R1623Q mutations may experience pro-arrhythmic consequences of lidocaine treatment
(79,80). Finally, our studies revealed that LQT-3 patients with the D1790C mutation benefit
from treatment with flecainide, but not from lidocaine (77,87).
Novel Developments in Mutation-specific Pharmacotherapy
and Tailor-made Drugs
A critical aspect of the development of gene- or mutation-specific therapeutic approaches
is the functional study of disease-related mutations. Whereas in the past, cardiovascular
drug discovery often depended on serendipity, more recently, drugs have arise from more
logical scientific approaches. Comprehensive understanding of the biophysical
mechanisms underlying ion channel dysfunction, ideally in combination with a detailed
picture of the protein structure and channel gating, will enable tailor-made design of drugs
that may prevent cardiac arrhythmias in a subset of patients with a particular genetic
susceptibility (93,94).
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Summary
In recent years, important breakthroughs in the understanding of the congenital long-QT
syndrome have followed the linkage to mutations in genes encoding cardiac ion channels.
It became clear that what had been classified under the name 'congenital long-QT
syndrome' actually represents a variety of different conditions caused by ion channel
mutations, most of which produce alterations in ionic currents, leading to the same end
result: prolonged ventricular repolarization. From both clinical and biophysical studies,
it gradually became evident that heterogeneity exists, even among ion channel mutation in
the same gene, which has important implications for both the comprehension of the
pathophysiologic mechanisms, and perhaps even more promising, for mutation-specific
therapeutic approaches.
In CHAPTER l, the background of the present thesis is provided. Manifestations of the
congenital long-QT syndrome include prolonged ventricular repolarization (QT-interval
on the ECC), a propensity for life-threatening ventricular tachyarrhythmias, syncope, and
sudden cardiac death. Current estimates suggest that this condition causes 3000-4000
sudden deaths in children and young adults each year in the US only. On the basis of the
genetic transmission pattern, two major clinical syndromes are recognized: the autosomal-
dominant form (Romano-Ward syndrome) with a pure cardiac phenotype, and the rarer
autosomal-recessive form (Jervell and Lange-Nielsen syndrome) characterized by the
association with congenital neuronal deafness. Strategies to identify individuals with the
congenital long-QT syndrome, with particular attention for the genotype-specific
manifestations, and treatment options for different categories of these patients,
are discussed in depth.
In CHAPTER 2, the physiology, molecular biology, biophysics, pharmacology,
modulation, and regulation of the cardiac sodium channel are reviewed. This review
focuses particularly on SCN5A mutations that cause congenital long-QT syndrome.
Some sodium channel mutations may cause action potential prolongation by inducing
sustained sodium channel activity during the action potential plateau phase. However,
for several other mutations the arrhythmogenic mechanisms have not been elucidated.
In order to investigate the biophysical phenotypes of Na+ channel mutations
linked to the congenital long-QT syndrome, we expressed recombinant cardiac Na+
channels in human embryonic kidney (HEK 293) cells. Properties of the voltage-gated
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Na+ channels were measured using whole-cell patch-clamp analysis. In CHAPTER 3,
the biophysical phenotype of the D1790C mutation was investigated. This mutation in the
carboxy-terminus of the Na+ channel can prolong the ventricular action potential despite
the absence of mutation-induced sustained Na+ channel current. Using the Luo-Rudy
model, computations of the ventricular action potential predicted that Di79oC-induced
changes in Na* channel activity prolong action potentials in a steeply heart rate-dependent
manner. This lengthening is not directly due to changes in Na+ entry through bursting
mutant channels but instead to alterations in the balance of net plateau currents by
modulation of calcium-sensitive exchange and ion channel currents.
A clinical study in carriers of the D1790G mutation revealed that the class IB
antiarrhythmic drug lidocaine was ineffective, whereas flecainide, a class IC sodium
channel blocker, corrected repolarization parameters in these patients. In CHAPTER 4,
we investigated the molecular basis of this divergence. The results of this study
demonstrate that the D1790C mutation confers a unique pharmacological response on
expressed channels. The therapeutic effect in carriers of this mutation is probably the
result of enhanced flecainide use-dependent block of D1790C channels. Furthermore,
these data suggest a role of the Na+ channel a-subunit C-terminus in the flecainide/
channel interaction.
In CHAPTER 5, the functional consequences of the novel E1295K mutation were
described. Biophysical analysis of the mutant channels indicated that the E1295K mutation
changes channel activity in a manner distinct from previously investigated LQT-3
mutations. The changes in gating shift the window of voltages at which Na+ channels do
not completely inactivate. The altered window current is likely to affect net membrane
current during terminal repolarization, which is most likely the mechanism for action
potential prolongation.
In CHAPTER 6, we describe the first case of a congenital long-QT syndrome
patient with functional 2:1 atrioventricular block due to a heterozygous mutation of the
SCN5A gene. The L619F mutation promotes an increase in sustained (non-inactivating)
current as well as an increase in Na+ channel window-current, two mechanisms which are
expected to delay ventricular repolarization. Importantly, the defective inactivation imposed
by the L619F mutation implicates a novel role for the domain l-ll linker in the Na+ channel
inactivation process.
In the final CHAPTER of this thesis (CHAPTER 7), the major findings are discussed
in the perspective of biophysical mechanisms underlying congenital long-QT syndrome
caused by SCN5A mutations. In addition, new insights in the complex interrelationship
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between channel gating, antiarrhythmic block, and long-QT syndrome Na+ channel
mutations are discussed. Finally, the implications for the development of mutation-specific
therapy for the long-QT syndrome are discussed.
In short, this thesis deals with the complex functional changes that occur in cardiac
sodium channels in patients afflicted by the congenital long-QT syndrome. The data
presented contribute to the comprehension that multiple, distinct gating defects in sodium
channels may cause long-QT syndrome through discrete arrhythmogenic mechanisms.
This notion is likely to increasingly contribute to the design of mutation-specific
pharmacotherapy based on unique gating features of long-QT syndrome-associated
sodium channels.
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Samenvatting
Het aangeboren lange QT-tijd syndroom is de meest voorkomende oorzaak van plotse
hartdood in mensen zonder structured hartlijden. De elektrische stroomvoorziening van
het hart regelt de synchrone samentrekking van de hartspier. Als gevolg van deze
samentrekking wordt het bloed door het lichaam rondgepompt. Bij het lange QT-tijd
syndroom is er sprake van een normaal hart, maar de stroomvoorziening van het hart kan
ineens verstoord raken. De naam van de ziekte verwijst naar het tijdsinterval tussen de
Q- en T-golf op het electrocardiogram (ECG). In deze QT-tijd herstelt het hart zich van een
samentrekking, om zo een volgende hartslag mogelijk te maken. Een afwijking in deze
herstelperiode kan een ontsporing van het hartritme veroorzaken. Hierdoor gaat het hart
chaotisch en ongecontroleerd kloppen, en kan daardoor geen bloed meer rondpompen,
waardoor mensen bewusteloos kunnen raken of snel kunnen overlijden.
Recentelijk is ontdekt dat het aangeboren lange QT-tijd syndroom wordt
veroorzaakt door een verandering in het erfelijk materiaal. Dergelijke DNA afwijkingen
(mutaties) treden op in genen, die de informatie bevatten voor ionkanalen in het hart.
Een goede functie van deze ionkanalen is essentieel voor een nauwkeurige aansturing
van de electrische activiteit in het hart.
In HOOFDSTUK i worden de klinische kenmerken van het lange QT-tijd syndroom
beschreven. Symptomen zijn onder andere een verlengd QT-interval op het ECC, een
verhoogde kans op hartritmestoornissen, en plotselinge dood. Op basis van het
overervingspatroon worden twee klinische syndromen onderscheiden: de autosomaal
dominant-overervende vorm, Romano-Ward syndroom genaamd, en het autosomaal
recessief-overervende jervell-Lange Nielsen syndroom, hetgeen vaak met doofheid gepaard
gaat. In dit hoofdstuk worden de strategieen besproken hoe deze patienten opgespoord
kunnen worden en wat de beste behandeling is voor elke subgroep van lange QT-tijd
syndroom patienten.
Het proefschrift biedt specifiek aandacht aan het lange QT-tijd syndroom type 3,
hetgeen veroorzaakt wordt door mutaties in het natriumkanaal. In HOOFDSTUK 2 wordt
derhalve de fysiologie, moleculaire biologie, biofysica, farmacologie, modulatie en regulatie
van het cardiale natriumkanaal besproken. In het bijzonder worden mutaties in het
natriumkanaalgen besproken, die het lange QT-tijd syndroom veroorzaken. Voor een aantal
mutaties is aangetoond dat ze het QT-interval kunnen verlengen door een soort lekstroom
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te veroorzaken in de zieke natriumkanalen. Echter, er wordt ook geconcludeerd dat voor
een aantal mutaties nog niet duidelijk is hoe ze het lange QT-tijd syndroom veroorzaken.
Om de biofysische eigenschappen van natriumkanaalmutaties te kunnen
onderzoeken, werd een celsysteem gebruikt waarin mutante kanalen tot expressie gebracht
werden. Middels de 'whole-cell patch-clamp' techniek konden de biofysische
eigenschappen van het voltage-afhankelijke natriumkanaal in detail onderzocht worden.
In HOOFDSTUK 3 werd de D1790G mutatie onderzocht. Deze mutatie bevindt zich in het
carboxy-terminale uiteinde van het natriumkanaal en kan de duur van het QT-interval
verlengen zonder de prototypische lekstroom te veroorzaken. Door gebruik te maken van
het Luo-Rudy computer model van de hartspiercel, werd aangetoond dat de D1790C-
gemduceerde veranderingen in de natriumkanaalactiviteit verlenging van het QT-interval
kunnen veroorzaken. Deze verlenging is waarschijnlijk het gevolg van indirecte
veranderingen die optreden in de functie van andere ionkanalen in het hart, hetgeen het
hart gevoeliger maakt voor hartritmestoornissen.
In een klinische studie in patienten met de Di79oG mutatie is aangetoond dat
het klasse IB antiaritmicum lidocaine geen effect heeft, terwijl flecainide, een klasse IC
natriumkanaalblokker, juist wel het QT-interval effectief kan verkorten. In HOOFDSTUK 4
werd de oorzaak van deze verrassende bevinding nader onderzocht. De resultaten van deze
studie tonen aan dat de D1790C mutatie unieke farmacologische eigenschappen geeft aan
de natriumkanalen. Het therapeutische effect in de mutatiedragers is waarschijnlijk het
gevolg van een versterkte 'gebruiks-afhankelijke' blokkade van D1790C kanalen door
flecainide. Tevens suggereren deze data dat het carboxy-terminale uiteinde van het
natriumkanaal een rol kan hebben in de interactie met flecainide.
In HOOFDSTUK 5 worden de functioned eigenschappen beschreven van de E1295K
mutatie. Een biofysische analyse toonde aan dat de E1295K mutatie de activiteit van de
natriumkanalen op een unieke manier verandert. Deze veranderingen in de
natriumkanaalgeleiding veranderen het gebied van voltages waarin het natriumkanaal niet
volledig sluit. Deze veranderde zgn. 'window' natriumstroom verandert waarschijnlijk de
totale hoeveelheid stroom in de hartspiercel aan het einde van de electrische herstelfase na
een hartslag, hetgeen de totale duur van het QT-interval kan verlengen.
In HOOFDSTUK 6 beschreven we voor het eerst een pasgeboren patient met het
aangeboren lange QT-tijd syndroom en 2:1 boezem-naar-kamer geleiding ten gevolge van
een heterozygote mutatie in het natriumkanaalgen. Biofysische analyse van de L619F
mutatie toonde aan dat er sprake was van natriumkanaal lekstroom, in combinatie met een
toegenomen 'window' natriumstroom. De functioned veranderingen ten gevolge van de
Nofe/ fnsfgMts in (he Congenital Long Q T j Syndrome | PACE 166
L619F mutatie duiden waarschijnlijk op een niet eerder onderkende rol van het gebied
tussen domein I en II in de sluiting van het natriumkanaal.
In het laatste hoofdstuk van dit proefschrift (HOOFDSTUK 7) worden de
belangrijkste bevindingen bediscussieerd in de context van de biofysische mechanismen
die het lange QT-tijd syndroom kunnen veroorzaken. Tevens worden de nieuwste inzichten
op het gebied van de natriumkanaal functie en farmacologie samengevat. Tenslotte worden
de implicaties voor de ontwikkeling van een mutatie-specifieke behandeling van lange
QT-tijd patienten besproken.
Concluderend kan worden gesteld dat de resultaten van de studies beschreven in dit
proefschrift hebben geleid tot meer inzicht in de ontstaanswijze van het lange QT-tijd
syndroom. Zo werd onder andere duidelijk dat hele subtiele veranderingen in de functie
van het natriumkanaal verantwoordelijk kunnen zijn voor potentieel dodelijke hartritme-
stoornissen. Deze kennis kan bijdragen aan het totstandkomen van een mutatie-specifieke
behandeling van patienten met deze ziekte. Zo zullen sommige mensen meer profijt
hebben van een pacemaker om een trage hartslag te voorkomen, terwijl andere mensen
(met andere natriumkanaal mutaties) beter beschermd worden tegen ritmestoornissen met
behulp van bepaalde medicijnen. Door een adequate behandeling van deze patienten kan
de incidentie van hartritmestoornissen, flauwvallen, en plotselinge dood worden
teruggedrongen.
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Summarium
LONGO Q T CONGENITA SYNDROMA MAIOR CAUSA EST MORTIS SUBITAE CARDIACAE ALIOQUI
SANORUM HOMINUM. AESTIMATIONES HODIERNAE CENSENT ISTAM CONDITIONEM
QUOTANNIS CAUSAM ESSE MORTIS SUBITAE CARDIACAE M M M - M M M M PUERORUM ET
IUVENUM SOLUM IN ClVITATIBUS AMERICAE UNITIS. A E G R O T I AFFECTI ESSE POSSUNT
PROLONGATIONE QT-INTERVALLI, SYNCOPA, VEL MORTE SUBITA CARDIACA. H l S TEMPORIBUS,
NOVISSIMA REPERTA IN ARTE GENETICA COMPREHENSIONEM MELIORAVERUNT LONGO Q T
CONGENITAE SYNDROMAE. M A N I F E S T U M EST MUTATIONES IN GENIS DEPOSITORIIS
INFORMATIONUM DE CANALIBUS IONICIS CARDIACIS CAUSAS ESSE HUIUS MORBI. RECTA
FUNCTIO HORUM CANALIUM IONICORUM ESSENTIALIS EST AD NORMALEM RECTIONEM
CONTRATIONUM CORDIS.
HAC THESIS DISSERATDE LONGO Q T SYNDROMA TYPO I I I ( L Q T - I I I ) ,
A MUTATIONIBUS CANALIS CARDIACI SODII CAUSATA. UTENDO SYSTEMATE CELLULARI
EMBRYONIS RENIS HUMANI ( H E K - C C X C I I I ) , DIVERSAE LQT- I I I MUTATIONES EXHIBITA
SUNT. DLVERSAE MUTATIONES CAUSANT DIVERSOS DEFECTOS IN FUNCTIONE CANALIS SODII.
ETIAM MANIFESTUM EST, INTER ALIA, TARDOS RHYTHMOS CARDIACOS MAGNA PERICULA ESSE
ARRHYTHMIAE CORDIS IN AEGROTIS LQT- I I I AFFECTIS. PHARMACOLOGICA STUDIA INDICANT
QUOD SINGULAE MUTATIONES EXHIBENT SENSIBILITATEM SINGULAREM DIVERSORUM
MEDICAMENTORUM.
REPERTA DESCRIPTA IN HAC THESI PRAEBENT NOVAS COGNITIONES CIRCA
DIVERSITATEM INTER LQT- I I I CANALIS SODII MUTATIONES. PLURI MECHANISMI CANALIS
SODII DISFUNCTIONIS DESCRIPTI SUNT, ET APPARENS EST QUOD PARVI DEFECTI
FUNCTIONALES PROVOCARE POSSUNT RHYTHMOS IRREGULARES ATQUE MORTEM SUBITAM
CARDIACAM. NOVAE COGNITIONUM ACQUISITIONES CIRCA EXACTOS DEFECTOS A
MUTATIONIBUS CANALIS SODII CAUSATOS, ETIAMQUE CIRCA EARUM SENSIBILITATEM
PECULIARUM MEDICAMENTORUM, MELIUS DIRIGENT THERAPIAM LONGO Q T - I I I SYNDROMA
AFFLICTORUM.
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